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ABSTRACT 
Hot-melt extrusion (HME) is one of the most widely used technologies in the plastic, rubber 
and food industries and it has also been extensively explored and used in academia and the 
pharmaceutical industry over the last decade. This project aims to investigate the efficiency 
of hydrophilic polymers to enhance the dissolution rate of poorly water-soluble APIs 
processed by HME. Indomethacin (INM) and famotidine (FMT) were selected as model 
active substances while polyvinyl caprolactam graft copolymer, Soluplus® (SOL) and 
vinylpyrrolidone-vinyl acetate copolymer grades Kollidon® VA64 (VA64) and Plasdone® 
S630 (S630) were used as hydrophilic polymeric carriers. For the purpose of the study, all 
drug-polymer binary blends at various ratios were processed by a Randcastle single screw 
extruder. The physico-chemical properties and the morphology of the extrudates were 
evaluated via x-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and 
scanning electron microscopy (SEM). INM and FMT exhibited strong plasticization effects at 
specific concentrations and were found to be molecularly dispersed within the polymer 
blends. The in vitro dissolution studies showed increased INM/FMT release rates for all 
formulations compared to that of pure APIs alone.  Ibuprofen was also embedded in a 
methacrylate copolymer (Eudragit® EPO) matrix to produce solid dispersions by hot-melt 
extrusion processing.  The obtained granules were incorporated into orally disintegrating 
tablets (ODTs).  The tablets were developed by varying the ratio of superdisintegrants such as 
sodium croscarmellose and cross-linked polyvinylpyrrolidone while a direct compression 
process was used to compress the ODTs under various compaction forces to optimize tablet 
robustness. The properties of the compressed tablets which included porosity, hardness, and 
friability and dissolution profiles were further evaluated and compared with commercially 
available Nurofen® Meltlet ODTs. In vitro dissolution of the extruded ODTs showed rapid 
release of ibuprofen compared to that of Nurofen® Meltlets. The in vitro and in vivo 
evaluation of the masking efficiency of hot melt extruded paracetamol (PMOL) formulations 
was examined. Extruded granules containing high PMOL loadings in Eudragit EPO® (EPO) 
or Kollidon® VA64 (VA64) were prepared by HME. Similarly propranolol HCl (PRP), 
diphenhydramine HCl (DPD), cetirizine HCl (CTZ) and verapamil HCl (VRP) were used as 
model cationic active substances while pH sensitive anionic methacrylic acid based methyl 
methacrylate coplolymers Eudragit® L100 (L100) and ethyl acrylate copolymer Eudragit® 
L100-55 (Acryl-EZE®) (L100-55) were used as polymeric carriers in order to produce taste 
masked extruded formulations determining drug-polymers intermolecular interactions. The 
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taste masking effect of the processed formulation was evaluated in vivo by a panel of six 
healthy human volunteers. In addition, in vitro evaluation was carried out by an Astree e-
tongue (Alpha MOS) equipped with seven sensors and Taste Sensing System TS5000Z 
(INSENT), respectively.  
The taste and sensory evaluation in human volunteers demonstrated that the formulation 
masked the bitter taste of the APIs and improved tablet palatability. In addition to that the 
taste sensing technology demonstrated taste improvement for all polymers by correlating the 
data obtained for the placebo polymers and the pure APIs alone. The e-tongue results were in 
good agreement with the in vivo evaluation. Molecular modelling (Gaussian 09) predicted the 
existence of two possible H-bonding types while Fourier Transform Infra-Red (FT-IR) and 
NMR studies confirmed drug-polymer interactions between the functional groups of both 
components (cationic drugs±anionic polymers). Furthermore, the intermolecular interactions 
evaluated by Flory-Huggins interaction parameters theory and X-ray photoelectron 
spectroscopy (XPS) showed stronger interactions between drug-polymer in L100 systems 
compared to that of L100-55 systems. The mechanism of the intermolecular interactions 
derived from this research showed the presence of H bonding between the amine group of the 
active substances and the carboxylic groups in the polymer. 
Hydrocortisone (HCS) was also embedded and extruded with ethyl cellulose N10 (EC N10) 
or ethyl cellulose Premium 7 (EC P7) in order to develop sustained release tablets processed 
by HME. The compressed tablets were subsequently coated with an enteric coating polymer, 
Eudragit® S100 (15-20%), which showed sustained release over 12 hrs with a lag time of       
2 hrs. Further analysis of the release mechanism of HCS from tablets was performed by 
implementing five different kinetic release models which confirmed that the release of HCS 
from both coated and uncoated tablets followed a first order kinetic model. 
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CHAPTER 1: INTRODUCTION 
1.0 Background 
 Over the last three decades hot-melt extrusion (HME) has emerged as an  influential 
processing technology in developing molecular dispersions of active pharmaceutical ingredients 
(APIs) into polymer matrices and has already been demonstrated to provide time controlled, 
modified, extended and targeted drug delivery resulting in improved bioavailability [1, 2, 3, 4]. 
HME has now provided opportunity for use of materials in order to mask the bitter taste of 
active substances [4]6LQFHWKHLQGXVWULDODSSOLFDWLRQRIWKHH[WUXVLRQSURFHVVEDFNLQWKH¶V
HME has received considerable attention from both the pharmaceutical industries and academia 
in a range of applications for pharmaceutical dosage forms, such as tablets, capsules, films and 
implants for drug delivery via oral, transdermal and transmucosal routes [5]. This makes HME an 
excellent alternative to other conventionally available techniques such as solvent evaporation, 
freeze drying, spray drying and so on (Table 1.1). In addition to being a proven manufacturing 
process, HME meets the goal of the US Food and Drug Administration's (FDA) process 
analytical technology (PAT) scheme for designing, analyzing as well as controlling the 
manufacturing process via quality control measurements during active extrusion process [6]. In 
this chapter, the hot-melt extrusion technique is reviewed based on a holistic perspective of its 
various components, processing technologies as well as the materials and novel formulation 
design and developments in its varied applications in oral drug delivery systems. 
 
1.1 Hot-melt extrusion (HME): Process technology 
 Joseph Brama first invented the extrusion process for the manufacturing of lead pipes at 
the end of the eighteenth century [7]. Since then, it has been used in the plastic, rubber and food 
manufacturing industry to produce items ranging from pipes to sheets and bags. With the advent 
of high throughput screening, currently more than half of all plastic products including bags, 
sheets, and pipes are manufactured my HME and therefore various polymers have been used to 
melt and form different shapes for a variety of industrial and domestic applications. The 
technology has proven to be a robust method of producing numerous drug delivery systems and 
therefore it has been found to be useful in the pharmaceutical industry as well [8]. Extrusion is the 
process of pumping raw materials at elevated controlled temperature and pressure through a 
heated barrel into a product of uniform shape and density [9]. Breitenbach first introduced the 
development of melt extrusion process in pharmaceutical manufacturing operations [10], 
however, Follonier and his co-workers first examined the hot melt technology to manufacture 
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sustained release polymer based pellets of various freely soluble drugs [11]. HME involves the 
compaction and conversion of blends from a powder or a granular mix into a product of uniform 
shape [9]. During this process, polymers are melted and formed into products of different shapes 
and sizes such as plastic bags, sheets, and pipes by forcing polymeric components and active 
substances including any additives or plasticisers through an orifice or die under controlled 
temperature, pressure, feeding rate and screw speed [9, 12]. However, the theoretical approach to 
understanding the melt extrusion process can be summarized by classifying the whole procedure 
of HME compaction into the following [13]:  
       1) feeding of the extruder through a hopper, 
       2) mixing, grinding, reducing the particle size, venting and kneading, 
       3) flow through the die, and 
       4) extrusion from the die and further down-stream processing (Fig. 1.1). 
 
 
 
Fig. 1.1: Schematic diagram of the HME process [12]. 
 
 The extruder generally consists of one or two rotating screws (either co-rotating or 
counter rotating) inside a stationary cylindrical barrel. The barrel is often manufactured in 
sections in order to shorten the residence time of molten materials. The sectioned parts of the 
barrel are then bolted or clamped together. An end-plate die is connected to the end of the barrel 
which is determined according to the shape of the extruded materials. 
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Table 1.1: HME and other conventional processing techniques; advantages and disadvantages. 
 
Technologies Advantages Disadvantages 
Hot-melt extrusion [1-6] - Solvent free 
- Fast and continuous process 
- Low cost 
- Small footprint 
- High recovery 
- In line monitoring 
- Temperature 
(thermolabile molecules) 
- Downstream processing 
Spray Drying [5] - Fast process 
- Flexible particle sizes 
- Solvent residues (toxicity 
issue) 
- Processing parameters 
- Small yield 
- Cost 
Freeze drying [5] - Mild condition 
- Suitable for thermolabile 
molecules 
- Solvent residues 
- Cost 
- Longer processing time 
- Cry protecting 
- Suitable solvent with 
high freezing point for 
sublimation process. 
Supercritical fluid 
processing [5] 
- Mild conditions - Limited solubility of CO2 
- Cost 
- Time 
- Phase separation during 
evaporation 
Solvent evaporation [5] - Mild condition - Solvent residues 
- Cost 
- Time 
- Suitable solvent 
- Phase separation during 
evaporation 
 
 
1.2 Equipment: single screw and twin screw extruder 
 A single screw extruder consists of one rotating screw positioned inside a stationary 
barrel at the most fundamental level. In the more advanced twin-screw systems, extrusion of 
materials is performed by either a co-rotating or counter-rotating screw configuration [9]. 
Irrespective of type and complexity of the function and process, the extruder must be capable of 
rotating the screw at a selected predetermined speed while compensating for the torque and shear 
generated from both the material being extruded and the screws being used. However, regardless 
of the size and type of the screw inside the stationary barrel a typical extrusion set up consists of 
a motor which acts as a drive unit, an extrusion barrel, a rotating screw and an extrusion die [13]. 
A central electronic control unit is connected to the extrusion unit in order to control the process 
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parameters such as screw speed, temperature and therefore pressure [14]. This electronic control 
unit acts as a monitoring device as well. The typical length diameter ratios (L/D) of screws 
positioned inside the stationary barrel are another important characteristic to consider whether  
the extrusion equipment is a single screw or twin screw extruder. The L/D of the screw either in 
a single screw extruder or a twin screw extruder typically ranges from 20 to 40:1(mm). In case 
of the application of pilot plant extruders the diameters of the screws significantly ranges from 
18-30 mm.  In pharmaceutical scale up, the production machines are much larger with diameters 
typically exceeding 50 - 60 mm [15]. In addition, the dimensions of a screw change over the 
length of the barrel. In the most advanced processing equipment for extrusion, the screws could 
be separated by clamps or be extended in proportion to the length of the barrel itself. A basic 
single screw extruder consists of three discrete zones: feed zone, compression and a metering 
zone (Fig. 1.2). Under the compression zone which is basically know as processing zone could 
be accompanied by few other steps such as mixing, kneading, venting etc [13, 15]. 
 
 
 
Fig. 1.2: Schematic diagram of a single screw extruder [10]. 
 
 The depth along with the pitch of the screw flights (both perpendicular and axial) differ 
within each zone, generating dissimilar pressures along the screw length (Fig. 1.3). Normally the 
pressure within the feed zone is very low in order to allow for consistent feeding from the 
hopper and gentle mixing of API, polymers and other excipients and therefore the screw flight 
depth and pitch are kept larger than that of other zones. At this stage of the process the pressure 
within the extruder is very low which subsequently gets increased in the compression zone. This 
result in a gradual increase in pressure along the length of the compression zone effectively 
imparts a high degree of mixing and compression to the material by decreasing the screw pitch 
and/or the flight depth [9, 15]. Moreover the major aim of the compression zone is not only to 
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homogenize but also compress the extrudate to ensure the molten material reaches the final 
section of the barrel (metering zone) in a form appropriate for processing. Finally the final 
section which is known as the metering zone stabilizes the effervescent flow of the matrix and 
ensures the extruded product has a uniform thickness, shape and size. A constant and steady 
uniform screw flight depth and pitch helps maintain continuous high pressure ensuring a uniform 
delivery rate of extrudates through the extrusion die and hence a uniform extruded product. 
 
 
 
Fig. 1.3: Screw geometry (extrusion) [9]. 
 
 In addition to the above mentioned systems, downstream auxiliary equipment for 
cooling, cutting, collecting the finished product is also typically employed. Mass flow feeders to 
accurately meter materials into the feed hopper, pelletizers, spheronizer, roller/calendaring 
device in order to produce continuous films and process analytical technology such as near infra-
red (NIR) and Raman, ultra sound, DSC systems are also options. Throughout the whole 
process, the temperature in all zones are normally controlled by electrical heating bands and 
monitored by thermocouples.  
 
 The single screw extrusion system is simple and offers lots of advantages but still does 
not acquire the mixing capability of a twin-screw machine and therefore is not the preferred 
approach for the production of most pharmaceutical formulations. Moreover, a twin-screw 
extruder offers much greater versatility (process manipulation and optimisation) in 
accommodating a wider range of pharmaceutical formulations making this set-up much more 
constructive. The rotation of the screws inside the extruder barrel may either be co-rotating 
6 | P a g e  
 
(same direction) or counter-rotating (opposite direction), both directions being equivalent from a 
processing perspective (Fig. 1.4). A greater degree of conveying and much shorter residence 
times are achievable with an intermeshing set-up. Furthermore, the use of reverse-conveying and 
forward-conveying elements, kneading blocks and other intricate designs as a means of 
improving or controlling the level of mixing required can help the configuration of the screws 
themselves to be varied [16].  
 
Fig. 1.4: A twin screw extruder and screws [9]. 
 
 
1.3 Advantages and disadvantages of HME  
 
Advantages 
 HME offers several advantages over conventionally available pharmaceutical processing 
techniques via appopriate selections of polymeric (thermoplastic) carrers as discussed in Table 
1.1, including: (a) increased solubility and bioavailability of water insoluble compounds, (b) 
solvent free non ambient process, (c) economical process with reduced production time, fewer 
processing steps, and a continuous operation, (d) capabilities of sustained, modified and targeted 
release, (e) better content uniformity in extrudates, (f) no requirements for the compactibility of 
active ingredients, (g) uniform dispersion of fine particles,  (h) good stability at changing pH and 
moisture levels and safe application in humans, (i) reduced number of unit operations and 
production of a wide range of performance dosage forms, and (j) a range of screw geometries [17, 
18, 19, 20, 21]
. 
Disadvantages 
However, HME has some disadvantages as well. The main drawbacks of HME include: 
thermal process (drug/polymer stability), use of a limited number of polymers, high flow 
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properties of polymers and excipients required and not suitable for relatively high heat sensitive 
molecules such as microbial species, proteins etc [20, 21]. 
 
1.4 Applications of HME  
 Extrusion technology is one of the most important fabrication processes in the plastic and 
rubber industries. Products made from melt extruded polymers range from pipes to hoses 
through to the insulated wires, cables, rubber sheeting and polystyrene tiles. Plastics that are 
commonly processed by HME technique include acrylics and cellulosics, polyethylene, poly 
propylene, polystyrene and vinyl plastics [9, 22].  In the food industry, extrusion has been utilized 
for pasta production with a widely used multitalented technique combining cooking and 
extrusion in a self-styled extrusion cooker [23]. In the animal feed industry and veterinary science, 
extrusion is commonly applied as a means of producing pelletized feeds, implants or injection 
moulding [24]. HME has successfully been applied in the formulation of fast dispersing PVP melt 
extrudates of poorly soluble active agents as solid molecular dispersions in the crop protection 
field [25]. 
 HME technology has already achieved a strong place in the pharmaceutical industry and 
academia due to several advantages over traditional processing methods such as roll spinning 
and grinding [18]. In addition to being an efficient manufacturing process, HME enhances the 
quality and efficacy of manufactured products and therefore over the past few years HME has 
emerged as a novel technique in pharmaceutical applications [15, 28]. The main use of HME is to 
disperse active pharmaceutical ingredients (APIs) in a matrix at the molecular level, thus 
forming solid dispersions [1, 26]. In the pharmaceutical industry, HME has been used for various 
applications, such as i) enhancing the dissolution rate and bioavailability of poorly soluble drugs 
by forming a solid dispersion or solid solution, ii) controlling or modifying the release of the 
drug, iii) taste masking of bitter APIs, and iv) formulation of various thin films [27]. 
 The bioavailability of an active ingredient is controlled by its aqueous solubility. 
Therefore, increasing the solubility of water insoluble drugs is still a real challenge in the 
formulation development process [26]. Due to the advent of high throughput screening (HTS) in 
the drug discovery process, the resultant compounds are often high molecular weight and highly 
lipophilic and therefore exhibit poor solubility [29]. Scientists have already tried to address 
solubility issues by various pharmaceutical interventions. Among the many methods available to 
improve solubility and dissolution rate, preparation of solid dispersions and solid solutions has 
gained vast attention. For that reason, HME has been successfully applied to prepare solid 
molecular dispersion of APIs into different hydrophilic polymer matrices [26, 29]. 
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1.5 Formulation research and developments to date 
 
 Despite the fact that initial research developments have focused on the effects of 
formulation and processing variables on the properties of the final dosage forms, [9, 30, 31, 34, 35] 
more recent investigations have focused on the use of HME as a novel manufacturing 
technology of solid molecular dispersions through to the development of mini-matrices, taste 
masked formulations and also sustained release formulations as well as paediatric formulations 
[26, 48]
. Early work by De Brabander et al. (2000) described the preparation of matrix mini-tablets 
which was followed by further investigations into the properties of sustained release mini-
matrices manufactured from ethyl cellulose, HPMC and ibuprofen [32, 33]. Extruded mini tablets 
showed minimised risk of dose dumping, reduced inter- and intra-subject variability. Recently, 
Roblegg et al. (2011) reported the development of retarded release pellets using vegetable 
calcium stearate (CaSt) as a thermoplastic excipient processed through HME, where pellets with 
a drug loading of 20% paracetamol released only 11.54% of the drug after 8 hours due to the 
significant densification of the pellets. As expected, the drug release was influenced by the pellet 
size and the drug loading [36]. A microbicide intravaginal ring (IVR) IVR was prepared and 
developed from polyether urethane (PU) elastomers for the sustained delivery of UC781 (a 
highly potent nonnucleoside reverse transcriptase inhibitor of HIV-1). PU IVRs containing 
UC781 were fabricated using a hot-melt extrusion process [37]. 
 
Moreover, a fourfold increase in the availability of propanolol in the systemic circulation 
was observed when the HME formulation was compared with a commercially available 
formulation (Inderal®). Over the last five years HME has been used largely to manufacture 
granules, pellets, immediate and modified release tablets, transmucosal/ transdermal films and 
implantable reservoir devices [3, 4, 9, 35, 38]. For instance, with respect to drug administration 
through the oral route, molecular solid dispersions of nifedipine [38], nimodipine [29] and 
itraconazole [39, 40, 41] have been successfully produced using HME technology. Amorphous 
indomethacin dispersions have been manufactured using pharmaceutically acceptable 
hydrophilic polymers by using HME technology [26, 42, 43].  
 
Furthermore, HME research developments have driven targeted drug delivery systems 
including enteric matrix tablets and capsule systems over the last few years [44, 45]. Miller et al. 
(2007) have demonstrated the ability of HME to act as an efficient dispersive process for 
aggregated, fine engineering particles to improve dissolution rate properties by enhancing 
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SDUWLFOHV¶ZHWWDELOLW\ [46]. A very interesting investigation of Verreck and co-workers (2006) [47] 
determined the use of supercritical carbon dioxide (scCO2) as a temporary plasticiser during the 
manufacture of ethylcellulose through HME. A significant reduction in the processing 
temperature was achieved using scCO2 without any disadvantageous effects on the extrudate. 
Macroscopic morphology was significantly altered due to expansion of the scCO2 in the die. 
The use of scCO2 increased the surface area, porosity and hygroscopicity of the final dosage 
forms. More recently Douroumis and co-workers used HME technique to effectively enhance 
the dissolutions of ibuprofen, indomethacin and famotidine through the effective formation of 
solid dispersions of active substances into the polymer matrices [26, 42]. 
 
The taste masking of bitter APIs is a major challenge especially for the development of 
orally disintegrating tablets (ODTs). HME has been reported to be an effective technique to 
mask the bitter tastes of various APIs by the use of taste masking polymers that create solid 
GLVSHUVLRQV WR SUHYHQW ELWWHU GUXJV IURP FRPLQJ LQ FRQWDFW ZLWK WKH SDWLHQW¶V WDVWH EXGV 
Breitkruitz et al. (2008) successfully applied HME in taste masking of sodium benzoate for the 
formulation of paediatric drugs [48]. More recently Gryckze et al. (2011) developed taste masked 
formulations of ibuprofen with Eudragit EPO polymer [42]. Basically, taste masking is achieved 
through intermolecular forces (e.g. hydrogen bonding) between the active substance and the 
polymer matrix by processing oppositely charged compounds through HME [42, 49, 50]. The 
extrusion of solid lipids using twin±screw extruders was introduced for the preparation of 
immediate or sustained release taste masked matrices [51]. In this process, occasionally called 
³VROYHQW± IUHHFROGH[WUXVLRQ´WKHOLSLGVDUHH[WUXGHGEHORZWKHLUPHOWLQJUDQJHV&RQVHTXHQWO\
the lipids are not melted during extrusion and build a coherent matrix with low porosity. In these 
studies, the effect of lipid composition and processing parameters such as the die diameter, the 
size of the extruded pellets, the screw speed and the powder feeding rates on the obtained drug 
release patterns were thoroughly investigated. Very recently, Breitkreutz et al. (2012) applied 
solid lipid extrusion at room temperature for the taste masked formulation development of the 
BCS Class II drug NXP 1210. NXP 1210 is an acidic, non-steroidal anti-inflammatory drug [52]. 
The lipophilic character is described by its log P value of 3. In this study, the authors 
investigated powdered hard fat (Witocan® 42/44 mikrofein), glycerol distearate (Precirol® ato 
5) and glycerol trimyristate (Dynasan® 114) as lipid binders. The lipid based formulations 
designed in this study was feasible for taste-masked granules or pellets containing poorly soluble 
drugs [52]. 
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 However, only a handful of research works have been reported in the use of hot-melt 
extrusion for the manufacture of films [53, 54]. Films can be defined as thin sheets containing one 
or more polymers with or without a plasticiser and may be used as a drug delivery system 
(device) or directly applied to facilitate a therapeutic effect as in wound dressings. Films are 
currently being produced mainly by solvent casting in which polymers (and excipients such as 
plasticisers) are dissolved in a suitable solvent until they form clear viscous solution (gel). While 
film preparation using the solvent±casting approach allows film uniformity, clarity, flexibility 
and adjustable thickness to accommodate drug loadings they are limited by decreased elongation 
or elasticity and increased film tensile strength when physical aging is applied [53]. Another, 
limitation associated with solvent cast films is the use of organic solvents for water insoluble 
polymers. The hazardous nature of most organic solvents and the residual solvents after drying 
affect the selection of the appropriate solvent [54±57] as well as complicated processing conditions 
and disposal of the associated waste, all of which create significant environmental concerns. As 
a result, alternative technologies are needed in the pharmaceutical industry to overcome some of 
the challenges described above. The two commonly used approaches include spray coating and 
hot melt extrusion with the latter becoming increasingly popular due to the many advantages it 
provides. Firstly, no solvents are used and fewer processing steps are required. In fact one of the 
key advantages of HME is the fact that extrudates can be obtained in a single processing step 
making it very economical. As far as films are concerned, there is no requirement for 
compressing of the active ingredients together with the excipients. The melting of the polymer 
into the molten state, coupled with the thorough initial mixing allows a more uniform dispersion 
of fine particles. Further, molecular dispersion of the drug helps improve its bioavailability [58].  
Hot melt extruded films are produced through a simple process involving blending of 
appropriate amounts of relevant polymer, drug and plasticiser into a uniform powdered mixture 
prior to feeding through the hopper of the preheated extruder and transferred into the heated 
barrel by a rotating extruder screw. Homogeneous films are obtained with thickness generally 
expected to be in the range less than 1 mm. Generally three main ingredients are required for 
successful formulation of hot melt extruded films i.e. film forming polymer, active ingredient 
and plasticiser [59]. The latter is required to impart flexibility to the final film which ensures ease 
of handling and application to the site of action. Occasionally, other additives are added to affect 
other functionally important properties such as bioadhesive agent which ensures that the film 
adheres to the mucosal surface for a long enough time to allow drug absorption or action. 
Different polymers and drugs have been employed and reported in the literature for obtaining 
drug loaded hot-melt extruded films for various indications and are summarised in Table 1.2.  
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Table 1.2: Different hot-melt extruded films comprising of different polymeric materials, 
plasticisers and active ingredients for various indications.  
 
Main polymer(s) Plasticiser/additive Main active 
ingredient(s) 
Types of films 
Acrylic [60, 61] 
Eudragit 
- Triacetin 
- Triethylcitrate 
Clotrimazole Bioadhesive 
Control release 
Hydroxypropylcellulose [60] 
Polyethylene oxide 
N/A Ketoconazole Bioadhesive films 
for Onychomyosis 
Fast release 
Hydroxypropylcellulose [62] 
Hydroxypropylmethylcellulose 
Polyethylene oxide 
Polyethylene glycol 3350 Lidocaine Water soluble 
Bioadhesive 
Hydroxypropylcellulose [65] Polyethylene glycol 400 Hydrocortisone 
Chlorphenirami
ne maleate 
Hydrophillic 
Bioadhesive 
Hydroxypropylcellulose [58] 
Polycarbophil 
Polyethylene glycol 3350 Clotrimazole Bioadhesive 
Fast release 
Polyethylene oxide[59] N/A Ketoprofen Bioadhesive 
Antifungal 
 
 Repka and co-workers have conducted extensive research on the use of HME for the 
manufacture of mucoadhesive buccal films. They successfully evaluated different matrix 
formers and additives for the processing of the blend prior to extrusion [61, 62, 63, 64]. In an early 
investigation, it was found that even though films containing exclusively HPC could not be 
obtained, the addition of plasticizers, such as triethyl citrate, PEG 2000/8000, or acetyltributyl 
citrate, allowed for the manufacture of thin, flexible, and stable HPC films  [65]. It has also been 
found that increasing the molecular weight of HPC decreased the release of drugs from hot-melt 
extruded films which resulted in dissolution profiles exhibiting zero-order drug release. 
According to the models applied in the research, the drug release was solely determined by 
erosion of the buccal film [66, 67, 68]. 
 Development of films by HME may present future opportunities to develop gastro-
retentive films for prolonged drug delivery and multi-layer films to modulate drug release for 
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oral and transdermal applications. The growing market in medical devices, including 
incorporating drugs into devices such as biodegradable stents and drug-loaded catheters will 
undoubtedly require HME manufacturing processes. These are required to be commercialised 
and perhaps may lead to new areas of collaboration across pharmaceutical, medical device and 
biotechnology research. 
 
1.6 HME in commercial products 
 HME related patents which have been issued for pharmaceutical systems have steadily 
LQFUHDVHGVLQFH WKHHDUO\¶V [69].  So far, the USA and Germany hold approximately more 
than half (56%) of all issued patents for HME in the market. Despite this increased interest, only 
a handful of commercialized HME pharmaceutical products are currently marketed. Several 
companies have been recognized to specialize in the use of HME as a drug delivery technology, 
such as PharmaForm and SOLIQS (Abbott). Recently, SOLIQS has developed a proprietary 
formulation which is known as Meltrex® and re-developed a protease-inhibitor combination 
product, Kaletra®. Kaletra is mainly used for the treatment of human immunodeficiency virus 
(HIV) infections. The formulated, melt extruded product was shown to have a significant 
enhancement in the bioavailability of active substances [70]. Furthermore, HME Kaletra® tablets 
were shown to have significant advantages for patient compliance (i.e. reduced dosing frequency 
and improved stability) compared to the previous soft-gel capsule formulation as recognized by 
the FDA decision to fast-track approval. Additionally, Nurofen (Meltlets® lemon) is available in 
the market as a fast dissolving tablet prepared by similar technique to HME [42]. Ibuprofen has 
been used as active substance in the Meltlets® tablets. Moreover, SOLIQS has also developed a 
fast-onset ibuprofen system and a sustained-release formulation of verapamil (Isoptin® SR-E) 
WKURXJKD+0(UHODWHGWHFKQRORJ\FDOOHGµ&DOHQGDULQJ¶WKDWZDVWKHILUst directly shaped HME 
product in the market.  
 
1.7 Summary 
 HME has proven to be a robust method of producing numerous drug delivery systems 
and therefore it has been found to be useful in the pharmaceutical industry enlarging the scope to 
include a range of polymers and APIs that can be processed with or without plasticizers. It has 
also been documented that HME is a solvent-free, robust, quick and economy favoured 
manufacturing process for the production of a large variety of pharmaceutical dosage forms.  
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1.8 Aims and objectives 
The purpose of this research study is to develop HME as an efficient technique for the 
formulation of various oral solid dosage forms with the aim of increasing the dissolution rate of 
some poorly soluble model APIs (i.e ibuprofen, indomethacin, famotidine) via the formation of 
solid dispersions. Also the evaluation of taste masking efficiency (in vivo and in vitro) of 
different polymeric matrices (via intermolecular hydrogen bonding) as well as characterizing all 
possible intermolecular interactions in the solid dispersions has been prioritised as second aim of 
this research.  
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CHAPTER 2: DISSOLUTION ENHANCEMENT OF POORLY WATER-SOLUBLE 
APIs PROCESSED BY HOT-MELT EXTRUSION (HME) USING HYDROPHILIC 
POLYMERS 
 
1.0 Introduction 
With the recent start of high throughput screening of potential therapeutically active 
ingredients, the number of poorly soluble drug candidates has increased sharply (about 25% to 
40%). The availability of water insoluble APIs into systemic circulation is highly controlled and 
dependent on its aqueous solubility and therefore increasing the solubility/dissolution of poorly 
soluble subtances for oral delivery is a challenging task in pharmaceutical processing and 
development. The manufacture of solid dispersions is considered one of the most attractive 
approaches to increase solubility and thus bioavailability of poorly soluble APIs [1]. Solid 
dispersions have been prepared by employing various approaches such as co-evaporation [2],  hot 
spin mixing [3], roll-mixing or co-milling [4], freeze-drying [5], spray drying [6,7] and supercritical 
fluid processing (SFP) [8]. 
Hot-melt extrusion (HME) is considered as an effective process in pharmaceutical 
industry for the formation of molecular dispersions in order to improve the bioavailabity of drug 
components which have low water solubility [9]. The melt extrusion process offers various 
advantages over conventional approaches such as it is a solvent-free process and therefore 
environmental friendly. Relatively low heat sensitive substances can be easily processed by 
HME as the exposure of the APIs is very short and processing temperatures can be lowered by 
selecting the appropriate drug carrier. Moreover, the melt extrusion process helps to convert 
crystalline active substances into the amorphous state as well as offers a chance to dissolve the 
drugs in the inert polymer matrix through the formation of solid solutions. Different case studies 
have been reported to increase solubility of various poorly soluble drugs [10] by HME including 
nifedipine, tolbutamide, lacidipine [11, 12], itraconazole [13, 14] and nitrendipine [15]. 
Famotidine (FMT)  is a histamine H2-receptor antagonist (H2RA) mainly used for the 
treatment of gastric-duodenal ulcers, symptomatic gastro-oesophageal reflux disease (GERD), 
erosive oesophagitis, management of hypersecretory conditions [16, 17] for paediatric populations 
[17]
. According to the Biopharmaceutical Classification System (BCS) FMT is classified as a 
class IV drug (low solubility, low permeability) [18]. Indomethacin (INM) is a non-steroidal anti-
inflammatory drug (NSAID) used to treat rheumatoid arthritis, osteoarthritis, alkylosing 
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spondylitis, tendinitis and headaches [19, 20]. It is known as a Class II active substance which 
exerts high permeability and low bioavailability [19] due to the poor water solubility.  The two 
drugs were chosen to represent the two classes and to compare the effect of HME on increasing 
their percent loading and dissolution properties which are important for improving their 
bioavailability. To the best of our knowledge, this is the first study comparing two different 
poorly water soluble drugs from two BCS classes for drug loading and drug dissolution 
properties. 
Both FMT and INM have been reported to be molecularly dispersed in various polymer 
matrices in order to provide quick release profiles [16,19,20,21]. In the present study, solid 
dispersions of relatively high loadings of INM and FMT (up to 40%) embedded in hydrophilic 
polymers such as SOL, VA64, and S630 were prepared using hot-melt extrusion in order to 
achieve faster dissolution profiles. The in vitro dissolution properties and physico-chemical 
properties of the solid dispersions were investigated and compared with the physical mixtures 
and the pure APIs alone. 
2.0 Materials and Methods 
2.1 Materials 
Indomethacin (INM) was purchased from Sigma Aldrich (London, UK) and Famotidine 
(FMT) was donated by Colorcon Ltd (Dartford, UK).  Soluplus and cross-linked 
polyvinylpyrrolidone kollidon VA64 were kindly donated by BASF (Germany). Plasdone S630 
was obtained from ISP. All HPLC solvents were of analytical grade and purchased from Fisher 
Chemicals (UK). 
2.2 Drug-polymer miscibility study by Hansen solubility parameters (į 
The Hansen [22] solubility parameters (į of both drugs as well as the polymers were 
calculated by considering their chemical structural orientations. In order to determine the 
theoretical drug/polymer miscibility, the solubility parameters were calculated by using the 
Hoftyzer and van Krevelen method [23] according to the following equation: 
)1.2(222 hpd GGGG    
Where, 
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i = structural groups within the molecule 
į =   the total solubility parameter. 
Fdi = molar attraction constant due to molar dispersion forces 
F2pi = molar attraction constant due to molar polarization forces 
Ehi = hydrogen bonding energy. 
Vi = group contribution to molar volume 
The average molecular weight was used to determine the solubility parameter of different 
polymeric excipients while the Bagley advanced solubility parameter equation and diagrams [24] 
were used to investigate the effect of hydrogen bonding compared to the combined solubility 
parameters (dispersion forces and polarization forces). 
2.3 Preparation of formulation blends 
The dry drug/polymer powders (100 g) were blended thoroughly in a Turbula TF2 mixer 
(Basel, Switzerland) for 10 min. As shown in Table 2.1, the drug content for the binary blends 
varied from 20 ± 40%.  For the FMT/VA64, FMT/S630 and INM/S630 the drug content did not 
exceed 20% due to the difficulty with extruding the powdered formulations.   
Table 2.1:  Drug/polymer percentages of the HME processed formulations. 
Drug Polymer Drug 
(%, w/w) 
Polymer 
(%, w/w) 
FMT SOL 20 80 
FMT SOL 40 60 
FMT VA64 20 80 
FMT S630 20 80 
Drug Polymer Drug Polymer 
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(%, w/w) (%, w/w) 
INM SOL 20 80 
INM SOL 40 60 
INM VA64 20 80 
INM VA64 40 60 
INM S630 20 80 
 
2.4 Hot-melt extrusion (HME) process 
Extrusion of all INM and FMT formulations was performed using a single screw 
Randcastle extruder (Model RC 0750, Cedar Grove, NJ) with a 0.2 mm rod die. The temperature 
profile from the feeding zone to the die was 105°C/113°C/118°C/122°C/120°C for all 
formulations with 15 rpm screw speeds. The extrudates (strands) were milled for 5 min to 
produce granules using a Pulverisette 6 ball mill (Fritsch, Germany) with 400 rpm rotational 
speed. The micronized particles were then passed through a 250 µm sieve. 
 
2.5 Thermal analysis 
A Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter 
(DSC) was used to carry out DSC analyses of pure actives, physical mixtures (PM) and 
extrudates. 2-5 mg of samples was placed in sealed aluminium pans with pierced lids. The 
samples were heated at 10°C/min from 0°C to 220°C under dry nitrogen atmosphere.  In 
addition modulated temperature scanning calorimetry (MTDSC) studies were performed from 
30oC to 150oC temperature range with an underlying heating rate of 1oC/min to further analyze 
the samples. The pulse height was adjusted to 1-2oC with a temperature pulse width of 15-30 s. 
2.6 X-ray powder diffraction (XRPD) 
XRPD was used to determine the solid state of pure active substances, physical mixtures 
and extruded materials using a Bruker D8 Advance (Germany) in two-theta (2ˠ) mode. A copper 
anode at 40 kV and 40 mA, parallel beam Goebel mirror, 0.2 mm exit slit, LynxEye position 
sensitive detector with 3° opening (LynxIris at 6.5 mm) and sample rotation at 15 rpm were 
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used. Each sample was scanned from 2 to 40° 2ˠ with a step size of 0.02° (2ˠ) and a counting 
time of 0.2 seconds per step; 176 channels active on the PSD making a total counting time of 
35.2 s/step. 
 
2.7 Particle size morphology and distribution 
Scanning electron microscopy (SEM) was used to study the surface morphology of the 
hot-melt extrudates. The samples were mounted on an aluminum stage using adhesive carbon 
tape and placed in a low humidity chamber prior to analysis. Samples were coated with gold, and 
microscopy was performed using a Jeol 5200, SEM operating at an accelerating voltage of 5 kV. 
The particle size distribution of the micronized extrudate granules of all formulations was 
measured by dry sieving. The method involved stacking of the sieves on top of each other and 
then placing the test powder (100 g) on the top sieve. The nest of sieves was subjected to a 
standardised period of agitation (20 min) and then the weight of the material retained on each 
sieve was accurately determined to give the weigh percentage of powder in each sieve size 
range. 
2.8 In vitro drug release studies 
In vitro drug release studies were carried out in 750 ml of 0.1 M hydrochloric acid  for 2 
hr using a Varian 705 DS dissolution paddle apparatus (Varian Inc. North Carolina, US) at 100 
rpm and 37 ± 0.5oC. After the 2 hr operation, 250 ml of 0.20 M solution of trisodium phosphate 
dodecahydrate were added into the vessel (buffer stage, pH 6.8) that had been equilibrated to 37 
°C. At predetermined time intervals, samples were withdrawn for HPLC assay. All dissolution 
studies were performed in triplicate 
Furthermore, the difference of the release profiles of different formulations was 
investigated by calculating the similarity factor (f2). The f2 value (Eq. (2)) is a logarithmic 
transformation of the sum-squared error of differences between the test Tj and reference 
products Rj over all time points (n = 5).         
)2.2(]100}))(1(1log[{50
1
5.02
2 ¦  u nj jj TRnf
     
                                                              
 
 
24 | P a g e  
 
2.9 HPLC analysis  
 The release of INM and FMT was determined by using HPLC, Agilent Technologies 
system 1200 series. A HYCHROME S50DS2-4889 (5 µm x 150 mm x 4 mm) column was used 
for both active substances. The wavelength was set at 260 nm and 267 nm for INM and FMT 
respectively. The mobile phase consisted of methanol/water/acetic acid (64/35/1 by volume) and 
the flow rate was maintained at 2 ml/min and the retention time was 4-5 min. For INM and FMT 
calibration curves (R2 = 0.999) were prepared with concentrations varying from 10 µg /ml to 50 
µg/ml and 20 µl injection volumes. 
3.0 Results and Discussion 
3.1 Miscibility studies by calculating solubility parameters (į) 
The estimation of the solubility parameters (į) was used to predict the miscibility of the 
active substances and the polymeric carriers [12,25,26]. Calculated solubility parameters indicate 
the probability of a drug molecule to be miscible with a large polymer molecule. In the 
calculation of solubility parameters three different forces are considered. It is believed that the 
compounds with similar values for solubility parameters are likely to be miscible because the 
miscibility is caused by balancing the energy of mixing released by inter molecular interactions 
between the components and the energy released by intra molecular interactions within the 
components [27]. The Hansen three dimensional solubility parameters are calculated by group 
contributions of dispersion forces, polar forces and hydrogen bonding forces using the Van 
Krevelen/Hoftyzer (1976) method [25]. 
The estimated solubility parameters are depicted in Table 2.2 and it can be seen that for 
all drug ± SRO\PHUFRPELQDWLRQVWKHǻįYDOXHVYDU\from 3.2 ± 5.2 MPa0.5 as derived by the Van 
Krevelen/Hoftyzer approach. Greenhalgh [26] classified compounds according to their difference 
in solubility parameters. The authors found out that compounds with a ǻį < 7 MPa0.5 were likely 
to be miscible, but lLNHO\WREHLPPLVFLEOHZLWKDǻį >10 MPa0.5. Since the determined solubility 
parameter differences between each drug and polymer are less than 7 MPa0.5, all three polymers 
are likely to be miscible with both of the APIs. Interestingly the ǻįYDOXHVIRU,10 and the two 
vinylpyrrolidone copolymer grades are slightly different although both appear to be miscible. 
This was attributed to the different molecular weights and the degree of cross ± linking of the 
two polymers. Similar differences can be observed for FMT and the vinylpyrrolidone 
copolymers. 
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Furthermore, by means of thermodynamic considerations Bagley et al.[24] concluded that 
WKH HIIHFWV RI įd DQG įp show close similarity and so introduced the combined solubility 
SDUDPHWHUįv, where  
)3.2(22 pdv GGG      
7KHSDUDPHWHUIRUFRPSRQHQWVRILQWHUPROHFXODUK\GURJHQERQGLQJįh and the combined 
parameter įv are plotted in a diagram to project the three-dimensional solubility parameter space 
into a two-dimensional plot which is called Bagley diagram (Fig. 2.1).  
 
Fig. 2.1: Location of polymers (open symbols) and APIs (closed symbols) within the Bagley 
plot. 
The two ± dimensional approach through plotting the Bagley diagram can provide more 
accurate prediction of the drug ± polymer miscibility. The drug polymer miscibility can be 
predicted by the distance (Ra(v)) using the Pythagorean theorem in the Bagley diagram and the 
two components are likely to be miscible when Ra(v) 03D0.5 [28]. Where 
 
        
)4.2(])()[( 212212)( hhvvvaR GGGG   
 
Only small differences can be observed for FMT and INM and all three polymers where 
the Ra(v) values are less than 5.6MPa0.5 suggesting again drug ± polymer miscibility for each 
formulation (Table 2.2). The estimated Ra(v) value for the FMT/VA64 is 5.87 MPa0.5 suggesting 
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immiscibility of the two components. However, the difference from the value given by Albers 
(2008) is marginal and the components were considered miscible.  
 
Table 2.2: Calculated solubility parameters of drug/polymers and compound distances in Bagley 
diagram. 
Sample 
įd 
(MPa0.5) 
įp 
(MPa0.5) 
įv 
(MPa0.5) 
įh 
(MPa0.5) 
įaverage 
(MPa0.5) 
¨į(INM) 
(MPa0.5)
 
¨į(FMT) 
(MPa0.5)
 
Ra(v) 
INM 
(MPa0.5) 
Ra(v) 
FMT 
(MPa0.5) 
INM 18.99 7.37 20.34 10.34 22.84 - - - - 
FMT 11.93 15.00 19.17 13.49 23.44 - - - - 
VA64 18.0 0.64 18.01 7.73 19.60 3.24 3.84 3.49 5.87 
SOL 15.14 0.45 15.15 12.18 19.43 3.41 3.99 5.54 4.23 
S630 13.0 8.80 15.70 9.17 18.18 4.66 5.26 4.79 5.54 
 
Nevertheless, both approaches confirmed the miscibility of the binary mixtures for all 
formulations. It is worth mentioning that the manufacturing of solid dispersions via HME 
depends also on the processing parameters such as temperature profile and screw rotation speed 
which are not taken into account in the estimated solubility parameters by Van Kreveln/Hoftyzer 
or Bagley. Thus, further process optimization is required for the manufacturing of solid 
dispersions in order to increase drug solubility.  
As can be seen in Table 1, no plasticizer was incorporated in the binary mixtures due to 
low glass transition temperatures of the selected polymers. All formulations were easily extruded 
at temperatures around 120oC even at high drug loadings. 
 
 
[Please see supplementary chapter 10, section 10.2 for examples of the calculation of 
solubility parameters of different drug and polymers by using Van Krevelen/ Hoftyzer equation] 
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3.2 Particle size morphology and particle size analysis 
SEM was used to examine the surface morphology of the drug and extrudates. The 
particle morphology of INM and FMT is illustrated in Fig 2.2. The particles size range for all 
extruded materials varied from 50-200µm after optimizing the milling process. The extrudates 
containing SOL, VA64 and S630 exhibited no drug crystals on the extrudate surface at 20 and 
40% drug loading with INM. Similarly, no FMT crystals were observed on the surface of 
polymeric extrudates at all drug concentrations.  
 
Fig. 2.2: SEM images (magnification x 500) of extruded formulations: (a) SOL/INM 20% (b) 
SOL/INM 40% (c) FMT/VA64 20% and (d) FMT/S630 20%. 
The particle size distribution (depicted in Fig. 2.3) shows particle sizes lower than    500 
µm for most formulations ranging from 40 ± 400 µm. A small percentage can be seen at sizes 
<40 Ǎm as the milling process was optimized to reduce fines in the final extruded batches. 
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Fig. 2.3: Particles size distribution of extruded formulations after milling (5 min; 400 rpm): (a) 
INM/SOL 20-40%, (b) FMT/SOL 20-40%, (c) INM/VA64 20-40%, and (d) INM/S630 20%, 
FMT/S630 20%. 
3.3 X-ray powder diffraction (XRPD) 
The drug ± polymer extrudates (E), including pure drugs and physical mixtures (PM) of 
the same composition were studied by X±ray analysis and the diffractograms were recorded to 
examine INM and FMT crystalline state.  As can be seen from Fig. 2.4a ±b  the diffractogram of 
pure INM and FMT showed distinct peaks at 10.17, 11.62, 17.02, 19.60, 21.82, 23.99, 26.61, 
șDQG
șUHVSHFWLYHO\$VVKRZQLQ)LJ2.4a, the physical mixtures of all INM formulations showed 
identical peaks at lower intensities suggesting that both drugs retain their crystallinity at loads of 
20 ± 40%. In contrast, no distinct intensity peaks were observed in the diffractograms of the 
extruded formulations even at high drug loadings. The absence of INM and FMT intensity peaks 
indicates the formation of a solid dispersion where the drugs are present in amorphous state or 
molecularly dispersed into the polymer matrix. 
 
29 | P a g e  
 
 
 
Fig. 2.4a: Diffractograms of INM formulations: pure INM (inset), (a) INM/S630 20% PM (b) 
INM/SC30 20% E (c) INM/ SOL 20% PM (d) INM/SOL 20% E (e) INM/SOL 40% PM (f) 
INM/SOL 40% E (g) INM/VA64 20% PM (h) INMO/VA64 20% E (i) INM/VA64 40% PM (j) 
INM/VA64 40% E (milling time 5 min at 400 rmp). 
 
 
The diffraction patterns of all FMT physical mixtures exhibited crystalline peaks    (Fig. 
2.4b) with reduced intensities corresponding to FMT. Similar to INM the diffractograms of the 
extruded FMT formulations were characterized by the absence of drug intensity peaks indicating 
amorphous or molecularly dispersed state.  
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Fig. 2.4b: Diffractograms of FMT formulations: pure FMT (inset), (a) FMT/S630 20% PM (b) 
FMT/S63020% E (c) FAM/SOL 20% PM (d) FMT/SOL 20% E (e) FMT/SOL 40% PM (f) 
FMT/SOL 40% E (g) FMT/VA64 20% PM (h) FMT/VA64 20% E (milling time 5 min at 400 
rmp). 
 
3.4 Differential Scanning Calorimetry (DSC) 
DSC was used to determine the solid state of both drugs, within the extruded 
formulations and compared with those of the physical mixtures. The DSC thermograms of pure 
INM and FMT showed sharp melting endothermic peaks at 162°C SRO\PRUSKLF IRUP Ȗ and 
&UHVSHFWLYHO\ZLWKDIXVLRQHQWKDOS\ǻ+RIDERXW-JDQG-J)LJ2.5a). 
Modulated temperature DSC (MTDSC) was used to analyse reversible heat flow of the pure 
polymers where amorphous SOL, VA64, and S630 exhibited glass transitions (Tg) at 68.7, 105.0 
and 105.5°C (Fig. 2.5a), respectively. As can be seen in Table 2.3 all drug ± polymer physical 
mixtures exhibited melting peaks of INM and FMT at lower temperatures and UHGXFHG ǻ+
values as the ratio of carrier increased.  
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However, the DSC thermograms of the PM showed broad endothermic transitions from 
127-163oC and 124-151oC that correspond to INM and FMT, respectively (Fig. 2.5 b-e). The 
absence of sharp melting endotherms in the active formulations suggests that both drugs are 
partially dissolved in the melted polymers. 
 
Fig. 2.5a: MTDSC thermograms of pure polymers and drugs. 
 
In the case of INM/VA64 extrudates, a single Tg was observed for both loadings 
indicating drug ± polymer miscibility. When the two components are miscible the Tg of the 
extruded sample should, according to the Gordon ± Taylor equation [29] be between their Tgs. 
For INM 20% and 40% loadings, the Tgs were lowered to 56.2oC and 57.2oC, respectively 
denoting INM ± VA64 miscibility. The INM glass transition temperature has been previously 
estimated at 42.3oC. The presence of a single Tg for the INM/VA64 extrudates suggests the 
presence of a glassy solid solution where INM is molecularly dispersed within the polymer 
matrices.  
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Table 2.3:  DSC thermal transitions for drugs, polymers and active formulations. 
Formulations Glass transition  
(oC) 
Melting endotherm 
(oC) 
Enthalpy 
ǻ+-J-1) 
INM - 162.0 109.6 
FMT - 165.5 158.5 
SOL 68.7 -  
VA64 105.0 -  
S630 105.5 -  
Physical mixtures (PM) and extruded formulations (EF) 
 PM EF PM Enthalpy EF 
ǻ+-J-1) 
INM/SOL 20% 60.6 52.7 162.4 2.1 
INM/SOL 40% 60.6 51.7 154.6 2.3 
INM/ VA64 20% 56.2 55.4 131.8 1.6 
INM/ VA64 40% 57.2 55.2 127.4 2.5 
INM/S630 20% 70.8 56.6 130.8 2.1 
FMT/SOL 20% 60.4 49.6 150.9 2.0 
FMT/SOL 40% 60.2 48.5 155.3 1.6 
FMT/VA64 20% 55.3 53.9 124.3 2.0 
FMT/S630 20% 69.2 51.9 143.8 1.4 
 
In addition, the determined Tg values (Fig. 2.5b) showed plasticization effect for INM as 
Tg decreased with increase in drug concentration.  
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Fig. 2.5b: DSC thermograms of INM and VA64 (physical mixtures and extrudates). 
 
This phenomenon was also observed for INM/SOL extrudates where a single Tg was 
detected at 52.70oC and 51.71oC for 20% and 40% INM loadings as shown in Fig. 2.5c. Both 
Tgs were found between the INM and polymer Tgs indicating the presence of molecularly 
dispersed INM. 
 
Fig. 2.5c:  DSC thermograms of INM and SOL (physical mixtures and extrudates). 
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By comparing the Tgs at different loadings, INM showed a plasticization effect for 
Soluplus. By analyzing the thermograms of the INM/S630 extrudates (Fig. 2.5d) it was 
concluded that INM was also molecularly dispersed in the carrier due to the single Tg at 56.57oC 
and the absence of the drug melting endotherm.  
 
Fig. 2.5d: DSC thermograms of INM and FMT with Plasdone S630 (physical mixtures and 
extrudates). 
 
Further evaluation of the DSC thermograms for the FMT ± polymer extrudates confirmed 
the existence of glassy solid solutions for all formulations. For each binary mixture only a single 
Tg was observed without any endothermic peak related to FMT (Fig. 2.5e). The Tgs of 
FMT/SOL at 20% and 40% loadings were detected at 49.55oC and 48.54oC respectively 
suggesting plasticization effect of FMT. In contrast, the thermograms of physical mixtures 
showed distinct FMT melting endotherms shifted at lower temperatures.  
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Fig. 2.5e: DSC thermograms of FMT and SOL (physical mixtures and extrudates). 
3.5 In vitro dissolution studies 
The dissolution profiles of INM and FMT from SOL, VA64 and S630 extruded (EXT) 
granules are shown in Fig. 2.6a- b. The dissolution rates of pure APIs were also investigated to 
signify the increase of the dissolution rates of the extruded formulations.  
Due to its low water solubility, the bulk INM powder showed very slow dissolution rates 
up to 5% within five hours. In contrast, the dissolution profiles of INM extruded formulations 
exhibited enhanced dissolution rates compared to the bulk INM powder as shown in Fig 2.6a. 
The extrudates of SOL, VA64 and S630 polymers at 20% INM loadings exhibited increased 
dissolution rates with 30 ± 40% released in 120 min and 55 ± 70% in 300 min. SOL  showed 
slightly increased released rates compared to VA64 and S630 without significant differences as 
shown by a Kruskal ± Wallis nonparametric test (p>0.05) (GraphPad, InStat, Software, US). 
Interestingly, the INM loading level was shown to have an effect on the dissolution rates. The 
drug dissolution rate at high drug loadings tended to increase with an increase in the INM level. 
This phenomenon was attributed to the plasticization effect of INM on VA64. Therefore, at 40% 
INM loading the drug release rate of INM/SOL and INM/VA64 granules was 55±65% in 120 
min and 75±80% in 300 min.  
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Fig. 2.6a: Drug release profile of pure INM, INM/SOL 20%, INM/VA64 20%, INM/S630 20%, 
INM/VA64 40% and INM/SOL 40% EXT. 
 
FMT demonstrated low dissolution rates with about 22% released  in 300 min whereas 
FMT/SOL 20% and FMT/VA64 20% presented about six times faster dissolution rates 
compared to pure API with more than 70% released within 120 min (Fig. 2.6b). The FMT/S630 
20% extrudates showed slightly lower dissolution rates compared to the other formulations but 
significantly higher than the pure active substance.  
 
Fig. 2.6b: Drug release profiles of pure FMT, FMT/VA64 20%, FMT/SOL 20% and FMT/S630 
20% EXT. 
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Nevertheless, more than 80% FMT was released from all drug/polymers formulations 
after 300min. Similar to INM the FMT/SOL granules at 40% loading showed faster dissolution 
UDWHVWRWKHORDGLQJZKLFKZDVDWWULEXWHGWRWKHGUXJ¶VSODVWLFL]DWLRQHIIHFW 
Furthermore, the difference of the release profiles of different formulations was 
investigated by calculating the similarity factor (f2). According to the FDA guidelines, release 
curves are considered similar when the calculated f2 is 50±100 [30]. The formulation containing 
pure APIs differs significantly from that of the active extruded formulations as all of the 
calculated f2 values fall into 10-20.07 range (Table 2.4). 
 
Table 2.4: Similarity factor (f2) for comparing release curves with respect to drug loading of 
INM and FMT formulations 
Formulations Difference Factor (f2) 
INM FMT 
INM/S630 20% 18.67 - 
INM/VA64 20% 20.07 - 
INM/VA64 40% 13.48 - 
INM/SOL 20% 17.91 - 
INM/SOL 40% 12.10 - 
INM PURE Ref - 
 
FMT/S630 20% - 17.27 
FMT/VA64 20% - 12.72 
FMT/SOL 20% - 11.63 
FMT/SOL 40% - 10.09 
FMT PURE - Ref 
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4.0 Conclusions 
In the current chapter HME processing was employed as a means to increase the 
dissolution rates of two water insoluble drugs. INM and FMT were extruded with SOL, VA64 
and S630 at different loadings up to 40% without the presence of traditional plasticizers. The 
extrusion process was optimized to produce amorphous solid dispersions of the drug substances. 
Further physico-chemical characterization studies confirmed the theoretical drug ± polymer 
miscibility for all binary mixtures as predicted by Greenhalgh and Bagley approaches. In 
addition, INM and FMT demonstrated plasticization effects and were found to be molecularly 
dispersed within the polymer matrices. Increased aqueous solubility was observed in both APIs 
mixtures with all three polymers and the extruded solid dispersions resulted in greater 
dissolution rates over the bulk drugs.  
Therefore, through the appropriate selection of a polymeric carrier solid dispersions of 
both INM and FMT can be prepared by hot-melt extrusion to improve the dissolution properties 
of the poorly water-soluble drugs.  Further work is warranted to determine whether the oral 
bioavailability of INM/FMT is increased for the solid dispersions with enhanced dissolution 
characteristics. 
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CHAPTER 3: DEVELOPMENT AND EVALUATION OF ORALLY DISINTEGRATING 
TABLETS (ODTS) CONTAINING IBUPROFEN GRANULES PREPARED BY HOT-
MELT EXTRUSION 
1.0 Introduction 
The development of oral disintegrating tablets (ODTs) has received increased interest 
among researchers and pharmaceutical industries over the last decade. ODTs are designed to 
disintegrate or dissolve rapidly on contact with saliva, in the absence of additional water, 
compared to the traditional tablet forms. ODTs provide several advantages as they combine the 
properties of both liquid and conventional tablet formulations [1±2]. ODTs are quickly ingested 
upon introduction on the tongue, thus eliminating the need to chew the tablet, swallow it intact, 
or take with water. Furthermore, administration of ODTs is favourable to paediatric and geriatric 
patients or people who find swallowing difficult and for the treatment of patients where 
compliance is difficult.  
However, as a result of the rapid ODT disintegration, the active substance comes in 
contact with the taste buds and the need for a pleasant taste becomes a key aspect for patient 
palatability. Thus the taste-masking of bitter active substances is a critical hurdle to overcome 
for the successful development of ODT formulations. In general, oral administration of bitter 
active substances through ODT formulations should provide an improved degree of palatability, 
increased patient compliance and a concomitantly beneficial therapeutic effect.  In the past, the 
methods of taste-masking in fast dissolving/disintegrating tablets included sweeteners and 
flavors. Nevertheless, these additives were not a sufficient means for complete taste-masking.  
Recent advances in technology have presented viable fomrulation alternatives to taste-mask 
bitter drugs. Several approaches have been reported which involve complexation [3, 4], freeze-
drying [5], microencapsulation [6, 7], fluidized-bed coating [8,9] and supercritical fluids [10, 11] for 
taste-masking purposes.  
 Hot-melt extrusion (HME) is widely used in the pharmaceutical industry as a process to 
prepare drug delivery systems such as granules, pellets, sustained release tablets and even 
transmucosal/transdermal systems. Among the other applications HME has been used to increase 
the bioavailability of water insoluble active substances [12 ± 14] by creating molecular dispersions. 
There are a few studies reported where ibuprofen (IBU) extrudates were prepared by HME using 
various polymeric matrices [15 ± 18] to obtain a powdered material. However, in these studies, IBU 
formulations were developed to provide sustained release profiles. Recently, hot-melt extrusion 
was introduced as an alternative taste masking technique [19] where, for example, anionic active 
substances can interact with the functional groups of positively charged polymers. These 
42 | P a g e  
 
interactions facilitate the creation of hydrogen ERQGLQJDQGFRQVHTXHQWO\PDVNWKHDFWLYH¶VELWWHU
taste.  
The aim of this study was to increase IBU dissolution rate and to incorporate the taste 
masked granules produced into robust ODT formulations. IBU is a well-known and widely used 
nonsteroidal anti-inflammatory drug (NSAID) with <1 mg/ml water solubility at room 
temperature (25oC) [20] $W SUHVHQW ,%8¶V RYHU-the-counter ODTs are marketed as Nurofen® 
(Meltlets) to treat migraine, headache and rheumatic/muscular pain.  
Here we report the development of an orally disintegrating tablet developed by HME of 
IBU-methacrylic pH-sensitive copolymer (EUDRAGIT® EPO) mixtures and the evaluation of 
the ODTs produced. To evaluate taste a sensory test was implemented using 10 healthy 
volunteers, which revealed significant taste-masking of the active in the formulations developed. 
For the development of ODTs the effect of the amount of superdisintegrant(s) on ODT hardness, 
friability and disintegration times were assessed in order to identify the optimum formulation. 
The use of superdisintegrants is a well known approach to formulate ODTs [2] where the 
physicochemical nature of the disintegrant determines the disintegration mechanism and 
consequently affects the disintegration times.  
 
2.0 Materials and methods 
2.1 Materials 
Ibuprofen (IBU) was purchased from Shasun Chemicals & Drugs Ltd. (London, UK) . 
Eudragit EPO polymer was kindly donated from Evonik Pharma Polymers (Darmstadt, 
Germany). Crospovidone (Polyplasdone XL10), croscarmellose, (Vivasol, JRS Pharma, 
Rosenberg, Germany), crosslinked polyvinylpyrrolidone (Kollidon CL and CL±SF, BASF, 
Germany) Pearlitol C160 (Roquette, France), Microcrystalline cellulose (Avicel 102, FMC), 
sodium stearyl fumarate (PRUV, JRS Pharma, Rosenberg, Germany), calcium hydrogen 
phosphate dehydrate (Emcompress, JRS Pharma, Rosenberg, Germany) were also donated and 
used as tablet excipients. SiO2 and MgSt were purchased from Sigma Aldrich, UK. Nurofen® 
Hotmelts Lemon with 200 mg taste masked IBU were purchased from Boots UK Ltd. for the 
comparative studies. The HPLC solvents were analytical grade and purchased from Fisher 
Chemicals (UK). Artificial saliva (pH 5.8) was used as a solvent medium in order to simulate 
oral disintegration. All materials were used as received.  
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2.2 Hot-Melt extrusion 
Hot-melt extrusion was carried out using a 18 mm Leistritz twin-screw extruder. Screws 
were co-rotated at a speed of 200 rpm; the temperature applied was 140°C. At this temperature, 
dissolution of the IBU in the polymer occurred. The drug-excipients composition consisted of 
IBU/EPO/Talc and IBU/EPO/Talc at a ratio of 25/25/50 and 50/40/10(% wt/wt). The extrudates 
were collected as strands with diameter of approximately 1.5 mm and milled under cryogenic 
milling (Retsch ZM 200 Ultracentrifugal, Germany) conditions (6000 rpm, 10 min) to obtain the 
final taste-masked granules.  
 
2.3 Particle size distribution measurements 
The particle size distribution of the produced IBU granules was measured by dry sieving. 
The method involved stacking of the sieves on top of each other and then placing the test powder 
(100 g) on the top sieve. The nest of sieves was subjected to a standardised period of agitation 
(20 min) and then the weight of the material retained on each sieve was accurately determined to 
give the weight percentage of powder in each sieve size range.  
 
2.4 Tablet preparation 
Development batches were prepared using batch sizes of 200 g. All materials were passed 
through a mesh sieve with an aperture of 800µm before use. The batches were blended with 
sodium stearyl fumarate (0.5%) in a Turbula TF2 mixer (Basel, Switzerland) for 5 minutes. 
Blends were directly compressed on a Flexitab trilayer tablet press (Oystar - Manesty, 
Germany) using 13 mm normal flat punches. Dwell time was set at 30 ms and the compaction 
force varied from 4-12kN.  
 
2.5 Flow properties and compressibility 
Compressibility index I &DUU¶V LQGH[ values of the different formulations were 
determined by measuring the tapped bulk and poured bulk volumes of the powders after 
subjecting to 100 taps in a graduated measuring cylinder using the following equation [21]: 
 
)1.3(100)1( u 
oV
VI
  
V is the freely settled volume of a given mass of a powder and Vo is the tapped volume of the 
same mass of powder. 
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2.6 Evaluation of tablets 
The prepared tablets were evaluated for the uniformity of thickness, hardness (Erweka TBH 
28, Frankfurt, Germany), friability (Erweka friabilator, model A3R, Frankfurt, Germany), and 
disintegration time (Erweka, model ZT4, Heusenstamm, Germany) according to USP22 
tests/2010. The diametral compression test defined by Fell and Newton [22] was used to 
determine the tensile strength T, using the formula:  
     
)2.3(2
Dt
PT S       
Where P (kP) is the applied stress, D (cm) is the diameter of the tablet, and t (cm)  is the tablet 
thickness. Three tablets from each batch were subjected to tensile strength determination.  
The solid fraction (SF) and porosity (ſ ZHUHFDOFXODWHGEDVHGRQWKHWUXHGHQVLW\ȡtrue), tablet 
volume (v), and tablet weight (Wt) as below [23]: 
)3.3(XU u true
twSF
   
    
)4.3(1 SF H
  
2.7 In vitro tablet disintegration test 
The tablet disintegration test was carried out using a TA-XDPlus texture analyzer (Stable 
Micro Systems) similar to a recent study [24]. The apparatus was calibrated with a 5 kg load cell 
and fitted with a flat-bottomed cylindrical stainless steel probe (P/25, 12mm in diameter and 
25mm in height).  In summary, the completely dry tablet is placed on the perforated grid and it is 
not in contact with the disintegration medium. The probe descends until a trigger force is 
detected where it gets in contact with the tablet placed on the grid and pushes the whole system 
downwards. The tablet then touches the medium and starts disintegrating. At this point, the TA 
apparatus is set to maintain a predetermined nominal force (50 g) for a given period of time (60 
s). For all the disintegration studies artificial saliva (pH 5.8) was used as a solvent medium in 
order to simulate oral disintegration. 
 
2.8 In vivo tablet disintegration and bitterness evaluation 
In vivo disintegration and taste masking evaluation was performed on 10 healthy human 
volunteers [25, 26] from whom informed consent was first obtained (approved by the Ethics 
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Committee of the University of Greenwich). The study is also in accordance with the Code of 
Ethics of the World Medical Association (Declaration of Helsinki). The healthy volunteers of 
either sex (age 18±25) were selected, trained and one tablet was held in the mouth after rinsing 
and the time required for complete disintegration of the tablet was recorded. The time when the 
tablet placed on the tongue disintegrated without leaving any lumps was taken as the end point.  
The disintegrated material was held in the mouth for another 60 seconds, and then spat out. The 
mouth was rinsed with water without swallowing the disintegrated material and, finally, the 
roughness levels were recorded on a numerical scale ranging from 0 to 3 where 0, 1, 2, and 3 
indicate no, slight, moderate, and high roughness, respectively. 
The equivalent of 200 mg of pure IBU was held in the mouth for 10 seconds and then spat out, 
and 1 ODT (containing equal amounts of IBU) was held in the mouth until complete 
disintegration (three tablets per trained volunteer). Bitterness was recorded immediately and at 
several intervals for 15 minutes according to the bitterness intensity scale from 0 to 3 where 0, 
0.5, 1, 2, and 3 indicate no, threshold, slight, moderate, and strong bitterness.  
 
2.9 Differential scanning calorimetry (DSC) 
The physical state of the pure drugs and the coated granules were examined by differential 
scanning calorimetry (DSC). The thermographs of each powder were obtained by using a 
Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter. Samples 
accurately weighed (2-3 mg) were placed in pierced aluminium pans and heated from 20 to 
260qC at a scanning rate of 10 qC min-1 in a nitrogen atmosphere. 
 
2.10 X-ray powder diffraction 
Samples of pure and loaded IBU were evaluated using a Bruker D8 Advance in theta-theta 
mode, Cu anode at 40 kV and 40 mA, parallel beam Goebel mirror, 0.2 mm exit slit, LynxEye 
Position Sensitive Detector with 3 degree opening and LynxIris at 6.5 mm, sample rotation at 
15rpm. The sample was scanned from 5 to 45o 2-theta with a step size of 0.02 degrees 2-theta 
and a counting time of 0.2 seconds per step; 176 channels active on the position sensitive 
detector making a total counting time of 35.2 seconds per step. 
 
2.11 In vitro drug release studies 
In vitro drug release studies were carried out in 750 ml of 0.1 M hydrochloric acid  for 2 hr 
using a Varian 705 DS dissolution paddle apparatus (Varian Inc. North Carolina, US) at 100 rpm 
and 37 ± 0.5oC. After 2 hr operation, 250 ml of 0.20 M solution of trisodium phosphate 
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dodecahydrate were added into the vessel (buffer stage, pH 6.8) that has been equilibrated to 37 
°C. At predetermined time intervals samples were withdrawn for HPLC assay. All dissolution 
studies were performed in triplicate 
2.12 HPLC analysis 
The amounts of released IBU were determined by HPLC. An Agilent Technologies system 
equipped with a NUCLEODUR® &3\UDPLGȝP[P[ mm column at 254 nm was 
used for the IBU HPLC assay. The mobile phase consisted of acetonitrile/water (1% acetic acid) 
(50:50, v/v). The flow rate was 1.0 ml/min and the retention time of IBU was 6.0 minutes. The 
IBU calibration curves (R2=0.999), at concentrations varying from 10 µg/ml to 200µg/ml, were 
used to evaluate all the samples with 10µl injection volume. 
 
3.0 Results and discussion 
3.1 Hot-melt extrusion process 
  The HME process was conducted at 140oC to produce smooth extrudates at two different 
IBU loadings of 25 and 40%. The Eudragit® EPO is an amorphous copolymer based on 
dimethylaminoethyl methacrylate and neutral methacrylic esters with a low glass transition 
temperature of 48.6oC [27].  Eudragit® EPO was chosen as the primary matrix-forming polymer 
due to its cationic nature that could facilitate drug-poO\PHU LQWHUDFWLRQV ,Q DGGLWLRQ (32¶V
solubility in gastric media up to pH 5 renders it an excellent carrier in order to provide 
immediate release of the active substance. Finally EPO is extremely thermally stable to 
withstand the HME process. For the purposes of the study no plasticizer was used as IBU has 
been found to present plasticising effects compared to traditional plasticizers [28]. Usually, 
plasticizers are low molecular weight compounds that convert rigid polymers into flexible ones 
by reducing their glass transition temperature. IBU has shown concentration-dependent 
plasticizing properties as it is homogenously dispersed on a molecular level in the ethylcellulose 
matrix by creating hydrogen bonding. However, it was important to add an anti±tacking agent 
such as talc to avoid tackiness of the EPO polymer.  
The tackiness of acrylic polymers increases with the amount of plasticizer and in this case with 
the IBU amount due to the softening of the polymer [29]. This effect is eliminated by adding the 
appropriate talc amounts. The extruded materials still presented some tackiness and thus 
micronization was carried out under cryogenic milling conditions. The particle size distribution 
obtained is depicted in Fig. 3.1 and shows low percentages of fine particles with only 4.5 % 
below 40µm. Similarly, a small particle fraction of 5% was observed between 400-500µm. The 
majority of the particles lay in the size range of 100-400µm.  
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The PM of formulation II (40% IBU) showed exactly the same comparable peaks with 
that of the pure drug (Fig. 3.2) indicating no drug-polymer interaction while IBU retains its 
crystallinity. In the diffractogram of Formulation I (25% IBU) only three intensity peaks could 
be identified at 9.43o, 18.80o, 28.57o 2 theta values, all of them belonging to talc. The 
characteristic IBU peaks disappeared indicating the presence of an amorphous state of IBU and 
possible drug-polymer interactions. 
 
Fig. 3.1: Particles size distribution of micronized IBU/EPO (40% loading) extrudates (Milling 
time 10 min at 6000 rmp). 
 
The IBU/EPO extrudates, including the physical mixture (PM) of the same composition and 
the pure active, were studied by X ±ray analysis. The diffractograms were recorded to examine 
the IBU crystallinity. As can be seen from Fig. 3.2,  the characteristic IBU intensity peaks could 
be identified at 6.03o, 12.09o, 16.48o, 17.55o, 18.75o, 20.02o, 22.13o, 24.47o, 24.99o șGHJUHHV 
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Fig. 3.2: X-ray diffraction patterns of pure IBU, physical IBU/EPO mixture and extruded 
IBU/EPO granules, respectively. 
 
When IBU was processed at 40% loading, no significant peaks were apparent in the 
diffractogram indicating amorphous IBU even at high drug loadings.  The diffractograms did not 
present any changes after one year storage and no IBU re±crystallization was observed. DSC 
was also used to study the IBU state within the EPO matrix. In Fig. 3.3 the IBU melting point 
was determined at 77.36oC and at 76.69oC for the physical mixture. The shift of the melting 
SRLQW LV DWWULEXWHG WR WKH ,%8¶V SODVWLFL]DWion effect. For the physical mixture the EPO glass 
transition temperature was unchanged at 54.97oC in comparison to the pure EPO (54.83oC). The 
thermogram of extruded IBU/EPO (40% loading) showed the absence of IBU melting and the 
existence of a single glass transition, Tg. In fact, Tg was lowered at 29.49oC clearly indicating 
that EPO has been plasticized by the IBU. The presence of a single Tg confirms the complete 
miscbility of IBU/EPO and the creation of a glassy solution where IBU is molecularly dispersed 
within EPO [27, 30].  
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Fig. 3.3: DSC thermograms of pure IBU, physical IBU/EPO mixture and extruded IBU/EPO 
granules, respectively. 
 
The IBU/EPO interactions and the existence of molecularly dispersed IBU have been 
confirmed by FTIR studies elsewhere [31]. The FT-IR findings elucidated a possible taste 
PDVNLQJ PHFKDQLVP DWWULEXWHG WR WKH LQWHUPROHFXODU LRQLF LQWHUDFWLRQV EHWZHHQ WKH ,%8¶V
IXQFWLRQDOFDUER[\OLFDQG WKH(32¶VGLPHWK\ODPLQRJURXSV ,%8FDQDFWDVDK\GURJHQGRQRU
with the hydrogen bonding acceptor dimethylamino group. The deprotonation of the -COOH 
facilitates the formation of a carboxylate salt and consequently builds a taste masking effect on 
the molecularly dispersed IBU. 
 
3.2 Powder and ODTs characterization 
The IBU/EPO extrudates (40% loading) were blended with five different superdisintegrants 
at concentrations varying from 2-20% (w/w) as shown in Table 3.1 prior to tablet compaction. 
$OOEDWFKHVZHUHFKDUDFWHUL]HGLQWHUPVRIFRPSUHVVLELOLW\E\&DUU¶VLQGH[GHWHUPLQDWLRQ7KH
excellent batch flowability and compressibility properties were attributed to the presence of 
microcrystalline cellulose, MCC, (Avicel 102), which is an excellent filler/flow-aid for direct 
compression with an average particle size of 90 µm. The addition of mannitol (Pearlitol C160) 
contributed as well to the improved tablet compressibility. 
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Table 3.1: Composition of ODT formulations 
 
IBU/Excipients 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 
(%) 
IBU*/EPO 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 
Avicel 102 12,5 10,5 8,5,0 2,5 12,5 10,5 8,5,0 2,5 12,5 10,5 8,5,0 2,5 12,5 10,5 8,5,0 2,5 12,5 10,5 8,5,0 2,5 
XL10 2,0 5,0 10,0 20,0 - - - - - - - - - - - - - - - - 
Vivasol - - - - 2,0 5,0 10,0 20,0             
XL - - - - - - - - 2,0 5,0 10,0 20,0 - - - - - - - - 
CL-SF - - - - - - - - - - - - 2,0 5,0 10,0 20,0 - - - - 
CL - - - - - - - - - - - - - - - - 2,0 5,0 10,0 20,0 
Mannitol 10,0 9,0 6,0 2,5 10,0 9,0 6,0 2,5 10,0 9,0 6,0 2,5 10,0 9,0 6,0 2,5 10,0 9,0 6,0 2,5 
Pruv 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 
 
*IBU loading was 40% 
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 As a general rule, the powder compressibility decreased when the amount of 
superdisintegrants was increased in all formulations (Table 3.2).  In many cases the presence 
of MCC (disintegrant nature) and mannitol (soluble diluents) has been reported to facilitate 
tablet disintegration. However, this was not observed in our studies as the formulations 
prepared in the absence of superdisintegrants showed high disintegration times (data not 
shown). As a result the improved disintegration times observed in this study should not be 
attributed to the existence of the aforementioned excipients.  
 
Table 3.2: Physical properties of powder blends and compressed tablets (n = 3). 
 
 F2 F6 F7 F10 F11 F13 F14 
Bulk density 
(g/cm3) 
29.00 35.00 36.30 33.70 37.30 38.30 42.30 
Tapped 
density 
(g/cm3) 
25.00 30.30 31.70 30.30 32.00 34.30 38.00 
Density 
(g/cm3) 
1.35 1.40 1.40 1.35 1.33 1.36 1.35 
&DUU¶V,QGH[ 
(%) 
13.8 13.40 12.60 10.10 14.20 10.44 10.16  
Tensile 
strength 
(kP/cm2) 
6.05 10.40 9.44  8.97 7.21 9.73 9.93    
Porosity 0.14 0.13 0.13 0.16 0.13 0.15 0.15 
 
 As is shown in Table 3.1 superdisintegrants with concentrations varying from 5-20%, 
under different compaction forces, were tested to evaluate their effect on the ODTs 
disintegration times. In general, the concentration of a superdisintegrant influences the 
relationship between the applied compaction force and the disintegration time [32]. For the 
purposes of the study four different grades of crosslinked N-Vinylpyrrolidone (XL, XL10, 
CL, CL-SF) and sodium croscarmellose (Vivasol®) were evaluated. The selected 
superdisintegrants differ in their particle size distribution, particle shape, porosity, 
compressibility, flowability and disintegration mechanism. The CL and CL-SF grades act as 
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disintegrants by absorbing water and the subsequent swelling leads to separation of the tablet 
particles. In contrast, XL10, XL and croscarmellose promote wicking via capillary action due 
to their high porosity. Subsequently, water is rapidly absorbed and disrupts the interparticular 
matrix bonds causing the tablet to fall apart [33]. 
 The superdisintegrant concentration versus the compaction force profiles in Fig. 
3.4(a-d) showed interesting results regarding the disintegration time performance of each 
superdisintegrant. At first, it can be seen that XL10 outperformed all superdisintegrants at 
low levels (2-5% wt/wt) while XL outperformed at high levels (10-20% w/w) respectively. 
The disintegration performance can be arranged in descending order for low levels as 
follows: XL10>XL>Vivasol>CL-SF>CL, while for high levels the order is 
XL>XL10>Vivasol>CL-SF>CL. For XL10 the optimum concentration level was between 5-
10% w/w with disintegration times varying between 8-20 sec while for 20% w/w 
disintegration times were increased without exceeding 60sec 2Q WKH RWKHU KDQG ;/¶V
optimum level was at 10±20% (wt/wt) showing substantial reduction to the disintegration 
times (Fig. 3.4C). The better performance of XL10 at low levels can be attributed to the 
smaller particle size of XL10 (30-50µm) compared to XL (100-130 µm) facilitating faster 
water absorbance. On the contrary, high XL10 levels led to increased disintegration times.  
Vivasol showed good disintegration times at high levels (10-20% wt/wt) and better 
disintegration times at compaction forces of 10-20 kN. Interestingly the addition of Kollidon 
CL±SF presented excellent disintegration times at concentrations of 2% w/w with 
compaction forces of 8 or 12 kN. This also could be attributed to the particles morphology 
facilitatiung faster water absorptions. 
 
 Further addition of CL ± SF amounts led to prolonged disintegration times but much 
lower than 60 sec. In contrast, the Kollidon CL grade showed poor performance for all 
concentrations and the entire range of compaction forces. This behaviour can be explained to 
some extent because of the small CL±SF (10-30µm) particle size compared to the CL grade 
(110 ± 130µm) similar to the other two crosslinked N-Vinylpyrrolidone grades (XL, XL10).  
 
 However, the different disintegration times of the five superdisintegrants are mainly 
attributed to the different disintegration mechanisms and the tablet porosities. The 
Polyplasdone (XL10, XL) and Vivasol grades posses both swelling and wicking properties. 
All the disintegration studies were carried out at pH 5.6, where these cross-linked polymers 
have similar swelling capacities (92, 90 and 85% respectively). 
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Fig. 3.4: Schematic diagram of ODT disintegration times at various compaction forces with 
a) 2%, b) 5%, c) 10% and d) 20% superdisintegrants. 
 
However, swelling is not the primary disintegration mechanism for XL10 and XL. XL10 
and XL can rapidly absorb water (wicking), due to their porous particle size morphology, and 
generate rapid volume expansion by increasing the hydrostatic pressure that causes tablet 
disintegration. In contrast, Vivasol has a fibrous non-porous particle structure which swells at 
slower rates and thus results in slower disintegration times. The Kollidon CL-SF grade has a 
fibrous particle shape (10-30 µm) and non-porous surface with swelling as the main 
disintegration mechanism.  CL-SF exhibits low swelling pressure (~25 kPa) and relatively 
increased times to reach 90% of the swelling capacity (35 sec) while CL grades exhibit high 
swelling pressure (170 kPa) and rapid swelling times (5 sec). It would be reasonable to 
expect, therefore, superior tablet disintegration times for the CL grades.  Nevertheless, CL±
SF grades present higher water uptake capacity (~7.0-8.5 g water/g polymer) to the CL 
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grades (3.5-5.5 g water/g polymer) and in combination with the smaller particle size, display 
faster disintegration times.   
 
 Fig. 3.5(a-d) depicts the tablet hardness versus the compaction force at various 
superdisintegrant concentrations and compaction forces. It can be seen that the hardness 
increased with concentrations up to 5% (wt/wt) for all superdisintegrants. When high 
disintegrant concentrations (>10% wt/wt) were used, the tablets became softer and the 
hardness decreased (except CL 20% w/w) as a result of modest compressibility. Another 
interesting observation for all disintegrants is that the hardness increased with an increase in 
the applied compaction force. The results obtained from friability studies indicate dissimilar 
behaviour for each disintegrant. For instance, Kollidon CL and Vivasol at 2-10% wt/wt 
displayed no impact of disintegrant level at 8-12 kN compaction forces but displayed high 
friability at concentrations of 20% w/w. On the other hand, XL and CL - SF showed very low 
friability at 2% levels and a slight increase from 5-20% levels.  In the case of XL10, the 
optimum friability was observed at 10% w/w levels. 
 
The rapid disintegration times described above are also related to tablet porosity as can be 
seen in Table 2. High porosity is a critical ODT parameter because it facilitates liquid 
penetration into the tablet and results in faster disintegration.  The estimated porosities for all 
ODT formulations were quite high, varying from approximately 0.13-0.16 without however 
compromising tablet mechanical properties. The hardness and friability studies demonstrated 
acceptable mechanical properties as mentioned above (Hardness about 7 Kp, friability 
<2.2%).  Nevertheless, the evaluation of the superdisintegrants at various concentrations 
listed in Table 3.1 revealed the tablet formulations with high porosity and adequate strength.  
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Fig. 3.5: Schematic diagram of ODTs hardness at various compaction forces with a) 2%, b) 
5%, c) 10% and d) 20% superdisintegrants. 
 
The ODTs friability was also investigated as a function of the superdisintegrant level 
and the applied compaction force (Fig. 6a-d). At 4 kN compaction forces, friability levels 
were very high for all superdisintegrants while at higher compaction forces of 8-12kN 
friability was significantly decreased. This is due to the compactability of the powder while 
punching the tablets. It is assumed that higher the compression forces better the hardness of 
the tablets thus lower the friability values.  
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Fig. 3.6: Schematic diagram of friability of ODTs at various compaction forces with a) 2%, 
b) 5%, c) 10% and d) 20% superdisintegrants. 
 
Analysis of the experimental findings in Figs. 3.4-3.6 allowed us to evaluate the 
robustness of the developed ODT formulations. A robust ODT should present unique features 
such as increased drug loading, taste masking, controlled release of API, rapid disintegration 
times, low friability and high crushing strength (hardness). The robustness of seven ODT 
formulations developed in the current study was evaluated in comparison to the commercial 
Nurofen® Meltlets. All tablet formulations were assessed in terms of disintegration times, 
hardness, friability, tablet weight and IBU loading. As can be seen in Fig. 3.7 the ODT 
formulations developed through HME processing presented better friability and comparable 
disintegration times to Nurofen® ODTs. 
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Fig. 3.7: Schematic diagram of ODTs disintegration times at various compaction forces with 
superdisintegrants at their optimal levels. 
 
 Interestingly, most of the ODTs developed showed relatively low hardness (2.7 - 4.0 
kP) without, however, affecting tablet friability. The Nurofen® tablets showed rapid 
disintegration times but also low hardness (4.4 kP) and high friability values.  ODTs with CL 
± SF at 2±5 % w/w proved to be robust with excellent disintegration times, hardness and 
friability. Similarly, the incorporation of XL, XL10 and Vivasol superdisintegrants produced 
high quality ODTs. An important aspect for the new generation ODTs is the capability to 
provide disintegration times of less than 30 sec without compromising tablet friability. This 
was feasible for the developed ODTs and Nurofen® tablets despite the high tablet weights 
that could possibly elevate friability levels.  
 
3.3 In vivo disintegration time and taste-masking evaluation 
The ODTs disintegration times were evaluated using the texture analyzer and in vivo 
disintegration methodologies. The average disintegration times in Table 3.3 did not reveal 
significant differences (p > 0.05) between the two approaches. The reason is that the texture 
analyzer method (artificial saliva, 37oC) simulates effectively the oral disintegration of ODTs 
providing a convenient means for accurate and reproducible determination of the 
disintegration times. 
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Table 3.3: Comparison of disintegration times of ODTs at various compaction forces (n=3).  
 
Formulations Disintegration Time  
Texture analyzer 
(sec) 
In ± vivo disintegration 
(sec) 
F2(12 kN) 11.40±0.6 13.50±1.2 
F6 (10 kN) 29.90±1.3 31.80±2.5 
F7 (10 kN) 23.90±1.2 25.20±1.8 
F10 (12 kN) 24.90±1.0 26.60±2.3 
F11 (12 kN) 17.70±0.7 19.30±2.0 
F13 (12 kN) 18.90±0.6 20.10±1.5 
F14 (10 kN) 19.80±0.9 20.60±1.8 
Nurofen® 18.40±0.9 20.30±2.0 
 
The taste-masking of the ODTs developed was of critical importance for this study. The 
embedding of the bitter IBU crystals with the EPO polymer matrix proved an efficient taste-
masking platform.  In Table 3.4 the perceived taste intensity studies in human volunteers 
VKRZHGFRQVLGHUDEOHPDVNLQJRI,%8¶VELWWHUWDVWH7KHGHJUHHRIELWWHUQHVVZDV]HURDIWHU
min for all formulations. In addition, the use of XL (10%) and CL-SF (5-10%) gave a smooth 
mouth feel. Nurofen® ODTs presented excellent taste-masking but with moderate roughness 
levels. The overall taste and sensory tablet evaluations showed excellent palatability. 
 
Table 3.4: Taste evaluation of ODTs on healthy human volunteers (average value, n=10).  
 
Formulations Degree of bitterness (DB) / roughness (DR) after time 
30 sec 1 min 2min 
 DB DR DB DR DB DR 
IBU 3 3 3 3 3 3 
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F2 0 0.5 0 1 0 1 
F6 0 0.5 0 1 0 2 
F7 0 0.5 0 1 0 2 
F10 0 0.5 0 1 0 1 
F11 0 0.5 0 0.5 0 0.5 
F13 0 0.5 0 1 0 0.5 
F14 0 0 0 0 0 0 
Nurofen® 0 1 0 1 0 2 
 
 
3.4 In vitro dissolution 
The main objectives IRU WKLV VWXG\ ZHUH WR LQFUHDVH ,%8¶V dissolution rate, achieve 
sufficient taste-masking and to provide simultaneous rapid release. The amorphous IBU state 
within the EPO polymer matrix is expected to provide increased dissolution rates.  
 
Fig. 3.8: 5HOHDVH SURILOHV RI 2'7V ZLWK ,%8(32 H[WUXGHG JUDQXOHV RI Ÿ  Ɣ
GUXJORDGLQJDQGŶ1XURIHQ 
 
 In Fig. 3.8, it can be seen that ODTs of 25% and 40% loadings of extruded IBU/EPO 
provided rapid cumulative release profiles compared to that of pure IBU. The release of pure 
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IBU has been reported 22% after 2 hrs [34]. In addition it was observed that increased IBU 
loading (40% - Formulation II) provided faster release rates in contrast to the 25% loading 
(Formulation I). This is attributed to the increased talc amounts (50%) in Formulation I. As 
mentioned earlier talc serves as an anti-tacking agent and because of its hydrophobic nature 
retards polymer hydration and the subsequent IBU release rate. Comparison of the extruded 
formulations with the Nurofen® tablets demonstrated similar release rates for 25% loading 
but a faster rate for the 40% IBU/EPO extrudates. Application of a Kruskal-Wallis non-
parametric test (p > 0.05) to the results showed no significant difference. Nevertheless, the 
HME extruded formulations showed excellent release patterns that could provide fast onset 
action in future clinical trials.   
 
4.0 Conclusions 
In this chapter we have demonstrated the manufacture of robust taste-masked IBU 
ODTs. For the purpose of the study IBU was hot-melt extruded and embedded within a 
Eudragit EPO polymer matrix. The in vivo taste-masking evaluation showed that HME 
processing can be used to mask efficiently the taste of bitter active substances without 
compromising tablet palatability. The ODTs developed showed disintegration times and 
crushing resistance similar to commercial Nurofen® tablets but improved tablet friability. 
Finally the increased IBU release rates of the developed ODTs were faster than the 
commercial Nurofen® tablets.  
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CHAPTER 4: TASTE MASKING OF PARACETAMOL BY HOT MELT 
EXTRUSION: AN IN VITRO AND IN VIVO EVALUATION 
 
1.0 Introduction 
The taste masking of bitter APIs is a major challenge especially for the development 
of orally disintegrating tablets (ODT) in pharmaceutical industry. Several approaches have 
been reported which involve fluidized-bed coating, supercritical fluids and coacervation 
approaches where effective taste-masking is achieved by applying polymeric coating layer to 
create a physical barrier around the drug [1, 2]. Other alternatives involve the use of 
complexing agents (cylcodextrins, ion exchange resins) through the formation of inclusion 
complexes or resonates [3]. Recently, taste masking approaches have employed taste 
suppressants molecules by blocking the gap junction channels ad hemichannels and thus 
suppressing the drugs taste [4,5]. However, there is an enormous need for more robust, cost 
effective and easy to scale ± up taste masking technologies. HME is a continuous, one step 
process that has been used for the development of solid dispersions of active substances for 
various applications [6, 7].  
Hot-melt extrusion (HME) has been employed as a novel technique for the 
formulation of oral solid dosage forms in pharmaceutical industries in the last decade. It was 
initially used in food and plastic industry but has attracted significant interest in the 
pharmaceutical manufacturing for the development of robust formulations. HME can be used 
to develop various formulations such as sustained release matrices [8±11]. It has also been 
introduced for taste masking purposes of bitter APIs by involving the use of taste masking 
polymers that create solid dispersions to prevent bitter drugs from coming in contact with the 
SDWLHQW¶VWDVWHEXGV[12±15].  
Taste masking can be achieved through intermolecular forces (e.g. hydrogen bonding) 
between the active substance and the polymer matrix by processing oppositely charged 
compounds [1, 2]. In addition, solid dispersions in which the drug is molecularly dispersed 
within the polymer matrix have shown effectivenes IRU PDVNLQJ RI WKH GUXJ¶V XQSOHDVDQW
taste. Successful taste masking requires development of HME processing conditions, 
drug/polymer ratio and selection of the appropriate formulation components (Hansen 
solubility parameters).  HME can be used for the development of robust formulations with 
increased patient palatability and compliance. Taste masking evaluation of pharmaceutical 
dosage forms is usually carried out by human taste panels (volunteers) and it can be used for 
further product optimization. However, the taste assessment is subject to the individuals 
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leading to significant variations while ethical, safety and toxicity issues should be also taken 
in account. Alternatively, in vitro electronic taste sensing systems can be employed to predict 
the taste of pharmaceutical formulations [3, 16, 17]. Commercially available electronic tongues 
(Astree e-tongue and INSENT sensing system) have been well studied and evaluated for taste 
masking purposes. The Astree e ± tongue (AlphaMOS, France) has been systematically used 
to evaluate the bitterness of pure active substances in comparison to formulated products. 
These e ± tongue studies showed very good correlation with human taste panels, 
reproducibility, low detection limits and high sensitivity [18].  
Paracetamol (PMOL) is a white crystalline powder with bitter taste mainly used as 
analgesic pain reliever and antipyretic. The main uses of paracetamol are the relief of 
headaches, minor aches and pains. In this study PMOL was used as a model drug for the 
purpose of taste masking. At the moment there are several over ± the ± counter products of 
orally disintegrating tablets (ODTs) where the active pharmacological agent is taste masked 
through various approaches.  
In the current study PMOL extrudates were prepared by optimizing the HME 
processing [19, 20] parameters in order to mask its taste efficiently. The extrudates were 
evaluated both by in vivo and in vitro studies where an electronic tongue analyzer was 
employed that captures the global taste profile. The electronic tongue can be a valuable tool 
for the development of pharmaceutical formulations by providing accurate and reliable taste 
patterns of the desired formulations. 
 
2.0 Materials and Methods 
2.1. Materials 
Paracetamol (PMOL) was purchased from Sigma Aldrich (Gillingham, UK). Eudragit 
EPO polymer was kindly donated from Evonik Pharma Polymers (Darmstadt, Germany). 
Crosslinked polyvinylpyrrolidone (Kollidon VA64) was also donated from BASF, Germany. 
The HPLC solvents were of analytical grade and purchased from Fisher Chemicals (UK). All 
materials were used as received.  
 
2.2. Calculation of Hansen solubility parameters 
The Hansen solubility parameters of the drug and the polymers were calculated from 
their chemical structures to check the miscibility of drug/polymer formulations using the 
Hoftyzer and van Krevelen method [21]. [Please see Chapter 2, Section 2.2 for more details] . 
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2.3. Hot-melt Extrusion (HME) process 
PMOL formulations with Kollidon VA64 and Eudragit EPO were mixed properly in 
100 g batches for 10 min each. A Turbula TF2 Mixer was used to blend the powder 
formulations for 10 min. The extrusion of all PMOL blends was performed using a 
Randcastle single-screw extruder (RCP0625) equipped with a 0.2 mm rod die. The drug-
polymers composition consisted of PMOL/EPO and PMOL/VA64 at a ratio of 40/60, 50/50, 
60/40 and 30/70, 40/60, 50/50 (% wt/wt) respectively. The temperature profile used for all 
IRUPXODWLRQVZDV&&&&&IURPIHHGLQJ]RQHĺ'LHZLWKVFUHZ
speed of 15 rmp (rev/min). The produced extrudates (strands) were milled to obtain granules 
(<500 µm). Grinding by ball milling carried out with a rotational speed of 400 rpm for 5 min 
each.  
 
2.4 Thermal analysis 
For the purposes of analysing the solid state of drug, polymers, their physical 
mixtures and the extruded formulations, differential scanning calorimetry studies (DSC) and 
temperature modulated (MTDSC) DSC were performed. The physical state of the pure drug, 
physical mixtures and extrudates was examined by using a Mettler-Toledo 823e (Greifensee, 
Switzerland) differential scanning calorimeter. Samples were prepared in sealed aluminum 
pans (2-5 mg) with a pierced lid. The samples were heated at 10oC/min under nitrogen 
atmosphere in a temperature range between 0 and 220oC. MTDSC experiments were 
performed from 30oC to 160oC temperature range with an underlying heating rate of 1oC/min 
to further analyze the samples. The pulse height was adjusted to 1oC with a temperature pulse 
width of 15-30 s. 
 
2.5 X-ray powder diffraction (XRPD) 
XRPD was used to assess the solid state of the extrudates where samples of pure and 
loaded PMOL were evaluated using a Bruker D8 Advance in theta-theta mode, Cu anode at 
40 kV and 40 mA, parallel beam Goebel mirror, 0.2 mm exit slit, LynxEye Position Sensitive 
Detector with 3 degree opening and LynxIris at 6.5 mm, sample rotation at 15 rpm. The 
sample was scanned from 2 to 40 degrees 2-theta with a step size of 0.02 degrees 2-theta and 
a counting time of 0.2 seconds per step; 176 channels active on the PSD making a total 
counting time of 35.2 seconds per step. 
 
 
67 | P a g e  
 
2.6. In vitro drug release studies 
In vitro drug release studies were carried out in 750 ml of 0.1 M hydrochloric acid  for 
2 hr using a Varian 705 DS dissolution paddle apparatus (Varian Inc. North Carolina, US) at 
100 rpm and 37 ± 0.5oC. After 2 hr operation, 250 ml of 0.20 M solution of trisodium 
phosphate dodecahydrate were added into the vessel (buffer stage, pH 6.8) that has been 
equilibrated to 37°C. At predetermined time intervals samples were withdrawn for HPLC 
assay. All dissolution studies were performed in triplicate. 
 
2.7. HPLC analysis 
The release of PMOL was determined by HPLC. An Agilent Technologies system 
equipped with a HICROM S50DS2ȝP[PP[ mm column at 276 nm was used for 
the PMOL HPLC assay. The mobile phase consisted of acetonitrile/water (1% acetic acid) 
(50:50, v/v). The flow rate was 1.5 ml/min and the retention time of PMOL was 3.6 minutes. 
The PMOL calibration curves (R2=0.999), at concentrations varying from 10 µg/ml to 50 
µg/ml, were used to evaluate all the samples with 20µl injection volume. 
 
2.8. In vivo taste masking evaluation 
In vivo taste masking evaluation was performed on 6 healthy human volunteers [22, 23] 
from whom informed consent was first obtained (approved by the Ethics Committee of the 
University of Greenwich, Ref No: UG09/10.5.5.12). The study is also in accordance to the 
Code of Ethics of the World Medical Association (Declaration of Helsinki). The healthy 
volunteers of either sex (3 males and 3 females, age 18±25) were selected, trained and the 
extruded granules were evaluated (no exclusion criteria). The equivalent of 200 mg of pure 
PMOL or PMOL extrudates (containing equal amounts of PMOL) were held in the mouth for 
60 seconds and then spat out. The selection of samples was random and in between two 
samples analysis mineral water was used tRZDVKHDFKYROXQWHHU¶VPRXWK7KHELWWHUQHVVZDV
recorded immediately according to the bitterness intensity scale from 0 to 5 where 0, 1, 2, 3, 
4and 5 indicate none, threshold, slight, moderate, bitter and strong bitterness, respectively.   
 
2.9. In vitro taste masking evaluation: Astree e-tongue 
The assays were realized on Astree e-tongue system equipped with an Alpha M.O.S. 
sensor set #2 (for pharmaceutical analysis) composed of 7 set of sensors (ZZ, AB, BA, BB, 
CA, DA, JE) on a 48-positions autosampler using 25 ml-beakers. Acquisition times were 
fixed at 120s. All the data generated on the Astree system were processed using 
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multidimensional statistics on AlphaSoft V12.3 software. Each sample (granules) was tested 
on the Astree e-tongue at least 4 times with three replicates for each sample for the statistical 
analysis. The average values between 100 and 120 s were used to build the maps. Astree 
sensors were cleaned up in deionised water between each sample measurement. Each sample 
was diluted for 60 seconds under magnetic stirring in 25 ml of deionised water to reach API 
concentration corresponding to a final PMOL dose of 200 mg. The mixtures were filtered 
with Buchner funnel fitted with filter paper of 2.5 µm pore size. 
 
3.0 Results and Discussion 
 
3.1. Solubility parameters and extrusion process 
The PMOL miscibility with EPO and VA64 was investigated prior to extrusion by 
estimating the Hansen solubility parameter using the method of Hoftyzer and van Krevelen 
for pure PMOL and both polymers. The prediction of drug/polymers miscibility in solid 
GLVSHUVLRQV KDV VXFFHVVIXOO\ EHHQ DFKLHYHG E\ WKH VROXELOLW\ SDUDPHWHUV į [24-27]. This 
miscibility is caused by balancing the energy of mixing released by inter-molecular 
interactions between the components by the energy released by intra molecular interactions 
within the components [21]. Three dimensional partial solubility parameters by Hansen (1969) 
calculated by group contributions of dispersion forces, polar forces and hydrogen bonding 
forces was provided byVan Krevelen/Hoftyzer (1976) and Fedors (1974). The theoretical 
approach of the solubility parameWHUVXJJHVWVWKDWFRPSRXQGVZLWKVLPLODUįYDOXHVDUHOLNHO\
to be miscible. The reason is that the energy of mixing from intramolecular interactions is 
balanced with the energy of mixing from intermolecular interactions. It was demonstrated 
that compounds ZLWKǻį <  7 MPa1/2 were likely to EHPLVFLEOHDQGFRPSRXQGVZLWKǻį >  10 
MPa1/2 were likely to be immiscible [28]. Thus, solubility parameters provide a simple and 
generic capability for rational selection of carriers in the preparation of solid dispersions [29]. 
As can be seen in Table 4.1, the difference between the calculated solubility parameters of 
the polymers and the drug indicate that PMOL is likely miscible with both polymers. By 
XVLQJWKH9DQ.UHYHOHQ+RIW\]HUWKHǻįYDOXHVIRU302/DQG(329$are 6.86 and 6.17 
respectively.  
However, a two dimensional approach proposed by Bagley et al. [30] was used also to 
predict drug ± polymer miscibility as shown in Table 4.1. By using the two ± dimensional 
DSSURDFK%DJOH\HWDOREVHUYHGWKDWįp DQGįd have similar thermodynamic effects in contrast 
WRįKDQGLQWURGXFHGWKHYROXPH± GHSHQGHQWVROXELOLW\SDUDPHWHUįYZKHUH 
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Table 4.1: Calculated solubility parameters of drug/polymers 
Sample 
įd 
(MPa1/2) 
įp 
(MPa1/2) 
įv 
(MPa1/2) 
įh 
(MPa1/2) 
įt 
(MPa1/2) ¨ į 
Distance 
Ra(v) 
PMOL 19.43 9.71 29.14 13.88 25.77 - - 
EPO 17.89 0.65 18.54 6.08 18.91 6.86 13.16 
VA64 18.0 0.64 18.64 7.73 19.60 6.17 12.17 
])()[( 212212)( hhvvvaR GGGG   
 
This method was further developed by Breitkreutz [31] and Albers [32] and used in 
predicting the duration of intestinal absorption for various drugs. The two±dimensional 
approach can provide more accurate prediction of the drug±polymer miscibility. The drug 
polymer miscibility can be predicted by the distance (Ra(v)) using the Pythagorean Theorem 
and the two components are condidered miscible when Ra(v) 03D1/2.   In our case it is 
obvious from Table 4. WKDW WKH įp values of the drug ± polymer combinations differ 
significantly indicating an effect on the predicted miscibility. HME quite often requires the 
addition of a plasticizer to lower the glass transition temperature of the polymers and thus to 
conduct the extrusion process at lower temperatures [6, 24]. However, plasticizers were not 
incorporated in our studies as both polymers present low glass transition temperature 
allowing samples to be processed at low extrusion temperature ranges. The absence of 
plasticizer did not affect the extrusion process.  
 
3.2. Thermal analysis and X ± ray solid state characterization studies 
DSC studies were performed to investigate the physical state of the drug within the 
polymer matrix. As can be seen in Fig. 4.1a the DSC thermogram of pure PMOL (calibrated 
by the peak onset) showed a sharp melting peak at 169oC (fusion enthalpy 33.40 J/g) with an 
onset of peak at 168oC where the amorphous EPO showed an endothermic peak at 48.4oC 
(onset 44.1oC) which corresponds to the glass transition temperature (Tg).   
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Fig. 4.1a: MTDSC thermograms of pure PMOL (inset) and Eudragit EPO, Kollidon VA64 
 
Previous studies [33±34] of pure PMOL reported the existence of three crystal forms, the 
Form III which is highly unstable (melting point at 148oC), the metastable orthorhombic 
(Form II) with melting point at 160oC and the stable monoclinic (Form I) with melting point 
at 170oC while the amorphous form has a glass transition at 23oC. The polymorphic form of 
PMOL that was used in the current study was the monoclinic Form I. The DSC scans of the 
PMOL/EPO extrudates (Fig. 4.1b) showed melting endotherms at 143.3oC, 148.5oC and 
151.5oC, respectively that correspond to 40, 50 and 60% PMOL loadings.  
 
Fig. 4.1b: MTDSC thermograms of PMOL/EPO extrudates at different PMOL loadings. 
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 The observed melting peaks are shifted to lower temperatures and the peak shapes are 
broader compared to those of pure PMOL suggesting the presence of crystalline PMOL. The 
observed melting peak of PMOL occurred between 143±152oC which is due to the presence 
of Form I PMOL in the polymer matrix. However, the shifts of the melting endothermic 
peaks can also be attributed to possible PMOL±EPO interactions without any changes in the 
crystal modifications.  The presence of Form I was confirmed by the X±ray characterization 
studies as described below. If the PMOL/EPO components are miscible the Tg of the 
extruded samples can be derived by the Gordon ± Taylor equation [35] and it will show a 
single Tg that varies between the Tg of the pure components. The EPO glass transition 
temperatures for the PMOL loaded samples (30-60%) are shifted at lower temperatures 
(45.9oC, 44.1oC, 41.7oC) and are slightly different from the estimated Gordon ± Taylor 
theoretical values at 36.0oC, 33.7oC, 31.6oC respectively. In addition, only a single Tg was 
observed for all PMOL/EPO ratios while the Tgs decreased with increase in PMOL 
concentrations showing partial drug ± polymer miscibility and PMOL plasticization effect. In 
total, the shifts of the melting PMOL peaks and EPO glass transition temperatures suggest the 
co±existence of molecularly dispersed and crystalline PMOL within the polymer matrix. 
Similar observations were reported by Qi et al. [36] for PMOL/EPO extrudates where PMOL 
was presented in two physical forms simultaneously. The calculated amorphous/crystallinity 
degrees [37] of the extruded formulations are shown in Table 4.2. It is obvious that the 
presence of crystalline PMOL is increased with the PMOL loading in each formulation.  
 
Table 4.2: Crystalline/amorphous percentage of the extruded PMOL formulations 
Formulation Amorphous 
(%) 
Crystalline 
(%) 
Tg 
(oC) 
Tm 
(oC) 
PMOL/EPO 40% 79.5 20.5 45.9 143.3 
PMOL/EPO 50% 75.5 24.5 44.1 148.5 
PMOL/EPO 60% 52.0 48.0          41.7 151.5 
PMOL/VA64 30% 100.0 - 85.8 - 
PMOL/VA64 40% 100.0 - 95.2 - 
PMOL/VA64 50% 100.0 - 93.5 - 
Tg: polymer glass transition, Tm: PMOL melting point 
 In contrast, the PMOL/VA64 extrudates showed two Tg peaks, one close to the Tg of 
bulk VA64 (105oC) and the other between 27 ± 42oC depending on the PMOL loadings.  Pure 
72 | P a g e  
 
VA64 showed a baseline shift at 105oC which is reported as Tg and there is another 
endothermic peak visible at about 200oC which correspond to decomposition of the polymer. 
As Fig. 4.1c shows the low temperature Tg is related to the PMOL loading with descending 
order of PMOL (30%)>PMOL (40%)>PMOL (50%) Æ(41.1oC, 37.7oC, 27.6oC) and are 
elevated at higher temperature in comparison to amorphous PMOL Tg (25oC). The 
transformation of PMOL from Form I to amorphous is supported by the disappearance of the 
melting endothermic peak at 169oC. As a result we could rule out the presence of molecularly 
dispersed PMOL within the VA64 matrix which can be recognised by the presence of one 
single mixed±phase Tg. In our case, the two consecutive glass transitions indicate the 
presence of amorphous mixtures and an amorphous/amorphous phase separation. This 
observation is not unusual as similar results have been observed for itraconazole/EPO100 
solid dispersions [38].  
 
Fig. 4.1c: MTDSC thermograms of PMOL/VA64 extrudates at different PMOL loadings. 
 
XRPD was employed to investigate the crystalline state of PMOL within the polymer 
matrices. The standard XRPD patterns of pure PMOL,   physical mixtures with Eudragit 
EPO, and extrudates are depicted in Fig. 4.2a.   
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Fig. 4.2a: Powder XRPD patterns of PMOL/EPO solid dispersion (SD) and physical 
mixtures (PM) systems: (a) PMOL pure (b) PMOL/EPO 60% PM (c) PMOL/EPO 60% Ext. 
(d) PMOL/EPO 50% PM (e) PMOL/EPO 50% Ext.50% (f) PMOL/EPO 40% PM (g) 
PMOL/EPO 40% Ext. 
 
Crystalline PM2/KDVGLVWLQFWFU\VWDOOLQHSHDNVDWșDQJOHVRI
    DQG  DQG D VHULHV RI VPDOOHU SHDNV DW GLIIHUHQW ș DQJOHV
ranging from 26.78-38.45°. The diffraction patterns of the physical mixtures of drug and 
polymers in three different ratios presented identical crystalline peaks to those of pure PMOL 
but at a lower intensity. The XRD patterns of extruded formulations showed increased 
amorphous trends compared to the pure PMOL due to the dispersion of the drug into the 
polymer matrix. Furthermore the diffraction patterns of all the PMOL±EPO extrudates 
confirmed the presence of Form I within the polymer matrices as no new distinct crystalline 
SHDNVDWGLIIHUHQWșFRXOGEHREVHUYHG [33]. The PMOL intensity peaks supported the DSC 
investigations where crystalline drug was detected in the binary mixtures. In contrast, for the 
PMOL±VA64 extrudates no distinct peaks were observed suggesting the presence of 
amorphous PMOL as shown in Fig. 4.2b. The absence of crystalline PMOL was detected for 
all drug loadings even at 50% PMOL.  The combined DSC and X±ray characterization 
studies revealed different PMOL crystalline states mainly depending on the polymeric carrier 
and its miscibility with the active substance.  
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Fig. 4.2b: Powder XRPD patterns of PMOL pure (DIF), PMOL/VA64 extruded (ext) and 
physical mixtures (PM) samples: (a) PMOL/VA64 50% PM (b) PMOL/VA64 50% ext (c) 
PMOL/VA64 40% PM (d) PMOL/VA64 40% Ext (e) PMOL/VA64 30% PM and (f) 
PMOL/VA64 30% Ext. 
 
3.3. In vivo and in vitro taste masking evaluation 
 The masking efficiency of the developed granules was evaluated in vivo with the 
assistance of six healthy human volunteers (age 18±25). The in vivo statistical data collected 
for the pure active substance, bulk polymers and the extruded formulations are summarized in 
Table 3. The data analysis showed significant suppression of the bitter taste for PMOL and 
strong influence of the polymeric carriers indicating the importance of drug loading in the 
final formulation.  
 Both polymers showed improved taste masking capacity for certain formulations with 
descending order VA64>EPO.  The PMOL/EPO extrudates presented masking effect for 
DFWLYHFRQFHQWUDWLRQVXSWRZLWKSDQHOOLVWV¶VFRUHVVKRZLQJVOLJKWELWWHUQHVV,Q)LJ4.3 
it can be seen that PMOL/EPO extrudates showed better taste suppression at 40% loading 
while at 60% no masking effect was observed. The PMOL/VA64 extrudates demonstrated 
similar masking effect where for PMOL loadings from 40 ± 50% the recorded scores 
suggested slight bitterness. The PMOL/VA64 (30%) extrudates showed improved masking 
effect with SDQHOOLVWV¶ scores indicating threshold values.  
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Interestingly, no difference was observed in the in vivo taste scores for both polymers at the 
VDPH302/ORDGLQJV)RUH[DPSOHDW302/ORDGLQJWKHDYHUDJHSDQHOOLVWV¶VFRUHZDV
identical for EPO and VA64 extrudates respectively. 
 
Fig. 4.3: Schematic representation of the taste scores of pure API, bulk polymers and the 
extruded formulations. 
 
 A novel in vitro approach to evaluate the taste masking efficiency of various 
pharmaceutical dosage forms and avoid problems related to human panelists is the use of 
electronic sensor arrays [39-42] known as electronic tongues (e ± tongue). Similar studies were 
performed by other researchers where a principal component analysis (PCA) of active 
formulations against the placebo was presented through PCA maps in order to determine the 
taste masking potency of various components [43-45].  For the purposes of the study pure 
PMOL, bulk polymers and extruded granules were processed as described in the previous 
section. The signal of the different formulations was represented on taste maps based on a 
projection obtained by PCA as depicted in Fig. 4.4a- b. These maps showed the relative 
repartition and proximity of bitterness for each formulation.  
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7 Astree sensors Taste masking efficiency of Kollidon VA64 polymer vs. paracetamol 
           (after 60s dissolution) 
Paracetamol 
100% 
Placebo formulation 
Active formulations 
Kollidon VA64 
100% Paracet. 30% 
Kollidon 70% 
Paracet. 50% 
Kollidon 50% 
Paracet. 40% 
Kollidon 60% 
Fig. 4.4a:  (OHFWURQLF WRQJXH ³WDVWH PDS´ *OREDO VLJQDO FRPSDULVRQ 3&$ DQDO\VLV RI WKH
electrode responses) between pure PMOL and extruded formulations with VA64 polymer 
after dissolution for 60 s. 
 
 According to Fig. 4.4a the active sample (100% PMOL) and placebo polymer (VA64) 
are well separated indicating a big distance and taste differences. Also, the taste map 
indicates significant discrimination between the placebo and the active extruded 
formulations. All three drug-polymer extruded samples are close to each other while 
relatively far from PMOL. This means a significant taste evolution and a masking 
improvement towards pure PMOL. Similar to Kollidon VA64 samples the same conclusions 
were observed for EPO polymer, despite a lowest distance from pure active to placebo 
formulation (Fig. 4.4b).  
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7 Astree sensors Taste masking efficiency of Eudragit polymer vs. paracetamol 
(After 60s dissolution) 
Paracetamol 
100% 
Placebo formulation 
Active formulations 
Eudragit  
100% 
Paracet. 40% 
Eudragit 60% 
Paracet. 50% 
Eudragit 50% 
Paracet. 60% 
Eudragit 40% 
 
Fig. 4.4b: (OHFWURQLF WRQJXH ³WDVWH PDS´ *OREDO VLJQDO FRPSDULVRQ 3&$ DQDO\VLV RI WKH
electrode responses) between pure and exrtuded formulations with EPO polymer after 
dissolution for 60 s. 
  
 The distance between active and polymer formulations are indicative of the taste 
potency of each polymer. The closer the formulation is located to the placebo and the larger 
the distances to the pure unpleasant PMOL are, the better the taste masking is [46]. A taste 
improved effect is thus observed for each of the three PMOL-VA64 extrudates compared to 
polymer alone (DI>80%). As shown in Fig. 4.6 a taste improvement is perceptible with 
VA64 with the highest average distance obtained for PMOL/VA64 at 30/70%.  
 In Fig.4.5 it can also be seen that the PMOL/EPO extrudates showed closer distances 
and lower DI to pure API. However, these distances suggest improved masking effect with 
the best result achieved for PMOL loading at 50%.  
78 | P a g e  
 
0
10
20
30
40
50
60
70
80
90
100
0
100
200
300
400
500
600
700
800
900
1000
Kollidon 100% Para.(30%)   
Kol.(70%)
Para.(40%)   
Kol.(60%)
Para.(50%)   
Kol.(50%)
Eudragit 100% Para. (40%) 
Eud.(60%)
Para. (50%) 
Eud.(50%)
Para. (60%) 
Eud.(40%)
DI
 (%)
Di
st
an
ce
 
to
 
pa
ra
ce
ta
m
o
l 
(10
0%
) 
7 Astree sensors 
Kollidon VA64 polymer OHYHO¶V efficiency 
vs. paracetamol dose 
Taste masking efficiency of polymers on paracetamol doses after 60s dissolution 
Eudragit polymer OHYHO¶V efficiency vs. 
paracetamol dose 
 
Fig. 4.5: Distance and discrimination comparison between signal of 100% PMOL 
formulation and each pRO\PHU¶VIRUPXODWLRQRQ$VWUHH(-Tongue (after 60s). 
 
 7KLVODVWUHVXOWLVVOLJKWO\GLIIHUHQWWKDQWKHSDQHOLVWV¶VFRUes. Furthermore, a sensory 
correlated model based on Partial Least Square (PLS) was built to evaluate the correlation 
with sensory scores as depicted in Fig. 4.6. The correlation model is valid (R²<0.8) despite 
dispersion and low discrimination between formulations (p value >0). 
 
7 Astree sensors Taste correlation of polymer¶VIRUPXODWLRQ vs. Paracetamol solution 
 
Kollidon VA64 polymer 
Paracetamol 
100% 
Paracet. 30% 
Kollidon 70% 
Paracet. 50% 
Kollidon 50% 
Paracet. 40% 
Kollidon 60% 
Eudragit polymer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2LV Pvalue=0.084 Pvalue=0.102 
Paracetamol 
100% 
Paracet. 40% 
Eudragit 60% 
Paracet. 50% 
Eudragit 50% 
Paracet. 60% 
Eudragit 40% 
 
Fig. 4.6: Correlation of human sensor\ GDWD ³5HIHUHQFH´ ZLWK $VWUHH Hlectronic tongue 
PHDVXUHPHQWV³0HDVXUHG´ 
DI (%) 
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 The in vitro e±tongue evaluation was in good agreement with the in vivo tests and it 
was able to identify the optimum taste masked formulations. The e- tongue can be proved an 
efficient approach to develop palatable and pleasant ± tasting products by replacing taste 
panelists.  
 
3.4. Dissolution studies 
Dissolution profiles of PMOL from PMOL/EPO 40-60% and PMOL/VA64 30-50% 
are shown in Fig. 4.7a, b.  The dissolution rates of PMOL for both EPO and VA64 extrudates 
were rapid and approximately 80% PMOL was released in 15 min while more than 92% was 
released in 30 min. Only a slightly lower release rate was observed for the PMOL/EPO at 50 
± 60% loadings which can be attributed to the higher crystalline matter of PMOL in the 
extrudates.  
 
Fig. 4.7a: Dissolution profiles of PMOL in PMOL/EPO extrudates (n=3). 
 
 As a result each of the extruded formulations can be applied for fast onset action 
dosage forms. Furthermore, PMOL release patterns for the first 60s were investigated to 
determine the actual drug amount released during the in vitro taste masking evaluation. The 
PMOL release was found to be dependent on the polymer grade and the actual drug loading. 
In the case of PMOL/EPO extrudates the release varied between ~ 9 ± 14% and the released 
drug amounts increased with increase in the drug loading. Similarly, the PMOL/VA64 
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exhibited the same trends but slower PMOL release patterns which varied from ~ 5 ± 7%. 
The study of the onset PMOL release is important in order to verify the ability of both 
polymers to be used as masking agents.  
 
 
Fig. 4.7b: Dissolution profiles of PMOL in PMOL/VA64 extrudates (n = 3). 
 
4.0 Conclusions 
In this chapter HME was employed as a processing technique to manufacture taste 
masked PMOL formulation by embedding the active substance either in Eudragit EPO or 
Kollidon VA64 polymer carriers. PMOL was found to be in crystalline or amorphous state 
depending on the polymer used for extrusion. The optimized formulations were evaluated in 
terms of taste masking efficiency both by in vivo human panellists and an electronic tongue. 
The extruded formulations of VA64 demonstrated better taste masking compared to those of 
EPO while the e ± tongue was found to be a valuable tool for taste masking assessments and 
formulation development.  
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CHAPTER 5: AN IN VIVO AND IN VITRO TASTE MASKING EVALUATION OF 
BITTER MELT EXTRUDED APIs 
 
1.0 Introduction 
 The taste of a pharmaceutical formulation has major influence on patient compliance 
to the medication and therefore the taste masking of bitter APIs is a major challenge 
especially for the development of orally administered dosage forms in pharmaceutical 
industry [1].  In reality, most or many of the active pharmaceutical substances have either an 
unpleasant taste, such as bitterness, sourness or saltiness. Some of them may often cause an 
irritating mouth feeling, including metallic and/or spicy taste or astringency. For these 
reasons, the need for a pleasant taste becomes a key aspect for patient palatability [2]. Taste 
masking of various bitter active ingredients can be carried out using various techniques 
depending on the type of APIs and the type of formulation [3]. 
 Currently, various taste masking methods are available. The most commonly used 
conventional methods are film coating [4] and adding sugars, flavours or sweeteners               
[3]
 which are often limited due to regulatory requirements. Freeze-drying                                    
[1]
, microencapsulation [5, 6], fluidized bed coating [1], high shear mixing [7], supercritical fluids 
[8, 9]
 and spay drying [10] have been reported to be used as successful techniques for the 
purposes of taste-masking various bitter active subtances. In addition to the afore mentioned 
conventional methods, different advanced and chemical taste masking approaches such as 
drug complexation by cyclodextrines [11, 12], ion exchange resins [13], prodrugs and different 
salt formations [14] have been reported in the literature. Similarly, HME was introduced as 
useful tool to produce polymeric extrudates with taste masking properties in a continuous 
process [15]. Different polymeric systems have already been implemented for taste masking 
purposes via the hot-melt extrusion (HME) processing and have been proved effective taste-
masking approach by applying polymeric coating layer that creates a physical barrier around 
the drug.  
 Gryckze et al. (2011) successfully claimed taste masking of ibuprofen was achieved 
through intermolecular forces (e.g. hydrogen bonding) between the active substance and the 
polymer matrix by processing oppositely charged compounds [2]. Later, similar results were 
observed by Maniruzzaman et al. (2012) where the authors successfully managed to mask the 
bitterness of paracetamol by applying the same mechanism [1]. In addition, solid dispersions 
where the drug is molecularly dispersed within the polymer matrix have shown effective 
PDVNLQJ RI WKH GUXJ¶V XQSOHDVDQW WDVWH 6XFFHVVIXO WDVWH PDVNLQJ UHTXLUHV GHYHORSPHQW RI
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HME processing conditions, drug/polymer ratio and selection of the appropriate formulation 
components. HME can also be used for the development of robust formulations with 
increased patient palatability and compliance.  
 Taste masking evaluation of pharmaceutical dosage forms is usually carried out by 
human taste panels as well as electronic taste sensing systems which can be employed to 
predict the taste of pharmaceutical formulations [1]. Commercially available electronic 
tongues such as a Astree e-tongue have been well studied and evaluated for taste masking 
purposes which showed very good correlation with human taste panels, reproducibility, low 
detection limits and high sensitivity [16, 17]. Furthermore, in comparison to final extruded 
formulations the Astree e±tongue (AlphaMOS, France) has been systematically used to 
evaluate the bitterness of pure active substances. 
 Cetirizine HCl (CTZ) and Verapamil HCl (VRP) are white crystalline powders with 
very bitter taste mainly used as antihistaminic group drug and used for treating high blood 
pressure, chest pain, and irregular heart rhythms, respectively. In this study both CTZ and 
VRP were used as model drugs for the purpose of taste masking.  
The purpose of this study was to develop and optimize CTZ and VRP based melt extruded 
granules in order to mask the bitter tastes. The extrudates were evaluated both by in vivo and 
in vitro studies where an electronic tongue analyzer was employed that captures the global 
taste profile correlating the in vivo data.  
  
2.0 Materials and methods 
 
2.1 Materials 
 Cetirizine HCl (CTZ) and Verapamil HCl (VRP) were purchased from Sigma Aldrich 
(London, UK). Eudragit L100 (L100) and Eudragit L100-55 (Acryl EZE-EZE) was kindly 
donated by Evonik Pharma Polymers (Darmstadt, Germany) and Colorcon Ltd respectively. 
The HPLC solvents were analytical grade and purchased from Fisher Chemicals (UK). All 
materials were used as received.  
 
2.2 Calculation of soubility parameters 
 The Hansen solubility parameters į of both drugs as well as the polymers were 
calculated by using the Hoftyzer and van Krevelen method [18, 19] as described in Chapter No 
2 (section 2.2). Bagley advanced solubility parameter diagrarms [20] were used to investigate 
the effect of the hydrogen bonding compared to the combined solubility parameters 
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(dispersion forces and polarization forces) derived from Bragley equation. [Please see 
Chapter 4, Section 2.2 for details] . 
 
2.3 Preparation of formulation blends and hot-melt extrusion (HME) processing 
 
 CTZ and VRP formulations with L100 and EZE to be extruded were mixed properly 
in 100 g batches for 10 min each. A Turbula (TF2, Basel) mixer was used to blend the 
powder formulations. The drug-polymers composition consisted of CTZ/L100, CTZ/EZE, 
VRP/L100 and VRP/EZE at a ratio of 10/90 wt/wt. Extrusion of all CTZ and VRP 
formulations were performed using a Randcastle single-screw extruder (RCP0625) equipped 
with a 5 mm rod die in 100°C/150°C/150°C/160°C/155°C (Feeder          Die) temperature 
profiles. The screw speed maintained for all extrusion was 15rpm. The produced extrudates 
(strands) were grinded by using a ball milling system to obtain granules (<500 µm). Grinding 
by ball milling was carried out with a rotational speed of 400 rpm for 5 min each. 
 
2.4 Scanning electron microscopy (SEM) 
 In order to examine the surface morphology of drug, polymers and extrudates by SEM 
the samples were mounted on an aluminum stage using adhesive carbon tape and placed in a 
low humidity chamber prior to analysis. Samples were coated with gold±palladium prior to 
the scans, and microscopy was performed using a LEO Supra 35 (Cambridge Instruments S 
360F). The system was operated at an accelerating voltage of 5 kV. 
 
2.5 Differential scanning calorimetry (DSC) 
 The physical state of the pure drug, physical mixtures and extrudates were examined 
by using a Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter. 
Samples were prepared in sealed aluminum pans (2-5 mg) with a pierced lid. The samples 
were heated at 10oC/min under nitrogen atmosphere in a temperature range between 25 and 
250oC.  
 
2.6 X-ray powder diffraction (XRPD) 
 XRPD was also used to assess the solid state of the extrudates where samples of pure 
and loaded APIs were evaluated using a Bruker D8 Advance (Germany) in two-WKHWD ș
mode, Cu anode at 40 kV and 40 mA, parallel beam Goebel mirror, 0.2 mm exit slit, 
LynxEye Position Sensitive Detector with 3 degree opening and Lynx Iris at 6.5 mm, sample 
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rotation at 15rpm. The sample was scanned from 2 to 40 degrees 2-theta with a step size of 
0.02 degrees 2-theta and a counting time of 0.2 seconds per step; 176 channels active on the 
PSD making a total counting time of 35.2 seconds per step. 
 
2.7 In vivo taste masking evaluation 
 In vivo taste masking evaluation for pure APIs, polymers and all active extruded 
formulations was performed in accordance to the Code of Ethics of the World Medical 
Association (Declaration of Helsinki). Six (6) healthy volunteers of either sex (age 18±25) 
were selected (Male = 3, female = 3) from whom informed consent was first obtained 
(approved by the Ethics Committee of the University of Greenwich, Ref: UG09/10.5.5.12) 
and trained. The equivalent of 100 mg of pure CTZ, VRP or CTZ/VRP extrudates (containing 
equal amounts of APIs) were held in the mouth for 60 seconds and then spat out. The 
selection of samples was random and in between of two samples analysis mineral water was 
XVHGWRZDVKHDFKYROXQWHHU¶VPRXWK7KHELWWHUQHVVZDVUHFRUGHGLPPHGLDWHO\DFFRUGLQJto 
the bitterness intensity scale from 1 to 5 where 1, 2, 3, 4 and 5 indicate none, threshold, 
moderate, bitter and strong bitterness.   
 
2.8 In vitro taste masking evaluation: Astree E-Tongue 
 The assays were realized on an Astree e-tongue system equipped with an Alpha 
M.O.S. sensor set #2 (for pharmaceutical analysis) composed of 7 specific sensors (ZZ, AB, 
BA, BB, CA, DA, JE) on a 48-positions autosampler using 25 ml beakers. Acquisition times 
were fixed at 120 s. All the data generated on Astree system were treated using 
multidimensional statistics on AlphaSoft V12.3 software. Each solution was tested on Astree 
e-tongue at least 4 times. 3 replicates were taken into account for the statistical treatment. The 
average values between 100 and 120 s were used to build the maps. Astree sensors were 
cleaned up in deionised water between each sample measurement. 
 
2.8.1 Sample preparation for Astree e-tongue 
 In vitro taste masking evaluation was carried out with an Astree e-tongue equipped 
with 7 different sensor VHWV7REHDVFORVHDV WR WKHSDQHOOLVWV WDVWH¶VFRQGLWLRQVHDFKGUXJ
was diluted for 60s under magnetic stirring in 25 ml of deionised water to reach API 
concentration corresponding to a final dose of 100 mg. Then solutions were filtered with 
Buchner funnel fitted with filter paper at 2.5µm pore size (Table 5.1). One single analysis 
was done for each API. 
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Table 5.1: Sample preparation for taste masking analysis 
 
Code Type Description Drug 
(%) 
Placebo 
(%) 
Drug 
(mg) 
Placebo 
(mg) 
Total 
(mg) 
Final 
Volume 
(ml) 
pH 
AD100 Active  CTZ 100 0 100 0 100 25 3.8 
PDA90 Placebo EZE 0 90 0 900 900 25 5.8 
ADA10 A. Form CTZ/EZE 10 90 100 900 1000 25 3.4 
PDE90 Placebo L100 0 90 0 900 900 25 3.0 
ADE10 A. Form CTZ/L100 10 90 100 900 1000 25 1.8 
AP100 Active  VRP 100 0 100 0 100 25 3.3 
PPA90 Placebo EZE  0 90 0 900 900 25 5.8 
APA10 A. Form VRP/EZE 10 90 100 900 1000 25 2.6 
PPE90 Placebo L100 0 90 0 900 900 25 2.8 
APE10 A. Form VRP/L100 10 90 100 900 1000 25 1.7 
 
 
2.9 In vitro drug release studies 
 In vitro dissolution study was carried out by using a Varian 705 DS dissolution paddle 
apparatus (Varian Inc. North Carolina, US) at 100 rpm and 37 ± 0.5oC. The dissolution 
medium pH was maintained as 1.2 by using 750 ml of 0.1 M hydrochloric acid for 2 hr. After 
2 hr operation, 150 ml of 0.20 M solution of dehydrogenate sodium ortho phosphate was 
added into the vessel to give the final pH of 6.8 that has been equilibrated to 37°C. At 
predetermined time intervals, samples were withdrawn for HPLC assay. All dissolution 
studies were performed in triplicate. The difference in the release profiles of different 
formulations were investigated by calculating the similarity factor (f2) The f2 value (Eq. 1) is 
a logarithmic transformation of the sum-squared error of differences between the test Tj and 
reference products Rj over all time points (n=6). 
 
)1.5(]100}))(1(1log[{50
1
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2.10 HPLC analysis 
 The release of CTZ and VRP was determined by HPLC. An Agilent Technologies 
V\VWHPHTXLSSHGZLWKD+<&520(ȝP[PP[ mm column at 276 nm and 
266 nm was used for the CTZ and VRP HPLC assay, respectively. The mobile phase 
consisted of methanol/water/ triethylamine (70:30:0.25, v/v). The flow rate was 1.5 ml/min 
and the retention time of CTZ and VRP was about 4 minutes. The CTZ and VRP calibration 
curves (R2 = 0.999), at concentrations varying from 10 µg/ml to 50 µg/ml, were used to 
evaluate all the samples with 20 µl injection volume. 
 
3.0 Results and discussion 
 
3.1 Solubility parameters and extrusion process 
 The theoretical approach derived from the solubility parameter suggests that 
compounds with siPLODUįYDOXHVDUHOLNHO\WREHPLVFLEOH7KHUHDVRQLV WKDW WKHHQHUJ\RI
mixing from intramolecular interactions is balanced with the energy of mixing from 
intermolecular interactions [21, 22]*UHHQODJKGHPRQVWUDWHGWKDWFRPSRXQGVZLWKǻį <  
7 MPa1/2 ZHUHOLNHO\WREHPLVFLEOHDQGFRPSRXQGVZLWKǻį >  10 MPa1/2 were likely to be 
immiscible [23].  
 As it can be seen in Table 5.2 the difference between the calculated solubility 
parameters of the polymers and the drug indicate that both CTZ and VRP are likely to form 
VROLG VROXWLRQVZLWKERWKSRO\PHUV%\XVLQJ WKH9DQ.UHYHOHQ+RIW\]HU WKHǻįYDOXHV IRU
CTZ/L100, CTZ/ EZE, VRP/L100 and VRP/EZE are 2.07, 0.97, 3.4 and 2.3 MPa1/2, 
respectively.  
 Furthermore, a more advanced two dimensional approach proposed by Bagley et al. 
[20]
 was used also to predict drug ± polymer miscibility as shown in Table 5.2. By using the 
two ± dimensional approach Bagley et al. introduced the volume ± dependent solubility 
SDUDPHWHUįYZKHUH 
)2.5(22 pdv GGG      
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Table 5.2: Solubility parameters calculations summery for both drugs and polymers 
Comp. įS 
(MPa1/2) 
įG 
(MPa1/2) 
įK 
(MPa1/2) 
įY 
(MPa1/2) 
į 
(MPa1/2) 
¨į 
CTZ 
(MPa1/2) 
¨į 
VRP 
(MPa1/2) 
Ra(v) 
CTZ 
 
Ra(v) 
VRP 
 
CTZ 5.42 17.50 9.60 18.32 20.68 - - - - 
VRP 5.12 17.31 6.95 18.05 19.35 - - - - 
L100 0.41 19.31 12.03 19.31 22.75 2.07 3.4 5.33 5.12 
EZE 0.25 18.22 11.69 18.22 21.65 0.97 2.3 5.22 4.95 
 
 
2
12
2
12 )()( hhvvavR GGGG  
 
 ,Q WKLV HTXDWLRQ įp DQG įd were observed to have similar thermodynamic effects in 
FRQWUDVWWRįK7KHWZR± dimensional approach can provide more accurate prediction of the 
drug ± polymer miscibility by calculating the distance (Ra(v)) using the Pythagorean Theorem 
(24, 25). In this theory two components are considered miscible when Ra(v) 03D1/2.   In 
WKLVVWXG\LWLVREYLRXVIURP7DEOHWKDWHYHQWKRXJKWKHįp values of the drug ± polymer 
combinations differ significantly it does not affect the predicted miscibility.  
 
3.2 Scanning electron microscopy (SEM) 
 Surface morphology was examined by SEM for both the drug and extrudates (EXT). 
The extrudates containing L100 and EZE exhibited no drug crystals on the extrudate surface 
with CTZ (Fig. 5.1). Similarly, no VRP crystals were observed on the surface in all drug/ 
polymer extrudates, indicating that VRP is also highly miscible with both anionic 
methacrylate co-polymers in order to form solid solutions. Thus, the SEM observations were 
also quite sensitive to elucidate the presence of drug/polymer miscibility as well as the 
formation of drug/polymers amorphous solid dispersions by complementing the thermal 
investigations. 
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Fig. 5.1: SEM images (magnification x 500) of (i) CTZ/L100 EXT, (ii) CTZ/EZE EXT, (iii) 
VRP/L100 EXT and (iv) VRP/EZE EXT. 
 
3.3 Differential scanning calorimetry (DSC) 
 Differential scanning calorimetry (DSC) was used to analyse the solid state of pure 
APIs, polymers, their binary mixtures and active extruded formulations. The overall findings 
from DSC results are summerized in Table 5.3.  
 
Table 5.3: Summary of DSC results of pure drugs, polymers and formulations 
 
Formulations Glass transition  
(oC) 
Melting endotherm/ enthalpy 
(o&ǻ+-J-1) 
CTZ 55.36 225.6/104.2 
VRP 51.65 145.9/106.5 
L100 164.38 - 
EZE 83.97 59.2 
 
93 | P a g e  
 
Physical mixtures (PM) and extruded formulations (EF) 
 PM 
(o&ǻ+-J-1) 
EF 
(o&ǻ+-J-1) 
PM 
(o&ǻ+-J-1) 
CTZ/L100 113.60 105.72/6.85 222.90/31.23 
CTZ/EZE 73.19 64.78/2.64 187.55/9.74 
VRP/L100 113.68 74.73/8.15 146.41/14.39 
VRP/CTZ 72.98 64.11/3.42 161.30/11.95 
 
 The DSC scan of pure CTZ and VRP in Fig. 5.2a showed an endothermic peak 
corresponding to its melting point at 225.6o&į+ = 104.2 J/g) and 145.9o&į+ = 106.5 J/g), 
respectively. Similarly, the pure polymers showed a Tg at 83.97oC corresponding to Eudragit 
L100-55 and 164.83oC corresponding to Tg of L100, respectively (Fig. 5.2a). 
 
Fig. 5.2a: DSC thermograms of pure APIs and polymers. 
  There was also a sharp melting peak present in EZE diffractogram at 59.2oC (data not 
shown) which could be due to the presence of crystalline plasticizers and other ingredients in 
the co-processed formulation of Acryl-EZE. Later, this melting peak was also visible in 
physical mixtures (PM) of both drugs (Fig. 5.2 b-c). Eventhough, all binary physical 
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drugs/polymers blends exhibits endothermic peaks (Fig 5.2b-c) corresponding to the initial 
substances at slightly shifted temperatures indicating the drug existence in its crystalline 
form, the melting peaks were absent in all extruded formulations.  
 
 
Fig. 5.2b: Thermograms of CTZ and VRP in L100 polymers sytems. 
Furthermore, the extruded formulations exhibited a broad Tg peak ranging from 64 to 
105oC indicating the conversion of the originally crystalline drugs into their amorphous forms 
during the HME process The range of one single Tg in the extruded formulation is in between 
the Tgs of drugs (CTZ at 55.36oC and VRP at 51.65oC) and polymers. This also confirms the 
formation of solid dispersions of drugs into the polymer matrices [21, 26] and also the 
drug/polymers miscibility. According to the Gordon Taylor equation, the miscible 
drug/polymers extrudates would exibit a broad single Tg at the intermediate position of the 
Tgs of amorphous drug and polymers [22]. Nevertheless, the characteristic peak of CTZ and 
VRP cannot be found in the thermograms of the extruded formulations, indicating that 
extruded formulation is different in physicochemical properties from the physical mixture of 
drug/polymer. This could be attributed to the amorphous dispersion of the drugs in molecular 
basis onto the polymer matrices. 
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Fig. 5.2c: Thermograms of CTZ and VRP in EZE (L100-55) polymers sytems. 
 
3.4 X-ray powder diffraction (XRPD) analysis 
 The findings form DSC has always been supplement by XRD studies. Therefore, drug 
± polymer extrudates, including pure drugs and physical mixtures of the same composition 
were studied by X±ray analysis and the diffractograms were recorded to examine both APIs 
physical (crystalline or amorphous) state. As depicted in Fig. 5.3a±b the diffractogram of 
pure CTZ and VRP presented distinct peaks ranging from 7-  ș DQG - ș
respectively. 
 
Fig. 5.3a: Diffractograms of CTZ/polymers formulations. 
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 As shown in Fig. 5.3a and b the PM of all formulations presented identical peaks at 
lower intensities suggesting that both drugs retain their crystalline properties. The Acryl EZE 
based systems for both drugs in PM exhibits distinct crystalline peaks due to the presence of 
crystalline plasticizer with co-processed amorphous L100-55 along with the active subtances. 
No crystalline distinct peaks were found in the extruded formulations in EZE systems. In 
contrast no distinct intensity peaks for both CTZ and VRP were observed in the 
diffractograms of the extruded formulations in L100 based formulations. The absence of CTZ 
and VRP intensity peaks indicates the presence of amorphous APIs in the extruded solid 
dispersion which confirms the DSC results. 
 
Fig. 5.3b: Diffractograms of VRP/polymers formulations. 
 
3.5 In vivo taste masking evaluations 
 The masking efficiency of the developed granules was evaluated in vivo with the 
assistance of six healthy human volunteers (age 18 ± 25). Bitterness was recorded for a period 
of two minutes according to the bitterness intensity scale from 1 to 5 where 1, 2, 3, 4, and 5 
indicate no, threshold, slight, moderate, and strong bitterness [1]. The statistical data collected 
from the in vivo study for the pure active substances and the extruded formulations are 
depicted in Fig. 5.4. The data analysis showed significant suppression (p> 0.05) of the bitter 
taste for both APIs & influence of the polymeric carriers and importance of drug loading in 
the final formulation. Both polymers showed effective taste masking capacity with 
descending order L100>EZE.  Furthermore, the HME formulations presented excellent 
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masking effect for active concentrations (10%) of both APIs. In Fig. 6.4 sensory data 
obtained from six volunteers interestingly showed the taste masking efficiency of L100 
substantially better than EZE for both of the APIs used. This could be attributed to the pH 
dependant dissolution properties of EZE S+FRPSDUHGWRWKDWRI/S+DVWKH
saliva represents a pH approximately 6 in healthy individuals. However, the sensory scores 
for both of the active APIs in different formulations are within the range (below 2) which has 
been demonstrated as optimum by in vitro evaluations. 
 
Fig. 5.4: Sensory taste scores of human volunteers for all formulations and pure materials.  
 
3.6 In vitro taste evaluations 
 To evaluate the in vitro taste masking, Astree e-tongue data were explored for both of 
the drugs using Principal Component Analysis (PCA) associated to complementary data 
processing. The distances between active and polymer solutions were calculated as they are 
indicative of taste masking power of the coating dose. Also, a Discrimination Index (DI in %) 
was determined for each solution. This indicator takes into account the average difference 
between the pairs to compare the dispersion of each sample as well. The closer the DI values 
to 100%, the longer the distance between groups and the lower the dispersion (less masking 
effects). The DI therefore helps to assess the level of significance of difference between the 
groups.  Sensory correlated models based on Partial Least Square (PLS) were also built to 
evaluate the correlation with sensory scores. The results are presented in the following 
sections for each drug. 
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 The taste map shows significant discrimination between placebo and active solutions. 
Liquid sensors are able to detect the presence of the drug in the coated formulations. 
Focusing on pure drug in water the complex with Eudragit polymer (L100) at 90% shows a 
better taste improvement compared to Acryl EZE coating (Fig. 5.5a). The distance proximity 
with placebo is about four times less important.  
 
Fig. 5.5a: Signal comparison between active and placebo formulations with Eudragit L100 
and Acryl-EZE coatings on cetirizine HCl and verapamil HCl (dissolution for 60s). 
 
 The correlation model is considered as valid and fits with panel perception (Fig 5.5b; 
R² > 0.8). But it should be taken with care as all data on sensory tests (number of panelists, 
variability on measurement) were not communicated.  
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Fig. 5.5b: Distance and discrimination comparison between signal of pure cetirizine HCl and 
YHUDSDPLO +&O IRUPXODWLRQ DQG HDFK SRO\PHU¶V IRUPXODtion on Astree e-tongue (after 60s 
dissolution). 
 
 However, CTZ at 10% in Eudragit L100 is perceived as less bitter compared to pure 
API which implies a good masking. On the other hand, CTZ in Acryl-EZE 90% is perceived 
by panelists as equivalent as Acryl-EZE taste but Astree system shows significant 
differences. The acidity of the media with Eudragit is close to drug pH in solution which may 
influence the global taste perception. As acid threshold is lower for liquid sensors, it explains 
the increased gap observed on PCA for Acry-EZE formulations. 
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Fig. 5.5c: &RUUHODWLRQ RI KXPDQ VHQVRU\ GDWD ³5HIHUHQFH´ ZLWK $VWUHH (OHFWURQLF WRQJXH
PHDVXUHPHQWV³0HDVXUHG´IRUERWKGUXJV. 
 
 The variation observed within solutions is important especially between Acryl-EZE 
solutions (Fig 5.5c). Eudragit solutions have a better proximity with a significant 
improvement of VRP taste.  This trend is likely to be linked with a pH influence as variation 
between pure Acryl in water (~6) and the media with the drug is more acidic (<3), which 
leads to a higher separation of couples. The difference of taste is less perceptible with 
Eudragit polymer as depicted in Fig. 5.5a. 
 PLS models showed a good correlation (Fig. 5.5c). Verapamil HCl was found to be 
not bitter by the panelists. The impact of Acryl coating dLGQ¶WDIIHFWWKHWDVWHDV$FU\O-EZE 
itself was also found to be not bitter which was not the case for Eudragit (threshold-moderate 
bitterness). However, the PLS highlights the same conclusions: sensory panel was sensitive to 
taste perception with Eudragit. The findings from standard deviations studies of both the 
drugs along with polymeric formulations are summarized in Table 5.4. The results showed 
good interpretation of taste masking of all excipients as SD < 50: Fair, SD < 30: good 
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Table 5.4: Mean standard deviation (SD) and relative standard deviation (RSD) for each 
solution. 
CTZ after 60s dissolutions 
Formulations Mean SD Mean RSD (%) Interpretations of SD 
AC100 9 1.8 Good 
ACA10 10 1.8 Good 
ACE10 8 1.3 Good 
PCA90 16 1.8 Good 
PCE90 8 1.2 Good 
PW 31 2.4 Fair 
VRP after 60s dissolutions 
AV100 9 0.6 Good 
AVA10 18 1.2 Good 
AVE10 8 0.6 Good 
PVA90 7 0.4 Good 
PVE90 11 0.9 Good 
PW 17 1.0 Good 
100u 
x
SDRSD
 
 
3.7 In vitro drug release profiles 
 The dissolution rates of CTZ for both L100 and EZE extrudates were quite fast and 
approximately 65% drug was released in 60 min while more than 80% was released in 3 hr 
(Fig 5.6a). Only a slightly higher release rate was observed for VRP based formulations 
which can be attributed to the less stronger interaction compared to CTZ with polymers in the 
extrudates [27]. The VRP release obtained after 3hr was above 95% (Fig 5.6b). As a result 
each of the extruded formulations can be applied for fast onset action dosage forms.  
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Fig. 5.6a: Release profiles of CTZ extruded formulations (paddle speed 100 rpm, pH 1.2 (6.8 
after 2 hr), n=3). 
 
 Furthermore, the difference of the release profiles of different formulations was 
investigated by calculating the similarity factor (f2). According to the FDA guidelines, release 
curves are considered similar when the calculated f2 is 50±100 [28]. The calculated difference 
factor of all extruded formulation are summarised in Table 5.5.  
 
Table 5.5: Similarity factor (f2) for comparing release curves of CTZ and VRP formulations 
Formulations Difference Factor (f2) Formulations Difference Factor (f2) 
CTZ/L100 Ref CTZ/L100 74.11 
When CTZ/L100 is Ref CTZ/EZE 74.11 CTZ/EZE 
VRP/L100 49.16 VRP/L100 86.77 
When VRP/L100 is Ref VRP/EZE 48.80 VRP/EZE 
 
 The derived release profile of extruded formulation containing CTZ/L100 differs 
significantly from VRP/L100 and VRP/EZE formulations whereas CTZ/L100 is quite similar 
to CTZ/EZE.  Similarly, VRP/L100 formulation exhibits similar release profile of VRP/EZE 
formulation as the calculated f2 value falls into 86.77 which in the 50-100 range according to 
the aforementioned FDA guidelines.  
103 | P a g e  
 
 
Fig. 5.6b: Release profiles of VRP extruded formulations (paddle speed 100 rpm, pH 1.2 (6.8 
after 2 hr), n=3). 
 
4.0 Conclusions 
 In this current chapter hot melt extrusion has been employed as a robust processing 
technique for the manufacture of taste masked formulations based on VRP and CTZ. Both of 
the APIs were found to be in amorphous state after extrusion due to the formation of solid 
dispersions. The optimized formulations evaluated by both in vivo and in vitro taste masking 
tests correlated with each other. The extruded formulations of L100 demonstrated better taste 
masking compared to those of EZE while the e ± tongue was found to be a valuable tool for 
taste masking assessments and formulation development. 
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CHAPTER 6: DRUG-POLYMER INTERMOLECULAR INTERACTIONS IN HOT-
MELT EXTRUDED SOLID DISPERSIONS 
 
1. Introduction 
 Over the last decades hot-melt extrusion (HME) has emerged as an  influential 
processing technology in developing solid  dispersions of active pharmaceutical ingredients 
(APIs) into polymer matrices and has already been demonstrated to provide time controlled, 
modified, extended and targeted drug delivery resulting in improved bioavailability [1, 2]. The 
formation of active solid dispersions through HME and therefore configuration of complexes 
due to macromolecular orientational relations in polymer networks has been of great interest 
in pharmaceutical research and development. Polymer complexes are classified by the nature 
of the association. The major classes of polymer complexes are the stereocomplexes, 
intermolecular hydrogen-bonded complexes and polyelectrolyte complexes [3,4]. 
 The polyelectrolytēdrug complexes have been the focus of several researchers and 
still very limited data is available concerning the understanding of the underlying 
mechanisms involved in the formation of drug-polyion complexes [5]. Different techniques 
have already been reported successfully to describe various drug-polymer interactions and 
analyse the drug-polyelectrolyte complexes. Pavli et al. described oppositely charged 
doxazosin mesylate (DM), a cationic drug and polyelectrolytes carrageenans interaction by 
special DM ion-selective membrane electrode methods constructing the binding isotherms 
treated by the Zimm̄Bragg theory and cooperative binding model [5].  Some other techniques 
which have already been established to analyse drug-polymers interactions are the dialysis 
equilibrium technique [6, 7],  Fourier transform infra-red spectroscopy (FTIR) and UV 
spectroscopy [8, 9], solid state NMR [10], drug±polymer interaction parameter model 11 and 
more importantly x-ray photo electron spectroscopy [10, 12].  
 
The X-ray photoelectron spectroscopy (XPS) can be employed as a valuable tool for 
the characterisation of polymer surfaces and it has made a significant contribution to the 
investigation of biomedical polymers but most importantly provides a quantitative elemental 
analysis and also information on the chemical bonding within the surface layers of the 
polymer as well as the prediction of the changes onto the material surface [10]. The increasing 
importance of XPS for many types of intermolecular interactions based analysis arises for 
several reasons; such as it can provide information about the actual composition and chemical 
state of surfaces and interfaces that dominate properties of interacting materials even in nano 
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scale or lower. XPS is more accurate and sensitive to presents precise surface analysis results 
of different type complexes compared to that of NMR and FTIR.  
 The types of the interaction to form polymeric complexes in the solid dispersions 
would normally depend on many factors such as nature of the polymer, degree of 
substitution, polymer chain configuration and length [13].  The H-bonding would also be more 
prominent in the longer side-chain polymers, where a larger number of groups are available 
for the interaction to occur. Furthermore, HME processing has been proved to facilitate drug-
polymer interactions leading to increase solubility of water insoluble drugs, taste masking of 
bitter actives and stable solid dispersions.  
Therefore, in order to investigate the type of potential drug-polymer interactions a 
comprehensive study was carried out using two model cationic drugs (propranolol HCl and 
diphenhydramine HCl) with with the anionic polymers, Eudragit L 100-55, Eudragit L100. 
The identification and understanding of this type of interactions can find ground in the 
development of solid dispersions in pharmaceutical industry 
 
2. Experimental sections 
2.1 Materials 
 Propranolol HCl (PRP) and Diphenhydramine HCl (DPD) were purchased from 
Sigma Aldrich (Gillingham, Kent, UK). Eudragit L100 (L100) and Eudragit L100-55 (L100-
55) were kindly donated by Degussa (Evonik, Germany) and Colorcon Ltd (Dartford, UK), 
respectively. The HPLC solvents were analytical grade and purchased from Fisher Chemicals 
(UK). 
 
2.2 Determination of drug-plymer miscibility by Hansen solubility parameters (į 
  The partial solubility parameters į of PRP and DPD as well as the anionic polymers 
were calculated by using Hoftyzer and Vankrevelen method [14] considering their chemical 
structural orientations in order to determine the theoretical drug/polymer miscibility. [Please 
see Chapter 5, section 2.2 for details] . 
 
2.3 Hot-melt extrusion process 
  Prior to the extrusion process, the dry drug/polymer powders (100g) were blended 
properly in a Turbula TF2 mixer (Basel, Switzerland) for 10 minutes. The drug polymer 
compositions consisted of PRP/L100 and PRP/L100-55 in the ratio of 10/90 (% wt/wt). 
Similarly, DPD/L100 and DPD/L100-55 were used in the ratio of 10/90 (% wt/wt). Extrusion 
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of all PRP and DPD formulations was performed using a single screw Randcastle extruder 
(RCP 0625, Cedar Grove, NJ) with a 0.2 mm rod die. The temperature profile from the 
feeding zone to die was 100°C/150°C/150°C/160°C/155°C for all formulations with L100 
and L100-55 with 15 rpm screw speed. The extrudates (strands) were milled for 5 min to 
produce granules using a Pulverisette 6 ball mill (Ritsch, Germany) with 400 rpm rotational 
speed. The micronized particles were then passed through a 250 µm sieve to separate out the 
particles to use under this threshold.  
 
2.4 Scanning electron microscopy (SEM) 
  SEM was used to study the surface morphology of the hot-melt extrudates. The 
samples were mounted on an aluminum stage using adhesive carbon tape and placed in a low 
humidity chamber prior to analysis. Samples were coated with gold±palladium, and 
microscopy was performed using a LEO Supra 35 (Cambrdige Instruments, S360) operating 
at an accelerating voltage of 5 kV. 
 
2.5 Thermal analysis by differential scanning calorimetry (DSC) 
  A Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter 
was used to carry out DSC runs of pure actives, physical mixtures and extrudates. Sealed 
aluminium pans were used to prepared sample. 2-5 mg of samples was prepared with a 
unpierced lid. The samples were heated at 10°C/min from -40oC to 220oC under nitrogen 
atmosphere. 
 
2.6 X-ray powder diffraction (XRPD) 
  XRPD was used to determine the solid state of pure active substances, physical 
mixtures and extruded materials using a Bruker D8 Advance (Germany) in two theta-theta 
(2ș) mode. For the study purposes a Cu anode at 40 kV and 40 Ma, parallel beam Goebel 
mirror, 0.2 mm exit slit, LynxEye Position Sensitive Detector with 3° opening (LynxIris at 
6.5 mm) and sample rotation at 15 rpm were used. Each sample was scanned from 2 to 40° 2ș 
with a stepsize of 0.02° 2șand a counting time of 0.1 seconds per step;  176 channels active 
on the PSD making a total counting time of 35.2 seconds per step. 
 
2.7 Molecular modelling 
  The monomeric structures of L100, L100-55, PRP and DPD were constructed by 
program Gaussview ()ULVFK¶V JURXS Gaussian Inc. Wallington CT) [15]. Hydrogen bonding 
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patterns were identified after energy optimisation at the B3LYP 6-31G* level using Gaussian 
09. In all of the drug/polymers combinations primarily two different H bonding were detected 
with up to 2Į °A distance. All possible H bondings were shown in dash line in the 
constructed figures. 
 
2.8 X-ray photoelectron spectroscopy (XPS) analysis 
  X-ray photoelectron spectra (XPS) were measured on a Kratos Axis Ultra-DLD using 
a monochromatic Al KĮ X-ray source (120 W) and an analyser pass energy of 160 eV (survey 
scans) or 20 eV (high resolution scans); the pressure during analysis was 1×10 -9 Torr.  All 
data were referenced to the C (1s) signal at 285.0 eV attributable to unsaturated C-C/C-H 
bonds [16]. Quantification and curve fitting was performed in CasaXPSTM (Version 2.3.15) 
using elemental sensitivity factors supplied by the manufacturer.  
 
2.9 Nuclear magnetic resonance (NMR) studies 
  NMR spectra were recorded on a Jeol ECA 500 NMR spectrometer, incorporating a 
5mm inverse probe (The 1H operating frequency was 500 MHz). 1H NMR spectra of the 
drugs, polymers and drug/polymer formulations were recorded using the standard Jeol pulse 
sequence. All samples were dissolved in CD3OD, degassed and then maintained at 25oC 
during data acquisition. Samples were referenced with respect to the solvent. The solution 
concentration of the drugs was 2 mg/ml, the polymer was18mg/ml, and the drug/polymer 
formulation was 20 mg/ml (the overall drug content in the formulations was 10%).  1H T1 
relaxation experiments were recorded for all samples using a standard inverse recovery 
H[SHULPHQW5HFRYHU\GHOD\VĲZHUH LQYHVWLJDWHGEHWZHHQPVDQGV7KHUHOD[DWLRQ
delay was set to be > 5T1. T1s were calculated from curve fitting, peak intensities, obtained 
from the spectra recorded for different recovery delays. Jeol, curve fitting software was 
utilised during this process.   
 
3. Results and discussion 
3.1 Determination of drug-polymer miscibility by Hansen solubility parametHUVį 
To predict the miscibility of the active substances and the polymeric carriers the 
Hansen solubility parameter was used [14, 17, 18]
.
  According to the Vankrevelen/ Hoftyzer 
equation the calculated solubility parameters for PRP and DPD are 21.94 MPa1/2 and 17.75 
MPa1/2, respectively whereas the solubility parameters for L100 and L100-55 are 22.75 
MPa1/2 and 21.65 MPa1/2, respectively. Since the determined difference in solubility 
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parameters between each drug and polymer are less than 7MPa1/2 (about 0-5 MPa1/2), both 
polymers are likely to be miscible with both of the APIs [19]. Thus, miscibility studies by 
solubility parameters provide a simple and generic approach for rational selection of carriers 
in the preparation of solid dispersions through the intermolecular interactions.  In the miscible 
drug-polymers based solid dispersions cationic active substances (PRP, DPD) can interact 
with the functional groups of the negatively charged polymers. These interactions facilitate 
the creation of hydrogen bonding between the active amide group of the APIs and carboxylic 
group of the polymers and consequently mask the API¶VELWWHUWDVWH [20]. 
 
3.2 Scanning electron microscopy (SEM) 
  SEM was used to examine the surface morphology of the drug and extrudates. The 
extrudates containing L100 and L100-55 exhibited no drug crystals on the extrudate surface 
with PRP (Fig. 6.1). Similarly, no DPD crystals were observed on the surface of polymeric 
extrudates in all drug/ polymers extrudates, indicating that DPD is also high miscible with 
both anionic methacrylate co-polymers. Thus, the SEM observations were also quite sensitive 
to elucidate the presence of drug/polymer miscibility by complementing DSC and XRPD 
investigations.  
 
Fig. 6.1: SEM images of (a) PRP/L100 (Magnification x 2000), (b) PRP/L100-55 
(Magnification x 10K), (c) DPD/L100 (Magnification x 500) and (d) DPD/L100-55 
(magnification x 10K) extruded formulations. 
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3.3 Differential scanning calorimetry (DSC) 
  DSC was employed in order to analyse the solid state of the processed drug/polymers 
binary mixtures (PM) and drug/polymer extrudates (EXT). The DSC thermograms of PRP 
and DPD in Fig. 6.2a showed an endothermic peak corresponding to melting points at 
166.65oC (ǻ+  -126.25 J/g) and 170.83o& ǻ+  -124.59 J/g) respectively. The bulk 
polymers showed Tgs at 83.97oC and 164.83oC corresponding to L100-55 and L100 
respectively (Fig. 6.2a).  
 
Fig. 6.2a: DSC thermograms of pure drugs and pure polymers. 
 
 The binary physical blends of DPD/L100 and DPD/L100-55 in Fig. 6.2b exhibited 
DPD endothermic peaks shifted at slightly lower temperatures of 139.19o&ǻ+ -15.14 J/g), 
153.62 o& ǻ+  -/g), respectively, indicating drug/polymer interaction to a small 
extent. The same shift at lower temperatures was observed for the Tgs of the polymers at 
114.46oC for L100 and 71.98oC for L100-55. 
Furthermore, the extruded DPD/L100 (and L100-55) complexes exhibited single glass 
transition peaks at 62.11 and 76.56oC, respectively, which denotes the presence of 
drug/polymers miscibility and formation of solid dispersions. Single Tg also indicates the 
presence of the APIs in amorphous forms [21].  When the two components are miscible the Tg 
of the extruded sample lies between the Tgs of the individual components (DPD has a Tg 
at14.80oC) according to the Gordon ± Taylor equation [19]. Similarly, PRP/polymers exhibited 
single Tg peaks at of 65.70oC (L100) and 54.52oC (L100-55) attributed to the presence of 
PRP in molecularly dispersed state within both polymer matrices (Supp. Fig. 1). The Tg of 
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PRP was determined at 34.74oC. Overall, DSC analysis confirmed the creation of molecular 
dispersions for all extruded formulations. 
 
Fig. 6.2b: DSC thermograms of DPD/L100 (PM), DPD/L100 (EXT), DPD/L100-55 (PM) 
and DPD/L100-55 (EXT). 
 
 
3.4 X-ray powder diffraction (XRPD) 
To examine PRP and DPD crystalline state diffractograms of pure drugs, the drug ± 
polymer extrudates and their binary physical mixtures were recorded by X±ray powder 
diffraction analysis.  As can be seen from Fig. 5.3,  the diffractograms of pure PRP and DPD 
presented distinct peaks at 8.38o, 9.71o, 12.51o, 16.72o, 19.49o, 21.26o, 22.06o, 23.59o, 25.07o, 
27.07o-39.07o ș DQG o, 12.39o, 18.61o, 20.34o, 22.03o, 24.87o, 26.55o, 31.45o ș
respectively. As shown in Fig. 6.3 the PM of all PRP formulations presented identical peaks 
at lower intensities suggesting that both drugs retained their crystallinity at loads of 10%. In 
contrast no distinct intensity peaks were observed in the diffractograms of the extruded 
formulations. The absence of PRP and DPD intensity peaks indicates the formation of a solid 
dispersion where the drugs are present in amorphous [22] state or molecularly dispersed into 
the polymer matrix. 
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Fig. 6.3a: Diffractograms of PRP formulations: PRP pure (inset), (a) PRP/L100 PM (b) PRP/ 
L100 extrudates (c) PRP/L100-55 extrudates (d) PRP/L100-55 PM. 
 
 Similarly, the diffraction patterns of all DPD physical mixtures exhibited crystalline 
peaks (Fig. 6.3b) with reduced intensities corresponding to DPD. The PRP the diffractograms 
of the extruded DPD formulations were characterized by the absence of drug intensity peaks 
again indicating amorphous [22] or molecularly dispersed state.  
 
Fig. 6.3b: Diffractograms of DPD formulations: DPD pure (inset), (a) DPD/L100-55 
exrudates (b) DPD/L100-55 PM (c) DPD/L100 extrudates and (d) DPD/L100 PM. 
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3.5 Intermolecular interactions of hot-melt extrudates 
3.5.1 Molecular modelling 
  Depending on the initial positioning of the PRP molecule, two hydrogen bonding 
patterns were identified (Fig. 6.4) after energy optimisation at the B3LYP 6-31G* level using 
Gaussian09 [23, 24]. Both the hydroxyl group and amine group within the drug molecule could 
form strong hydrogen bonds with the monomer, as indicated by the optimal distances 
between the H-bond donor and acceptor. Furthermore, the chloride ion was placed within the 
proximity of the H bonds in structures. After re-optimisation, the H-bonding interaction 
formed with the hydroxyl group was broken due to the presence of the chloride ion while the 
H-bond interaction with the amine group was not affected (Fig. 6.4) Therefore, calculations 
indicate that the hydrogen bond identified based on PRP, DPD, L100 and L100-55 
formulations is most likely formed between the amine group of the drug molecule and the 
carbonyl groups of the polymer.   
 
Fig. 6.4: Molecular modelling of drugs/polymers (Gaussian 09). 
 
3.5.2 X-ray photoelectron spectroscopy (XPS) 
  The surface elemental ratios of PRP, DPD, polymers and the extruded formulations 
determined experimentally by XPS [25] are shown in Table 6.1 and are compared with the 
theoretical values derived from the structural formula  [26]. The experimental results were in 
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good agreement with the anticipated theoretical values. PRP predominantly contained O 
(8.56%) and C (83.53%) atoms. Similarly, DPD contained C (88.05%) and O (4.34%) atoms.  
 
Table 6.1:  Position and percentage area of O, C, N and Cl atoms of bulk APIs, polymers and 
extrudates             
 O, 1s C, 1s N, 1s Cl, 2p 
Formulation 
Area 
(%) 
Area 
(%) 
Area 
(%) 
Area 
(%) 
PRP 8.56 83.53 4.16 3.75 
DPD 4.34 88.05 4.20 3.41 
L100 24.83 75.17 - - 
L100-55 51.48 25.78 - - 
PRP/L100 23.51 75.87 0.63 - 
PRP/L100-55 43.14 39.41 0.23 0.24 
DPD/L100 23.66 75.82 0.53 - 
DPD/L100-
55 
45.05 35.00 - 0.26 
 
 
 The main differences in the spectra are observed in the C (1s) peaks around ~284.85 
(C-C or Ring) and 290.85 eV (-COO- / O-C-O groups).  Fig. 6.5a shows that extruded 
formulation of PRP/L100 produced C peaks at ~284.85 eV with increased intensity. The high 
intensity of the peak is an indication of the concentration of a particular species, suggesting 
reaction of ester/carboxylic acid functionalities from polymers and drugs to yield C-OH or C-
O-C like hydrocarbon chains in the extruded materials [12].   
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Fig. 6.5a: XPS BE peaks of C 1s PRP, L100 and PRP/L100 formulations. 
 
Both DPD and L100 show a C-C/C-C-H peak at BE = ~285.10 eV [27] while they 
appear slightly shifted at ~284.97 eV in DPD/L100 formulation (Fig 6.5b).  
 
Fig. 6.5b: C 1s BE peaks of DPD, L100 and DPD/L100 formulations. 
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 Since L100 contained higher proportions of C atoms compared to DPD, the peak 
shifts could be due to the positive charge effect of electropositive atom next to C-C/C-C-H 
bonds in extrudates. In the extruded formulation peaks representing C-Ring structures at BE= 
~ 292.20, 294.20 eV from DPD and bonds at 289.27 eV from L100 have been eliminated by 
C-O-O/ O=C-O-O structures in the DPD/L100 formulation at about ~ 289.07 eV. At the same 
time peaks at 285.07 eV and 286.37 eV from DPD have shifted by +0.60eV and +0.40 eV 
respectively in the final formulation. This could be attributed to the interaction of C-C bonds 
shifting to a ±C-O-O-/ N-C=O/ =OC (O)-O-OH complex structure. 
 In comparison to the pure L100-55 polymer (Supp. Fig. 3), in the PRP/L100-55 
extrudates few specific peaks are submerged exhibiting new formed peaks due to the drug-
polymer interactions where most of the C-COO or C-O bonds peaks have been shifted 
slightly. The BE peaks at ~285.0 eV represent C-C structures and two other slightly more 
shifted peaks at ~286.67eV and ~288.97eV represent new formed C-COO- or -C-O bonds in 
the PRP/L100-55 extruded formulation [27, 28]. In addition, peaks at BE= ~285.07eV (-C-C) 
from pure polymer in combination with peaks from pure drug at ~284.94eV (-C-C),     
~285.84 eV formed a new peak at BE= ~285.0 eV representing new formed ±C-C bonds in 
the extruded formulation. At the same time peaks at ~285.87eV, ~286.77eV from L100-55 
and peaks at ~286.84eV from pure drug exhibit a new peak at BE= ~286.67eV (-C-COO/ -
C=O) in the extruded formulation. Similarly, the peak at ~288.97 eV of the extruded powders 
is due to the interactions of two groups from drug/polymer at ~290.64eV and ~289.17eV 
respectively.  
DPD/L100-55 formulation has showed peaks at ~285.07 eV represents C-C structure and two 
other slightly more shifted peaks at ~286.77eV and 289.70eV represent newly formed C-
COO- or -C-O bonds [12].  
 The O (1s) peak at ~533.34 eV in PRP represents mainly a C-O-C structure while for 
the bulk L-100 polymer the peak at BE = ~533.63 eV suggests COOH/ COOCH structures 
(Supp. Fig.2). In the extruded formulations, a slight peak shift of +0.27eV from 
BE=532.67eV (in polymer) indicates the formation of C-OH or C-O-C at BE = ~532.90 eV. 
The presence of O (1s) peak at BE= ~534.40 eV in the extruded formulation (peak shift 
+0.77eV from both pure API and polymer) represents the ester/carboxylic acid 
functionalities. This is due to the interaction of drug-polymer molecules within the extruded 
polymer matrix. A possible outline of bonds could be represented as follows: 
           -O-C- + C-O-O-C / C-O-O-                           C-O-H / C-O-C   ............................ (i) 
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  For the extruded DPD/L100 samples the following shifts can be observed; from the 
BE assignment peaks of O atoms in L100, only two peaks at BE = ~ 532.67 eV and ~533.63 
eV are visible and have been shifted to ~532.27 eV and ~533.77 eV respectively 12 in the 
extruded samples. Mainly -OH/ -O-OH/-C=O bonds are changed to -C-C(O)-O bonds in the 
extruded formulation. The peak at BE= ~533.30 eV in DPD represents C-O bonds which was 
later shifted to ~533.77eV BE (DPD/L100) (Fig. 6.5c).  
 
Fig. 6.5c: O 1s peaks of DPD, L100, DPD/L100 and PRP, L100-55, PRP/L100-55 
formulations. 
 
 In the case of PRP/L100-55 formulations (Fig 6.5c), it is obvious that O (1s) BE 
peaks at ~532.87 eV from L100-55 and peaks at ~533.34 eV from PRP are shifted at ~532.70 
eV and ~533.20 eV respectively at the point of extrusion. The newly formed peak at 
~533.10eV (~532.70 eV + ~533.20 eV) is the combination of two C-O bonds from drug-
polymer complex representing new C-O-O-C bonds. One single O (1s) BE peak for 
DPD/L100-55 formulation (Supp. Fig. 4) at BE= 533.01 eV resulted from the combined peak 
shifts of DPD (BE = ~533.3eV) and L100-55 (BE= ~532.87eV). Another newly formed peak 
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at ~533.01 eV is the combination of C-O/-O-O bonds from polymer/drug and represents C-O-
O-C or C(O)-O-O bonds [27, 28].  
 The N (1s) binding energy (BE) of ~402.035 eV (Fig.6.5d) in PRP suggests the 
protonation of the NH+ group while Cl (2p) energy of ~198.035 eV significantly supports that 
conclusion [26]. The N (1s) energy of ~402.8 eV in PRP/L100 extrudates represents further 
protonation effect of N atom as NH4+ which is described by the equation (ii) below. The N 
(1s) binding energy (BE) of ~402.6 eV (Fig. 5d) in DPD suggests similar effect in relation to 
the protonation of the NH+ group while the slightly reduced Cl (2p) energy of ~197.495 eV 
compared to pure PRP also significantly supports the statement.  
 
 N-H+                NH4+ / NH2 +   (next to electron withdrawing group)    ...................... (ii)  
 
 The N 1s peak at BE= ~402.80 eV is in good agreement with the previously observed 
protonation of amide group by Beamson and Briggs [16].  The BE peak at ~402.80 eV (higher 
than typically observed for amines BE= ~399 eV - 400.5 eV and much more for ±NH2+ 
group) for N1s is an indication of C-O-NH2+ structure whereas the O atom peak at ~534.40 
eV shows the same [16].  These results strongly indicate an interaction between the amide 
group of the API and ester/carboxyl group of the polymer (L100) through the available H-
interactions or hydrogen bridges (Fig. 6.5d).   
 
Fig. 6.5d: N 1s peaks of PRP and DPD formulations. 
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 N 1s peaks from PRP/L100-55 and DPD/L100-55 also complement the observations 
from PRP/L100 and DPD/L100 formulations. The N (1s) energy of ~402.9 eV in DPD/L100 
formulation represents a positive shift of the peak position to the right by +0.40 eV.  This is 
due to the additional protonation effect of N atom converted to NH4+.  The N 1s peak at BE= 
~402.90 eV suggests protonation of the amide group as observed for the PRP/L100 
formulation. The BE peak at ~402.90 eV for N1s is an indication of C-O-NH2+ structure with 
longer peak shift than that of PRP/L100. As before, we concluded that a strong interaction 
between the amide group of API and ester/carboxyl group of polymer through the available 
H-interactions has taken place.   
The protonation effects of N 1s in the extruded formulations were significant and 
showed high peak shifts which are summarised in Table 6.2. From the binding energy 
assignments determined by XPS it is presumed that the higher the peak shifts the more 
significant the protonation [29], therefore stronger intermolecular interactions.  
 
Table 6.2: N 1s peak shifts in all extruded formulations with both drugs 
PRP Formulations DPD Formulations 
Form. Peak Position  
(eV) 
Net shift  
( eV) 
Form. Peak Position  
(eV) 
Net shift  
( eV) 
PRP Pure ~ 402.04 - DPD Pure ~ 402.5 - 
PRP/L100 ~ 402.80 + 0.76 DPD/L100 ~ 402.9 + 0.40 
PRP/L100-55 ~ 402.47 + 0.43 DPD/L100-55 ~ 402.77 + 0.27 
 
 From Table 6.2 it is obvious that the peak shifts of N 1s in PRP/L100 are 
higher compared to the other formulations demonstrating the a high protonation effect and 
thus stronger drug ± polymer  interaction. The ascending order of the protonation effects in 
the extudates is PRP/L100>PRP/L100-55>DPD/L100>DPD/L100-55. Therefore, even 
though both drugs were found molecularly dispersed through DSC studies the XPS analysis 
showed different magnitude of interactions even with counterpart polymer grades. The XPS 
observations demonstrate a direct relation of the drug ± polymer miscibility and 
intermolecular interactions.   
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 Finally, the XPS analysis confirmed the molecular modelling predictions and verified 
the presence of H ± bonding between the drug ± polymer functional groups facilitated by 
HME processing.  
 
3.5.3 Nuclear magnetic resonance (NMR) studies 
  
1H NMR spectroscopy can be used to monitor changes in molecular chemical 
environments by studying the movement of NMR signals (chemical shift) such as the 
changes in the 1H NMR spectra of drug and drug/polymHU VROXWLRQV &KHPLFDO VKLIW į
locations of drug and polymer 1+VLJQDOVZHUHLGHQWLILHGDQGǻįYDOXHVZHUHFDOFXODWHGDIWHU
comparison with the spectra from the drug/polymer formulations. 
 
 
Fig. 6.6a: Molecular structure of PRP and DPD (NMR peak assignment). 
 
Table 6.3 presents 1H NMR chemical shift data and assignments for PRP, DPD, L100 
and L100-55 (data not shown). Assignments have been annotated with respect to the 
molecular structures of both drugs presented in Fig. 6.6a. It should be noted, that the broad 1H 
NMR signals from the L100 sample have been tentatively assigned with respect to the 
polymeric repeat unit. There are a number of well resolved multiplets that are also observed 
in the 1H NMR spectrum of the commercial polymer, Eudragit L100, but the origin of these 
signals cannot be obtained. The 1H NMR spectra for drug/polymer complexes follow very 
similar assignments as seen for the individual molecules (Table 6.3). For example, peak 
broadened, PRP, aromatic signals can be observed at 8.28 ppm (H2), 7.81 ppm (H5), 7.39 
ppm (H8) and 6.95 ppm (H9), in the PRP/L100 complex. 
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Table 6.3:  1H NMR assignments for drugs and polymer (samples were dissolved in 
CD3OD). 
Propranolol HCl Diphenhydramine HCl Eudragit L100 
Chemical 
shift/ ppm 
Assignment Chemical shift/ 
ppm 
Assignment Chemical 
shift/ ppm 
Assignment 
1.38 H15, 16 2.87 H10, 11 0.80 -1.40 H1, 3 
3.23 ± 3.40 H13 a,b 3.38 H9 1.80 ± 2.24 H2 
3.49 H14 3.75 H8 3.62 H4 
4.17- 4.26 H11 a,b 5.52 H7   
4.40 H12 7.27 +¶   
6.94 H9 7.34 +¶¶   
7.38 H8 7.39 +¶¶   
7.44 -7.51 H3, 4, 7     
7.81 H5     
8.27 H2     
 
In Fig. 6.6b significant changes can be observed for the peak widths found in the 1H NMR 
spectra of the drug and the drug/polymer formulations. This can be easily seen with respect to 
the aromatic 1H signals found only in the drug, resulting in the chemical shift locations 
between 6.5 and 8.5 ppm. The peak width is proportional to transverse relaxation (T2), which 
arises as the result of magnetic field differences in the sample. As T2 becomes shorter (faster 
relaxation), the peak width increases. The peak broadening of the 1H NMR signals after 
formulation could be attributed to changes in local magnetic fields arising from 
intramolecular and intermolecular interactions in the sample. Indeed, it has been stated that 
changes in the T2 can be attributed to decreases in rotational freedom of small molecules in 
WKHSUHVHQFHRIDµUHFHSWRU¶WRZKLFKWKH\FDQLQWHUDFW [30].  
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Fig. 6.6b: 1H NMR spectra of all PRP and DPD formulations. 
 
 To investigate the potential interactions found within the drug/polymer formulation, 
1H NMR inverse recovery experiments were carried out  to analyse spin relaxation times [31, 
32]
. Differing relaxation rates of nuclear spins can be related to aspects of molecular structure 
and additionally to internal molecular motion. The rationale of these experiments was to look 
at potential changes of the drugs molecular motion, before and after HME processing. Indeed, 
it would be assumed that the free drug (with a low molecular weight) would have quite a high 
molecular motion leading to fairly high T1 relaxation delays. After extrusion, any possible 
interactions between the drug and polymer would result in a decrease in the amount of 
molecular motion observed for the drug. T1 relaxation times are particularly sensitive to 
intermediate molecular motions which result in short T1s. Molecules which have fast or slow 
molecular motion can have comparable T1s (Supp. Fig. 5-8). 
 In Table 6.4, significant changes (p>0.05) between the T1 relaxation times for the 
drugs and the drug/polymer solutions can be observed. It is expected that low molecular 
weight present relatively fast molecular motion in solution. The decrease in T1 of the extruded 
drug ± polymer blends indicates a slowing in the molecular motion of the compounds. This 
result would infer that there is some type of molecular interaction between the drugs and 
polymers in methanol solutions, although the proximity of the interactions cannot be 
elucidated. 
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Table 6.4:  A comparison of T1 relaxation times for drug and drug/polymer solutions. 
 
Sample 1H NMR T1 range of drug protons 
Propanolol HCl 1.0 - 3.7 seconds 
 Propanolol HCl/ Eudragit L-100 0.05 ± 0.5 seconds 
Diphenhydramine HCl 1.5 ± 4.3 seconds 
Diphenhydramine HCl / Eudragit L-100 0.4 ± 1.6 seconds 
 
4.0 Conclusions 
HME has successfully been employed as a robust technique to form solid dispersions 
of both APIs into polymer matrix through intermolecular interactions. The existence of 
amorphous APIs into the polymer matrices has been confirmed by thermal analysis. The 
NMR method and molecular modelling indicated the presence of intermolecular interactions 
between drug and polymer molecules. The XPS analysis has finally confirmed the 
mechanism of the interaction through H-bonding between the carboxyl group of the anionic 
methacrylate co-polymer and the amide group of the active substances.  
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CHAPTER 7: EVALUATION OF THE INTERRELATION BETWEEN 
INTERMOLECULAR INTERACTIONS AND TASTE MASKING EFFICIENCY OF 
TWO ANIONIC POLYMERS IN MELT EXTRUDED SOLID DISPERSIONS 
1.0 Introduction 
 To date, masking the unpleasant taste of bitter APIs has been a real challenge for 
patient compliance and therefore various taste masking approaches have already been 
developed. The most commonly technologies are film casting by adding flavours or 
sweeteners [1,2]. Freeze-drying [2], spary drying [4], microencapsulation [5, 6], fluidized bed 
coating [2], high shear mixing [7] and supercritical fluids [8] have also been reported to be used 
for taste-masking purposes. HME has been introduced as a novel approach to mask the taste 
of bitter actives by enhancing drug-polymer interactions [9].   
It has been reported in the literature that HME technique has successfully managed to 
mask the bitterness of ibuprofen and paracetamol through intermolecular forces (e.g. 
hydrogen bonding) between the active substance and the polymer matrix [2, 10]. In these 
studies the active substances were molecularly dispersed within the polymer matrices 
resulting effective taste masking of the dUXJ¶VXQSOHDVDQW WDVWH6ROLGOLSLGH[WUXVLRQLVDOVR
another suitable HME approach to produce extrudates of bitter APIs with improved taste 
properties. Recently, Breitkreutz et al. developed taste masked lipid based formulation by 
extrusion with NXP 1210, a BCS class II drug (anti inflammatory) [11].     
The taste masking evaluation of pharmaceutical dosage forms is evaluated both by in 
vivo and/or in vitro taste analysis. For the in vitro taste masking analysis commercially 
available electronic tongues have been employed to evaluate the masking effect. The e -
tongues demonstrate very good correlation with human taste panels, reproducibility, low 
detection limits and high sensitivity [12, 13].  
Various techniques have already been reported successfully to describe various drug-
polymers interactions such as the dialysis equilibrium technique [14, 15], UV spectroscopy      
[16, 17]
, solid state NMR [18], drug±polymer interaction parameter model [19], Fourier Transform 
Infrared (FT-IR) and more importantly X-ray photo electron spectroscopy [16, 20]. X-ray 
photoelectron spectroscopy (XPS) has proved a potent tool for the characterisation of 
polymer surfaces and it has made a significant contribution to the analysis of biomedical 
polymers. Similarly FT-IR has been accepted as sensitive technique to elucidate the structural 
changes in the active formulations [16]. The lattice-based Flory±Huggins (F±H) theory is a 
well known theory describing polymer±solvent or polymer±polymer interactions based on the 
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Gibbs free energy change before and after mixing [21]. It has been reported in the literature 
that F-H theory could successfully be applied in order to determine the interaction parameter 
therefore signifying the interactions strengths between two compounds during their melting. 
A small molecule drug±polymer pair is analogous to a solvent±polymer system and has 
potential to be described by the F±H theory. The recent publications applying the F±H theory 
in this area focus on obtaining the F±H interaction parameter, Ȥ, by the melting point 
depression method [22, 23].  Extractions of the maximum information out of the F±H theory 
and prediction of the thermodynamics of pharmaceutical binary systems is still of great 
interests in pharmaceutical research and developments. 
In this study, both the FT-IR and XPS were used to identify the strength and types of 
the possible drug-polymer interactions. Similarly the F-H interaction parameter of the model 
system determined at two different conditions using the Nishi±Wang [24] equation based on 
melting point data and Hildebrand and Scott [25] correlation, respectively was further 
evaluated to interrelate them with the taste masking efficiencies of two different anionic 
model polymers (Eudragit L100-55, Eudragit L100) in the extruded solid dispersions of 
propranolol HCl and diphenhydramine HCl.  
2.0 Materials and methods 
2.1 Materials 
 Propranolol HCl (PRP) and Diphenhydramine HCl (DPD) were purchased from 
Sigma Aldrich (London, UK). Eudragit L100 (L100) and Eudragit L100-55 were kindly 
donated by Evonik Pharma Polymers (Darmstadt, Germany) and Colorcon Ltd respectively. 
The HPLC solvents were analytical grade and purchased from Fisher Chemicals (UK). All 
materials were used as received.  
2.2 Hansen solubility parameters: prediction of drug/polymer miscibility  
The Hoftyzer and van Krevelen method was used to calculate all drug polymer 
solubility parameters by considering the chemical structural orientations [26] and two ± 
dimensional approach introduced by Bagley et al. [27] was used to predict the combined 
thermodynamic effects on the drug-polymers miscibility over hydrogen bonding energy. 
[Please see Chapter 6, Section 2.2 for more details] . 
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2.3 Flory Huggins (F-H) theory for the prediction of drug/polymer interaction 
parameter 
 The F±H interaction parameter, Ȥ, was correlated with temperature dependence, as in 
many simplified cases. The interaction parameter of the model system was determined at two 
different conditions using the Nishi±Wang [24] Eq. 7.1 equation based on melting point 
depression data and Hildebrand and Scott [25] Eq. 7.2 correlations with solubility parameter, 
respectively. The F-+LQWHUDFWLRQSDUDPHWHUȤIRUDOORIWKHGUXJSRO\PHUVELQDU\PL[WXUHV
were calculated by using the following equations. The value determined by Eq. 7.1 represents 
the interactions between the two substances, specifically at the melting temperature, which 
may not be extrapolated to other temperatures. 
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Where, ȣis the molar volume of the repeating unit, m is the degree of polymerization,  ĳis 
WKHYROXPH IUDFWLRQDQGȤ LV WKH FU\VWDOOLQH± amorphous polymer interaction parameter, Tm 
and Tom is the crystalline melting peak and amorphous Tg in the system, respectively. 
F-+ LQWHUDFWLRQ SDUDPHWHU Ȥ FDQ EH DOVR HVWLPDWHG by the method developed by 
Hildebrand and Scott according to Eq. 7.2 [25]. 
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Where, R is the gas constant, T is the absolute temperature, and v the volume per lattice site 
DQGįdrug DQGįpoly are solubility parameters of drugs and polymers respectively. 
2.4 Differential Scanning Calorimetry (DSC) 
The physical state of the pure drug, physical mixtures and extrudates were examined 
by using a Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter. 
Samples were prepared in sealed aluminum pans (3-5 mg) with a pierced lid. The samples 
were heated at 10oC/min in a temperature range between 0 and 220oC under nitrogen 
atmosphere.   
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2.5 Hot-melt extrusion (HME) processing 
 Drug/polymer blends were blended in 100 g batches for 10 min each with a Turbula 
(TF2, Basel) mixer. The extrusion of all bathces was performed using a Randcastle single-
screw extruder (RCP0625) equipped with a 5 mm rod die at 
100°C/150°C/150°C/160°C/155°C (Feeder --> Die) temperature profiles and screw speeds at 
15 rpm. The drug-polymer composition consisted of PRP/L100, PRP/L100-55, DPD/L100 
and DPD/L100-55 at ratios of 10/90 wt/wt. The produced extrudates (strands) were grinded 
by using a Ball Milling system (Retsch, Germany) to obtain granules (< 500 µm at a 
rotational speed of 400 rpm for 5 min.  
2.6 Particle morphology and size distribution 
SEM was used to study the surface morphology of all hot-melt extrudates. The 
samples were mounted on an aluminum stage using adhesive carbon tape and placed in a low 
humidity chamber prior to analysis. Samples were coated with gold, and microscopy was 
performed using a Leica Cambridge Instruments (S360F), SEM operating at an accelerating 
voltage of 5 kV.  
In order to determine the particle size distribution of the micronized extrudate 
granules a dry sieving method was applied. The method involved stacking of the sieves on 
top of each other and then placing the test powder (100 g) on the top sieve. The nest of sieves 
was subjected to a standardised period of agitation (20 min) in order to give the weight 
percentage of powder in each sieve size range. 
 
2.7 In vivo taste masking evaluation 
 In vivo taste masking evaluation for pure APIs, polymers and all active extruded 
formulations was performed in accordance to the Code of Ethics of the World Medical 
Association (Declaration of Helsinki) [28]. Six (6) healthy volunteers of either sex (age 18±25) 
were selected (Male = 3, female = 3) from whom informed consent was first obtained 
(approved by the Ethics Committee of the University of Greenwich, Ref: UG09/10.5.5.12) 
and trained. The equivalent of 100 mg of pure DPD, PRP or DPD/PRP extrudates (containing 
equal amounts of APIs) were held in the mouth for 60 seconds and then spat out. The 
selection of samples was random and in between of two samples analysis mineral water was 
XVHGWRZDVKHDFKYROXQWHHU¶VPRXWK7KHELWWHUQHVVZDVUHFRUGHGLPPHGLDWHO\DFFRUGLQJWR
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the bitterness intensity scale from 1 to 5 where 1, 2, 3, 4 and 5 indicate none, threshold, 
moderate, bitter and strong bitterness.   
 
2.8 In vitro taste masking evaluation: TS-5000Z sensing system 
 The assays were realized on TS-5000Z taste sensing system equipped with a BASIC 
sensor set (for pharmaceutical analysis) which are suitable for basic APIs composed of 10 
specific sensors (AAE, CT0, CA0, C00, AE1, AC0, AN0, BT0, GL1 ) on a 48-positions 
autosampler using 25 ml beakers. Acquisition times were fixed at 120s with a BT0 negatively 
charged sensor. All the data generated on TS-5000Z system were treated using 
multidimensional statistics. Each solution was tested on TS-5000Z at least 4 times and 
triplicates were taken into account for the statistical treatment. Sensors were then cleaned up 
in references solutions (30 mM KCl + 0.3 mM tartaric acid) between each sample 
measurement. The samples were dissolved in 50 mL of 10 mM KCl aq. solutions and further 
diluted to prepare 0.03, 0.1, 0.3, and 1 mM solutions as standards. Then solutions were 
filtered with Buchner funnel fitted with filter paper at 2.5 µm pore size. 
2.9 Molecular modelling 
 The monomer of L100, dimer of L100-55, PRP and DPD were constructed by 
program Gaussview [29]. Hydrogen bonding patterns were identified by placing the drug 
molecule within the proximity of the L100 and L100-55, respectively and then 
energy optimised at the B3LYP/6-31G* level using Gaussian09 [30]. Based on these optimised 
configurations of drug-polymer interactions, the binding energy was calculated using Ebinding= 
-[Ecomplex-(Edrug+Epolymer)] with each energy term obtained at the M06-2x/6-31G** level [31] 
after single point calculations. A counterpoise procedure [32] was employed to correct for the 
effect of basis set superposition error (BSSE). In all of the drug/polymers combinations 
primarily two different H bonding were detected with the donor-acceptor distance at ~2 Å. 
All possible H bondings were shown in dash line in Table 4. 
2.10 Fourier Transform Infra-Red (FT-IR) analysis 
 FTIR analysis was performed on the drug, polymer, drug_/polymer physical mixtures, 
and complex using Perkin Elmer PE1600 (Massachusetts 02451 
USA) Fourier Transform Infrared Spectra according to the KBr disc method from 400 ± 3600 
wavelength/cm-1 range. 
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2.11 X-ray photoelectron spectroscopy (XPS) analysis 
 X-ray photoelectron spectra (XPS) were measured on a Kratos Axis Ultra-DLD using 
a monochromatic Al KĮ X-ray source (120 W) and an analyser pass energy of 160 eV (survey 
scans) or 20 eV (high resolution scans); the pressure during analysis was 1×10 -9 Torr.  All 
data were referenced to the C(1s) signal at 285.0 eV attributable to unsaturated C-C/C-H 
bonds [33]. Quantification and curve fitting was performed in CasaXPSTM (Version 2.3.15) 
using elemental sensitivity factors supplied by the manufacturer.  
 
3.0 Results and discussions 
3.1 Predictions of drug/polymer miscibility: solubility parameters 
The calculated solubility parameters of APIs and polymers are shown in Table 7.1. 
The difference between the calculated solubility parameters of the polymers and the drug 
indicate that both PRP and DPD are likely to be miscible with both polymers since the 
difference of the calculated solubility parameters are not more than 7MPa1/2.  
 
Table 7.1: Solubility parameters calculations summery for both drugs and polymers 
Comp. įS 
(MPa1/2) 
įG 
(MPa1/2) 
įK 
(MPa1/2) 
įY 
(MPa1/2) 
į 
(MPa1/2) 
¨į 
PRP 
(MPa1/2) 
¨į 
DPD 
(MPa1/2) 
Ra(v) 
PRP 
 
Ra(v) 
DPD 
 
PRP 3.67 19.30 9.90 19.64 21.94 - - - - 
DPD 4.05 16.39 5.44 16.89 17.75 - - - - 
L100 0.41 19.31 12.03 19.31 22.75 0.81 5.0 3.26 4.67 
L100-55 0.25 18.22 11.69 18.22 21.65 0.29 3.9 3.59 4.22 
2
12
2
12 )()( hhvvavR GGGG  
 
Being slightly diverted from the Van-Krevelen equation, Bagley proposed a more 
advanced two dimensional equation to predict the drug-polymers miscibility known as 
Bagley equation [27].  
The two ± dimensional approach can provide more accurate prediction of the drug ± 
polymer miscibility by calculating the distance (Ra(v)) in Bagley diagram using the 
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Pythagorean Theorem. In this theory two components are considered miscible when Ra(v) 
03D1/2 [26].   
 
3.2 Flory Huggins (F-H) theory for the prediction of drug/polymers interaction 
parameter 
 In order to determine the F-H interaction parameter between both drugs and polymers 
the heat of fusion of crystalline PRP and DPD as well as the Tg of both polymers and melting 
peaks of APIs (Table 2) were determined by DSC experiments. In the DSC thermograms the 
pure PRP and DPD showed a sharp melting peak at 166.65oC and 170.83oC, respectively 
ZLWKDQHWKHDWRIIXVLRQHQWKDOS\ǻ+YDOXHVRI26.25 J/g and 124.59 J/g, respectively. 
The Tg observed for both polymers are at 164.38oC for L100 and 83.97oC for L100-55 (Acryl 
EZE).  
Molecular volumes of the two different polymers L100 and L100-55 as well as active 
substances were estimated from functional group contribution. As shown in Table 7.2 the 
molecular volumes of PRP and DPD are 269.96 cm3 and 284.24 cm3, respectively. By 
implementing both the Eqs. 7.1 & 7.2, WKHDYHUDJHYDOXHRIȤLVFDOFXODWHGDVVKRZQLQ7DEOH
7.3.  
 In this case, since the drug content is essentially low (ĳDrug = 10%), the accurate 
determination of the onset point of the melting endothermic peak became difficult. However, 
accurate interaction parameter by using F-H theory has successfully been implemented in our 
study as the interaction parameter depends on multiple factors such as crystalline melting 
temperature of APIs, Tg of polymers, molecular volumes and degree of polymerisations etc 
which have successfully been determined  from the thermal analysis of drug-polymer binary 
mixtures. The negative interaction parameter in Table 7.3 indicates that there is a net 
attraction force between species in a binary mixture which is favourable for all compositions 
DWREVHUYHGPHOWLQJWHPSHUDWXUHRIERWK$3,VDQGDOVRVDPHIRUWKH7J¶VRIERWKSRO\PHUV
[34] 7KHUHIRUH WKH KLJKHU WKH DEVROXWH YDOXH RI Ȥ WKH VWURQJHU WKH LQWHUDFWLRQV EHWZHHQ
drug/polymers species. In Table 7.3, it can be seen that L100 facilitates stronger interactions 
with both the drugs compared to those of L100-55. To make the case stronger this 
observation was confirmed by both approaches (Nishi-Wang and Hildebrand-Scott). 
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Table 7.2: DSC findings of all APIs and polymers as well as general information of all 
polymers and active subtances 
Compound Heat of Fusion  
ǻ+-J 
Melting peaks 
(oC) 
Glass transition 
 (Tg) oC 
Molecular 
weight/volume 
(cm3) 
PRP 126.25 166.65 34.74 295.34/269.96 
DPD 124.59 170.83 14.80 291.35/284.24 
L100 - - 164.38 12500/100000 
L100-55 - - 83.97 320000/271186 
 
Table 7.3: Calculation of F±H interaction parameter of different Drug±Polymer extruded 
formulations 
Form. Volume Fractions (ø) Nishi-Wang Ȥ Hildebrand ± Scott Ȥ 
RPR/L100 10:90  -0.2240 -2.89 X 10-4 
PRP/L100-55 10:90 -0.0826 -3.70 X 10-5 
DPD/L100 10:90 -0.2099 -1.10 X 10-4 
DPD/L100-55 10:90 -0.0774 -6.7 X 10-5 
 
3.3 SEM and particle size analysis 
SEM was used to examine the surface morphology of all extruded formulations as 
depicted in Fig 1. The particles size range for all extruded materials varied majorly from 50-
200µm after optimizing the grinding process. The extrudates containing both L100 and L100-
55 exhibited no drug crystals on the extrudate surface after extrusion with PRP (Fig 7.1a-b). 
Similarly, no DPD crystals were observed on the surface of polymeric extrudates in both 
polymeric systems. The particle size distribution depicted in Fig. 7.2 shows particle sizes for 
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all formulations ranging from 40 ± 400 µm. A very small percentage can be seen at sizes 
ȝPDVWKHPLOOLQJSURFHVVZDVRSWLPL]HGWRUHGXFHILQHVLQWKHILnal extruded batches.    
 
Fig. 7.1: SEM images (magnification x 500) of the extruded formulations (a) PRP/L100 and 
(b) DPD/L100-55. 
 
 
Fig. 7.2: Particle size distribution of L100 and L100-55 based formulations with both drugs 
(milling time 5 min, 400 rmp). 
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3.4 In vivo and in vitro taste masking evaluation 
 The masking efficiency of the developed granules was evaluated in vivo with the 
assistance of six healthy human volunteers (age 18 ± 25). The statistical data collected from 
the in vivo study for the pure active substances and the extruded formulations are depicted in 
Fig. 3a. The data analysis showed significant suppression of the bitter taste for both APIs & 
influence of the polymeric carriers and importance of drug loading in the final formulation. 
Both polymers showed effective taste masking capacity with descending order L100>EZE.  
Furthermore, the HME formulations presented excellent masking effect for active 
concentrations (10%) of both APIs. In Fig. 7.3a sensory data obtained from six volunteers 
interestingly showed the taste masking efficiency of L100 significantly better than EZE for 
both of the APIs used. This could be attributed to the pH dependant dissolution properties of 
(=( S+   FRPSDUHG WR WKDW RI / S+   DV WKH VDOLYD UHSUHVents a pH 
approximately 6.0 in healthy individuals. However, the sensory scores for both of the active 
APIs in different formulations are within the range (below 2) which has been demonstrated as 
optimum by in vitro evaluations. 
 
Fig. 7.3a: Sensory scores of all formulations by panellist (n = 6).  
 The in vitro masking effect of the extruded formulations in artificial salive was 
evaluated by using the INSENT TS-5000Z e±tongue and the interpretation of the 
experimental findings is discussed below. The distances percentage (%) between active 
subtances and formulation solutions were estimated in four phases of time distances (0.5 min, 
1 min, 10 min and 30 min) as they are indicative of taste masking power of the extruded 
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formulations.  In addition, the Discrimination Index (DI in %) was determined for each 
solution.  
 
Fig. 7.3b: Normalised DI (%) of all drug/L100 formulations in four different time scale. 
 This indicator takes into account the average difference between the pairs to compare 
each other as well as the discrimination index (DI) of each sample. The closer the DI values 
to 0%, the longer the distance between groups and the higher the discrimination (high 
masking effects). The DI will help then to assess the significance of difference between the 
groups.  The results are presented in the following sections for each drug in (Fig. 7.3b and 
Fig. 7.3c). 
 In Fig. 7.3b the bitter taste suppression of DPD in the active formulation with L100 is 
quite significant even after 30 min as the DI index (%) is only about 2% (very close to 0%-
means no taste). Similarly, PRP/L100 extruded formulation did not show that much closer 
taste suppression compared to the L100 system but still about 60% DI has been determined 
by the BT0 sensor thus indicating taste masking. 
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Fig. 7.3c: Normalised DI (%) of all drug/L100-55 formulations in four different time scale. 
 The taste graph shows significant discrimination between all active formulations and 
active substance solutions (Fig. 7.3c). The bitter taste of DPD has successfully been masked 
up to 35% (DI 65%) while for PRP only 5% (DI 95%). EZE has demonstrated its taste 
masking efficiency for both the APIs but not as significant as L100.   
 Liquid sensors are able to detect the presence of the drug in the coated formulations 
(up to 0.3 mM API). Focusing on pure drug in reference solution (artificial saliva) the 
complex with L100 (Fig. 7.3b) at 90% shows a better taste improvement compared to Acryl 
EZE coating (Fig. 7.3c). This could be highly attributed to the pH dependency of both 
polymers. L100 is soluble in pH above 6.5 while L100-55 (EZE) is soluble in slightly lower 
pH range therefore in the artificial saliva solutions the electronic tongue sensor did perceive 
the taste of bitter APIs from the dissolved polymer matrices.   
 Sensory correlated models were built to evaluate the correlation with sensory scores. 
The correlation model is considered as valid and fits with panel perception (Fig 7.3d; R² > 
0.9). However, the correlation studies show the same conclusions: sensory panel was sensible 
to taste perception with Eudragit L100. The correlation studies depicted in fig. 3d also 
complemented the sensory findings from the panelists score to conclude the statement that 
L100 has better taste masking efficiency than L100-55 (EZE). 
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Fig.7.3d. Relationship between results of taste sensors and human taste scores for similar 
tastes (the standard deviations on the x- and y-D[HVDUHWKHGLIIHUHQFHEHWZHHQWKHSDQHOLVWV¶
scores and measurement error (n = 6), respectively). 
In Fig. 7.3d, TS-5000Z taste sensing system (INSENT, Japan) showed different 
sensitivity to each sample with a high correlation (0.94) to the taste scores, suggesting that 
this sensor responds selectively according to bitterness intensity and does not detect just 
quantitative information. 
3.5 Molecular Modelling 
 Molecular modelling results indicated that both the hydroxyl group and amine group 
within the drug molecule could form strong hydrogen bonds with the monomeric form of 
L100 and L100-55, as indicated by the optimal distances between the H-bond donor and 
acceptor (Table 7.4). However, presence of the chloride ion could disrupt the H-bond 
between the hydroxyl group and the carboxylate group (data not shown). PRP showed a total 
binding energy ranging from 6.0 -15.9 kcal/mol with both of the polymers used. DPD showed 
a similar range (8.6 ± 17.5 kcal/mol) as shown in table 7.4. In addition, both drugs require 
higher binding energy to interact with L100-55 in comparison to L100, as indicated by the 
binding energy calculation. Higher binding energy is indicative of more energy required to 
break the H bonds apart, therefore enhanced stiffness of the drug/polymer binary mixtures 
that may result in less movements of the molecules during the extrusion to form significant 
interactions. All conformations showed very strong binding energy specifying strong 
interaction possibilities between both drugs and polymers. 
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Table 7.4: Binding energy calculation of drug/polymer pair based on the chemical structure 
(Gaussian View 9). 
Drug-polymer combination Conformation (Approx.) Binding energy (Kcal/mol) 
L100-PRP(a) 
  
 
9.4 
L100-PRP(b)  
  
 
6.0 
L100-DPD 
 
 
8.6 
L100-55-PRP(a)  
  
 
15.9 
L100-55-PRP(b) 
 
 
15.9 
L100-55-DPD(a) 
 
 
12.0 
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L100-55-DPD(b) 
 
 
17.5 
 
3.6 Fourier Transform Infra-Red (FT-IR) analysis 
 FT-IR is one of the most potent techniques which have already been used to study 
interactions in drug/polymer blends by providing valuable information regarding the 
oppositely charged ionic drug/polymer interactions at the molecular level [35]. By showing the 
emergence of additional bands or alterations in wave number position or broadening of 
functional groups compared to the spectra of the pure drug and polymer, the FTIR spectra 
gives an indication of drug/polymer interactions. The FTIR spectra in the absorbance mode 
for the PRP/anionic polymers formulations and DPD/ polymers formulations are shown in 
Fig. 7.4a ± 4b.  
 
Fig 7.4a:  FT-IR spectra of PRP extruded formulations. 
The characteristic bands of CO- vibrations of the carboxylic acid groups are shown at 
~1705 cm-1 and of the esterified carboxylic groups at ~1735 cm-1. The FTIR spectra of the 
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PRP/ polymers extruded in comparison with the pure materials are shown in Fig 4a, which 
show a new absorption band at 1560 and 1555 cm-1 for PRP/ L100 and PRP/ L100-55, 
respectively. This is considered to be the result of the addition of amine group to a solution of 
the carboxylic acid. During the ionization process the resonance is possible between the two 
CO- bands within COO- groups. 
 As a result, the characteristic CO- absorption is replaced by the band of an auto-
symmetrical vibrations of the COO- structure and is used as a diagnosis of the COO- group in 
the 1555- 1560 cm-1 region of the FTIR spectra [36, 37]. A strong and extensive interaction 
between anionic methacrylate polymers and cationic drug PRP is therefore indicated by the 
presence of carboxylic groups in the structure, enabling the formation of hydrogen bonds 
with the amine group of the drug. Similarly, DPD/ L100 and DPD/ L100-55 extruded 
formulations showed emergence of new bands at 1550cm-1 region (Fig. 7.5b) which 
significantly complement the similar interactions mechanism as PRP formulations. 
 
Fig 7.4b:  FT-IR spectra of DPD extruded formulations. 
3.7 X-ray Photoelectron Spectroscopy (XPS) analysis 
 In order to show the surface elemental ratios of PRP, DPD, polymers and the extruded 
formulations determined experimentally by XPS various surveys are depicted in Fig.7.5a-b as 
a comparison with the anticipated theoretical values derived from the structural formula [38].  
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Fig 7.5a: XPS surveys of pure PRP, DPD, L100 and L100-55. 
According to the surveys the PRP/L100, PRP/L100 55, DPD/L100 and DPD/L100-55 
showed the amount of N atoms as 0.63%, 0.23%, 0.53% and 0.21%, respectively simply 
indicating lower amount of N atom present in the final extruded formulations. 
 
Fig. 7.5b: XPS surveys of extruded formulations. 
 The N (1s) binding energy (BE) of ~402.035 eV (Fig. 7.5c) in PRP and of ~402.5 eV (Fig. 
5d) in DPD suggests the protonation of the NH+ group  while the slightly higher values of N 
(1s) energy (~402.8 eV) in PRP/L100 extrudates represents further protonation effect of N 
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atom as NH4+.  This observed N 1s peak at BE= ~402.80 eV is in good agreement with the 
previously observed protonation of amide group by Beamson and Briggs [33]. The BE peak at 
~402.80 eV (higher than typically observed for amines BE= ~399 eV - 400.5 eV and much 
more for ±NH2+ group) for N1s is an indication of C-O-NH2+ structure whereas the O atom 
peak at ~534.40 eV shows the same [18, 20]. These results strongly indicate an interaction 
between the amide group of the API and ester/carboxyl group of the polymer (L100) through 
the available H-interactions or hydrogen bridges (Fig. 7.5c).   
 
Fig. 7.5c: N 1s BE peaks of PRP and extruded formulations. 
 Similarly, N 1s peaks from PRP/L100-55 and DPD/L100-55 also complement the 
observations from PRP/L100 and DPD/L100 formulations. The N (1s) energy of ~402.9 eV 
in DPD/L100 formulation suggests protonation of the amide group as observed for 
aforementioned PRP/L100 formulation. The BE peak at ~402.90 eV (Fig. 7.5d) for N 1s is an 
indication of C-O-NH2+ structure with longer peak shift than that of PRP/L100. As before, we 
concluded that a strong interaction between the amide group of API and ester/carboxyl group 
of polymer through the available H-interactions has taken place.    
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Fig. 7.5d: N 1s BE peaks of DPD and DPD based extruded formulations. 
 Furthermore, the calculations of N coefficients for all extruded formulations indicated 
the strength of the intermolecular interactions within the solid dispersions. The calculated N 
coefficient for all extruded formulations is summerized in table 3. From the Table 7.5 it quite 
clearer that the N coefficient values for L100 systems are smaller than that of L100-55 
systems. It has been reported that the lower the N-coefficient, the higher the amount of 
protonised N atoms in cationic drugs, the stronger the interaction between polymer and APIs 
[39]
.  
Table 7.5: Estimated N coefficient values of different formulations. 
Formulations N 1s Binding Energy Calculated N Coefficient 
1st Fitting (eV) 2nd Fitting (eV) 
PRP/L100 63 100 0.63 
PRP/L100-55 58.51 49.49 1.18 
DPD/L100 45.97 54.03 0.85 
DPD/L100-55 51.19 48.81 1.05 
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8.0 Conclusions 
 The presence of intermolecular interactions has successfully led the HME to be a 
robust technique to form solid dispersions of both APIs into polymer matrix. The existence of 
amorphous APIs into the polymer matrices has been confirmed by thermal analysis while an 
in vivo and in vitro taste masking analysis has substantially complemented each other 
showing the masking potential of L100 better than L100-55. The molecular modelling 
outlined a possible presence of intermolecular interactions between drug and polymer 
molecules and estimated the strength. The findings from FT-IR and XPS analysis has finally 
confirmed the mechanism of the interaction through H-bonding between the carboxyl group 
of the anionic methacrylate co-polymer and the amide group of the active substances as well 
as the interaction strength. These studies finally confirm that the stronger the integrations 
better the taste masking in an opposite charged drug/polymers based extruded solid 
dispersions. 
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CHAPTER 8: SUSTAINED RELEASE HYDROCORTISONE TABLETS 
PROCESSED BY HOT-MELT EXTRUSION (HME) 
 
1.0 Introduction 
 As noted previously, hot-melt extrusion (HME) has been developed as a novel technique 
for the formulation of oral solid dosage forms in pharmaceutical industries in recent years      
[1]
.  A wide variety of downstream processing equipment allows the manufacture of various 
solid dosage forms including pellets, granules, tablets, capsules and films with different 
pharmaceutical applications. These solid dosage forms can provide sustained, modified or 
targeted release by controlling both formulation and processing parameters. Despite the fact 
that initial research developments have focused on the effects of formulation and processing 
variables on the properties of final dosage forms, [2-5] more recent investigations have focused 
on the use of HME as a novel manufacturing technology of solid molecular dispersions 
through to the development of sustained release formulations as well as paediatric 
formulations [6,7]. Early studies through HME processing have described the preparation of 
matrix mini-tablets which was followed by further investigations into the properties of 
sustained release mini-matrices manufactured from ethyl cellulose, HPMC and ibuprofen     
[8,9]
. Extruded mini tablets showed minimized risk of dose dumping and reduced inter- and 
intra-subject variability. Very recently, vegetable calcium stearate (CaSt) was reported to be 
used in the development of retarded release pellets using as a thermoplastic excipient 
processed through HME, where pellets with a paracetamol loading of 20% released only 
11.54% of the drug after 8 hours due to the significant densification of the pellets. As 
expected, the drug release was influenced by the pellet size and the drug loading [10]. A 
microbicide intravaginal ring (IVRs) IVR was prepared and developed from polyether 
urethane (PU) elastomers for the sustained delivery of UC781 (a highly potent non-nucleoside 
reverse transcriptase inhibitor of HIV-1). PU IVRs containing UC781 were fabricated using a 
hot-melt extrusion process [11]. 
 Chrono-pharmaceutical dosage forms are designed to release the drug at the desired time 
and improve therapeutic efficacy and patient compliance. Time-release formulations could be 
a useful tool in effecting chrono-pharmacotherapy because their unique drug release properties  
could take advantage of circadian rhythms in physiologic and pathologic functions. HME 
technique could be applied as a robust tool to formulate sustained release formulations          
[12, 13]
. &RUWLVRO LV QRUPDOO\ SURGXFHG E\ WKH DGUHQDO JODQGV ZKLFK UHJXODWHG E\ WKH EUDLQ¶V
hypothalamus and the pituitary gland. The hypothalamus sends "releasing hormones" to the 
pituitary gland which responds by secreting other hormones that regulate growth, thyroid, 
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testosterone and adrenal function. One of the pituitary gland's main functions is to secrete 
ACTH (adrenocorticotropin), a hormone that stimulates the adrenal glands. When the adrenals 
UHFHLYH WKH SLWXLWDU\¶V VLJQDO LQ WKH IRUP RI $&7+ WKH\ UHVSRQG E\ SURGXFLQJ FRUWLVRO
Completing the cycle, cortisol then signals the pituitary to lower secretion of ACTH. 
Hydrocortisone (HCS) is a synthetic form of corticosteroid administrated when the body is 
deficient in the natural hormone. It is used to treat allergy, inflammation, asthma, collagen 
diseases, adrenocortical deficiency, shock and some neoplastic conditions including acute 
lymphoblastic leukaemia. It generally possesses low bioavailability when they are orally 
administrated and topically applied whereas some patients are found to have severe allergic 
response towards intravenous injection [14]. 
 The drug release rate is difficult to control in all existing conventional sustained-release 
tablets as drug absorption is influenced heavily by its transition rate in the gastrointestinal 
tract, resulting in wide variations in the oral bioavailability [15]. It has been reported that a 
multiple-unit dosage form can overcome this problem to a certain extent; however, it requires 
a primitive manufacturing technology [16, 17]. It is therefore the purpose of this study to 
implement HME to develop a new dosage form that overcomes these biological and 
technological problems. A formulation development study on the novel HCS sustained-release 
tablets is hereby reported along with the analysis of the release mechanism of all prepared 
sustained-release tablets. 
   
2.0 Materials and methods 
2.1 Materials 
 Hydrocortisone (HCS) was purchased from Sigma Aldrich (London, UK). Ethyl 
Cellulose N10 (EC N10) and Ethyl Cellulose EP7 (EC P7) were kindly donated by Harceulis 
(Darmstadt, Germany) and Colorcon Ltd respectively. Eudragit S100 (S100) was provided by 
Evonik Industries (Darmstadt, Germany). SiO2 and MgSt were purchased from Sigma 
Aldrich, UK. The HPLC solvents were of analytical grade and purchased from Fisher 
Chemicals (UK). All materials were used as received.  
2.2 Calculation of solubility parameters 
[Please see Chapter 7, Section 2.2 for details] . 
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2.3 Preparation of formulation blends and hot-melt extrusion processing 
 HCS formulations with EC N10 and EC P7 were mixed properly in A Turbula (TF2, 
Basel) mixer in 100 g batches for 10 min each, prior to the extrusion process. Drug/polymer 
ratios used were 10-30:90-70 wt/wt for both polymers. Extrusion of all formulations were 
performed using a Randcastle single-screw extruder (RCP0625) equipped with a 5-mm rod 
GLH LQ &&&&& IURP IHHGLQJ ]RQH ĺ 'LH WHPSHUDWXUH SURILOHV 
The screw speed maintained for all extrusions was 15 rpm. The extrudates (strands) produced 
were ground by using a ball milling system with a rotational speed of 400 rpm for 5mins each 
to obtain granules (<500 µm). Out of all different drug/polymer extruded formulations 
prepared, 10/90 wt/wt ratio was selected for both polymers in order to justify the active 
dosage of HCS in commercial products (10 mg).  
2.4 Scanning electron microscopy (SEM) and particle size analysis 
 In order to examine the surface morphology of drug, polymers and extrudates by SEM 
the samples were mounted on an aluminium stage using adhesive carbon tape and placed in a 
low humidity chamber prior to analysis. Samples were coated with gold±palladium prior to 
the scans, and microscopy was performed using a LEO Supra 35 (Cambridge Instruments, 
S630F). The system was operated at an accelerating voltage of 5 kV. 
2.5 Differential scanning calorimetry (DSC) 
 The physical state of the pure drug, physical mixtures and extrudates were examined 
by using a Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter. 
Samples were prepared in sealed aluminium pans (2-5 mg) with a pierced lid. The samples 
were heated at 10oC/min under nitrogen atmosphere in a temperature range between -40 and 
250oC.  
2.6 X-ray powder diffraction (XRPD) 
 XRPD was also used to assess the solid state (crystalline or amorphous) of the 
extrudates where samples of pure and loaded APIs were evaluated using a Bruker D8 
Advance (Germany) in theta-theta mode, Cu anode at 40 kV and 40 mA, parallel beam 
Goebel mirror, 0.2 mm exit slit, LynxEye Position Sensitive Detector with 3 degree opening 
and Lynx Iris at 6.5 mm, sample rotation at 15rpm. The sample was scanned from 5 to 40 
degrees 2-theta with a step size of 0.02 degrees 2-theta and a counting time of 0.2 seconds per 
step; 176 channels active on the PSD making a total counting time of 35.2 seconds per step. 
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2.7 Tablet preparation and characterization 
 Extruded granules were used to prepare 10mm diameter robust tablets by using a 
Oyester Manesty Trilayer tablet press with a final weight of 250 mg (10 mg HCS). All 
excipients used for the tablets were adjusted as in Table 8.1. All prepared tablets were then 
characterised to determine the hardness, thickness and friability.  Enteric coating solution 
(15-25%) was then prepared by dissolving a pH dependent methacrylic polymer (Eudragit) in 
organic solvents (acetone, isopropyl alcohol) followed by addition of 20% plasticizer (PEG 
2000) under magnetic stirring until a clear solution was made. FD&C No 2 blue dye was 
added and the solution was homogenized for 10 min using an Ultra Turrax homogenizer. 
Coating process was conducted by uniform spraying (Copley pan coater) of the coating 
solution onto the tablets. The process parameters were adjusted as pump flow rate 2.0 rpm, 
pressure 4 psi, fan speed 77%, agitation 44%, temperature 45oC. 15% coating showed better 
uniformity and optimum dissolution rates therefore all coated tablets will be referred as 15% 
coating throughout this chapter. 
Table 8.1: Tablet contents for each of the extrudates. 
Tablet Content Percentage Composition 
(%) 
Weight 
(g) 
Extruded Material (HCS/EC N10/ EC P7) 40.0 40.0 
Eudragit RSPO 5.0 5.0 
Lactose 28.5 28.5 
HPMC 603 25.0 25.0 
Silicon Dioxide (Sio2) 0.5 0.5 
Magnesium Stearate 1.0 1.0 
Total 100.0 100.0 
 
2.8 In vitro drug release studies 
 In vitro dissolution study was carried out by using a Varian 705 DS dissolution paddle 
apparatus (Varian Inc. North Carolina, US) at 100 rpm and 37 ± 0.5oC. The dissolution 
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medium pH was maintained as 1.2 by using 750 ml of 0.1 M hydrochloric acid for 2 hr. After 
2 hr operation, 150 ml of 0.20 M solution of dehydrogenate sodium ortho phosphate was 
added into the vessel to give the final pH of 6.8 and the temperature equilibrated to 37°C. At 
predetermined time intervals, samples were withdrawn for HPLC assay and replaced with 
fresh dissolution medium. All dissolution studies were performed in triplicate.  
 
2.9 HPLC analysis 
 The release of HCS from the prepared tablets was determined by HPLC. An Agilent 
7HFKQRORJLHVV\VWHPHTXLSSHGZLWKD+<&520(ȝP[PP[ mm column at 
243 nm was used for the HCS HPLC assay. The mobile phase consisted of methanol/water/ 
acetic acid (54:45:1, v/v/v). The flow rate was 1.5 ml/min and the retention time of HCS was 
about 4 minutes. The HCS calibration curve (R2=0.999), at concentrations varying from    10 
µg/ml to 50 µg/ml, were used to evaluate all the samples with 20 µl injection volume.  
2.10 Analysis of drug release mechanism 
 Zero order kinetics, first order kinetics, Hixson±Crowell, Higuchi and Korsmeyer±
Peppas models were used for the analysis of the dissolution mechanism taking the rate 
constant obtained from these models as an apparent rate constant. The drug release patterns 
from both coated and uncoated tablets were analyzed by release kinetics theories [18-22], as 
follows: 
 
Zero order kinetics: )1.8(tKF ot   
 Where F t represents the fraction of drug released in time t and K0 the apparent release rate 
constant or zero order release constant. 
 
First order kinetics: )2.8()1ln( 1tKF    
Where F represents the fraction of drug released in time t and K1 is the first order release 
constant. 
Higuchi model: )3.8(2/12tKF   
Where F represents the fraction of drug released in time t and K2 is the Higuchi dissolution 
constant. 
 
Hixson±Crowell model: )4.8(3/13/10 tKWW st    
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Where, W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the 
remaining amount of drug in the pharmaceutical dosage form at time t and Ks is a constant 
incorporating the surface volume relation. 
Dividing Eq. (8.4) by 3/10W  and simplifying: )5.8(1)1( 33/1 tKF    
Where F í Wt/W0) and F represents the drug dissolved fraction at time t and K3 is the 
release constant). When this model is used, it is assumed that the release rate is limited by the 
drug particle dissolution rate and not by the diffusion that might occur through the polymeric 
matrix. 
Korsmeyer±Peppas model: )6.8(4 ntKF   
Where K4 is a constant incorporating the structural and geometric characteristics of the drug 
dosage form, n is the release exponent (e.g. zero order release when n = 1, for tablets n = 
0.89), indicative of the drug release mechanism and F represents the drug dissolved fraction 
at time t. This model is generally used to analyze the release of which mechanism is not well 
known or when more than one type of release phenomena is involved.  
 
3.0 Results and discussion 
3.1 Solubility parameters and extrusion process 
The calculated solubility parameter of HCS, EC N10 and EC P7 were 22.60, 25.61 
and 25.27 MPa1/2, respectively. The difference between the calculated solubility parameters 
of the polymers and the drug indicates that HCS is likely to form solid dispersions with both 
polymers EC N10 and EC P7. By using the Van Krevelen/Hoftyzer equation, WKHǻįYDOXHV
for HCS/EC N10 and HCS/EC P7 were 3.01 and 2.67 MPa1/2, respectively.  
 
3.2 Scanning electron microscopy (SEM) 
Surface morphology was examined by SEM for both the drug and extrudates. The 
extrudates containing both polymers exhibited no drug crystals on the extrudate surface with 
HCS (Fig. 8.1). Similarly, the absence of HCS crystals on the surface in all drug/ polymer 
extrudates indicates the presence of amorphous solid dispersions of the API into the polymer 
matrices [13]. Thus, the SEM observations were quite sensitive to elucidate the presence of 
drug/polymers amorphous solid dispersions by complementing the thermal investigations 
(DSC, XRD). 
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Fig. 8.1: SEM images of [(a), (b)] HCS/ EC N10 (magnification x500 and 10K, respectively) 
and [(c), (d)] HCS/EC P7 extruded formulations (magnification x500 and 10K, respectively). 
 
3.3 Differential scanning calorimetric (DSC) 
 Differential scanning calorimetry (DSC) was used to analyse the solid state of pure 
API, polymers, their physical mixtures (PM) and active extruded formulations (EXT). The 
overall findings from DSC results are summarized in Figs 8.2a and b. The DSC scan of pure 
HCS in Fig. 8.2a showed an endothermic transition corresponding to its melting point [23] at 
226.12o&į+ = 114.92 J/g, peak height 17.80 mW) with an onset at 223.82oC. Similarly, the 
pure polymers showed Tg at 133.01oC corresponding to Tg of EC N10 and 117.61oC 
corresponding to Tg of EC P7, respectively (Fig. 8.2a). Even though, all binary physical 
drugs/polymer blends exhibit endothermic peaks (Fig 8.2b) corresponding to the initial 
substances at slightly shifted temperatures indicating the drug existence in its crystalline 
form, the melting peaks were absent in all extruded formulations. In the drug/polymer 
physical mixture (PM) of HCS/ EC N10 formulation, two endothermic peaks were visible 
(Fig 8.2b), one at 202.87oC į+ -J corresponding to the melting peak of crystalline 
HCS present in the mixture and another one at lower temperature range at 72.27oC 
corresponding to the Tg of EC N10. Similar transitions were observed in the HCS/EC P7 
system as well where the endothermic peak at 185.86oC į+ -J corresponds to the 
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HCS melting transition and 61.66oC to the Tg of EC P7. This huge shift of the melting peak 
of HCS in HCS/ EC P7 is due to the lower glass transition temperature value compared to 
that of EC N10. This also suggests that EC P7 would be more effective than EC N10 for 
processing HCS below the melting temperature. Furthermore, the extruded formulations 
exhibited a broad endothermic peak ranging from 47.83 to 49.19 oC indicating the presence 
of the drugs in their amorphous forms. It has been observed previously [23] that the position of 
shifted endothermic peak in the extruded formulations is in between the thermal transitions of 
amorphous drug and polymers. 
 
Fig. 8.2a: DSC transitions of pure polymers and drug. 
 This thermal phenomenon complements the formation of solid dispersion of miscible 
HCS in the amorphous polymer matrices [24]. Nevertheless, the characteristic peak of HCS 
cannot be found in the heating curve of the extruded formulations, indicating that the soild 
state of the extruded formulations are different having the HCS present in amorphous form 
compared to the drug/polymer physical mixtures.  
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Fig. 8.2b: DSC transitions of HCS/EC N10 and HCS/ EC P7 physical mixtures (PM) and 
extruded formulations (EXT). 
3.4 X-ray powder diffraction (XRPD) analysis 
 The drug ± polymer extrudates, including pure drugs and physical mixtures of the 
same composition were studied by X±ray analysis and the diffractograms were recorded to 
examine the API crystalline state.  As depicted in Fig. 8.3 the diffractograms of pure HCS 
presented distinct peaks at 5.75, 14.50, 16.08, 17.42, 18.79, 19.42, 23.22, 29.21, 30.14 2ș
values.  
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Fig. 8.3: XRD diffractograms of extruded formulations and binary mixtures [PM = physical 
mixtures and EXT = extruded formulations]. 
The physical mixture of both formulations presented identical peaks at lower 
intensities suggesting that both drugs retain their crystalline properties. No crystalline distinct 
SHDNV ZHUH IRXQG LQ WKH H[WUXGHG IRUPXODWLRQ LQ (& 3 V\VWHPV  99% amorphous). In 
contrast almost no distinct intensity peaks (apart from a very low intensity peak at about 15 
șSRVLWLRQ for HCS was observed in the diffractogram of the extruded formulation in EC 
1V\VWHPDPRUSKRXV7KHDEVHQFHRI+&6LQWHQVLW\SHDNVLQGLFDWHVWKHSUHVHQFH
of amorphous APIs in the extruded solid dispersion. 
 
3.5 Tablet characterization 
 Results obtained from tablet characterization are summarized in Table 8.2. All 
prepared tablets prepared were 250 mg in weight with a mean thickness of 3.44 mm (SD = ± 
0.012) for HCS/EC N10 formulations and 3.50 mm (SD = ± 0.010) for HCS/ EC P7. The 
difference in the thickness of two different polymeric systems is attributed to the difference 
of the compactability of the powder formulations. This phenomenon has also been observed 
by the observed hardness values of the tablets in two different polymers. As compactablity is 
directly proportional to hardness, the HCS/EC P7 showed higher hardness value compared to 
that EC N10. It is always preferential to have the hardness of normal sustained release tablet 
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in the range of 10-12 kP. However, in our case we observed slightly lower hardness value 
than expected but the all tablets still seemed to be very robust as the weight loss percentage 
after 10 min in friability test was only 0.01. This could be due to the presence of elastic 
polymers (Eudragit ESPO) in the final tablet composission. The elasticity present in the 
tablets has finally managed to attribute this lower hardness value with less friability and thus 
higher robustness. 
Table 8.2'UXJSRO\PHU¶VGHVFULSWLRQWDEOHWFKDUDFWHUL]DWLRQ. 
 
Form Weight 
(mg) 
Thickness 
(mm) 
Average 
(mm)/SD 
 
Hardness 
(kP) 
Average 
(mm)/SD 
 
Friability 
(%) 
HCS / 
EC N10 
250.0 3.45  
3.44/±0.012 
6.2  
6.0/±0.15 
 
 
0.01 
 
250.0 3.43 6.0 
250.0 3.45 5.9 
HCS / 
EC P7 
250.0 3.50  
3.50/±0.010 
6.1  
6.1/± 0.10 
 
0.01 
 
250.0 3.49 6.2 
250.0 3.51 6.0 
 
3.6 In vitro dissolution studies 
 Polymeric coating of the compressed tablets with 15% pH dependent polymer proved 
sufficient to provide 2 hrs lag time in an acidic medium (Fig. 8.4). The composition of the 
matrix core of the final tablet formulation included a combination of hydrophilic (HPMC) 
and lactose along with extruded ethylcellulose to control HCS release patterns. The 
combination of all three ingredients provided retarded release profiles of HCS at higher pH 
values when the dissolution of the coating layer occurred [25]. The release profile was also 
controlled from the polymer amount coated on the surface of the matrix tablet.  
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Fig. 8.4: HCS release profiles in both coated and uncoated tablets. Each result shows the 
meanrS.D. (n = 3). 
 The release mechanism from the tablets can be described as a diffusion process of the 
drug through the slow release polymers matrix. The slow dissolving nature of EC polymers 
hinders the dissolution medium penetration and consequently controls the drug dissolution 
and diffusion rate [25]. While processing through HME the active substance was covered by 
EC matrix which resulted in retarded release of HCS over 12 hrs. Moreover, the polymeric 
coating level indicated a controlling effect due to its slow dissolution, irrespective of the 
tablet composition. Lower coating levels (15%) allowed greater penetration of the dissolution 
medium.  
3.7 Analysis of release mechanism 
 Analysis was performed by the above equations using water as the dissolution test 
medium. Obtained results for release rate constants as well as R2 values for all tablets are 
summerized in table 8.3. Neither coated nor uncoated tablets fit with equation (8.1), zero 
order release model, which represents zero order kinetics. Concerning equations (8.2)±(8.6), 
regression analyses were performed in the ranges in which linearity was observed. The first 
order kinetics model plot shows the relationship between the logarithm of the drug residual 
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rate and time on the basis of Eq. (8.2). Fig. 8.5a shows the results with both coated and 
uncoated tablet. 
 
Fig. 8.5a: Semi logarithmic plot of the unreleased fraction of HCS as a function of time 
according to a first order kinetics model. Each result shows the meanrS.D. (n = 3). 
 
 Analyses were performed in the ranges in which linearity was maintained with both 
coated and uncoated tablets. The HCS release from both tablets was affected slightly by 
coating. In uncoated tablet, satisfactory linearity was observed throughout the test (R2 = 
0.9709 - 0.9922) as shown in table 8.3 for both polymers, and the release pattern was 
apparently linear release.  In the coated tablets, satisfactory linearity was not observed up to 
two hours of dissolution study as no HCS was released due to the pH dependant polymer 
coating. After two hours, with the increase pH, HCS started releasing and therefore a 
satisfactory linearity between the logarithm of drug residual rate and time was observed 
throughout the rest of the test (R2 = 0.9153 - 0.9295). 
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Fig. 8.5b: A plot of the HCS released as a function of time according to the Higuchi model. 
Each result shows the meanrS.D. (n = 3). 
 
 The Higuchi model plot shows the relationship between the drug release rate and the 
square root of time on the basis of Eq. (8.3) which is depicted in Fig. 8.5b. It shows the 
results of HCS release from HME tablets. Analyses were performed in the ranges in which 
linearity was maintained with both coated and uncoated tablets (R2 = 0.9040 - 0.9498). The 
release from the coated tablet was slightly affected by the coating as expected; however, the 
release from uncoated tablet was quite linear throughout the test.  
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Fig. 8.5c: A plot of the cubic root of unreleased fraction of HCS from tablets as a function of 
time according to the Hixson±Crowell model. Each result shows the meanrS.D. (n = 3). 
  
 According to the Hixson±Crowell model plot which shows the relationship between the 
cubic root of the drug residual rate and time on the basis of Eq. (8.5) results are depicted in 
Fig 8.5c. Hixson and Crowell showed that the law of cubic root is valid in uniform particles. 
This equation is based on the assumption that the release occurs only in the vertical direction 
relative to the matrix surface, and that the release progresses with proportional decreases in 
all dimensions of the matrix, which maintains its shape [17]. Analyses were performed in the 
ranges in which linearly was maintained with both tablets. The release from coated tablets 
was not linear as the R2 value was found to be (0.8829 - 0.8964). On the other hand, the HCS 
release from coated tablets according to the Hixson-Crowell model is quite linear throughout 
the whole test (R2 = 0.9622 - 0.9838). According to the Hixson-Crowell theory of drug 
release it is presumed that the release progression has been maintained with the decreases in 
all dimensions of the matrix due to the applied coating on the tablet surfaces and thus 
maintained the shapes of the tablets. 
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 Eq. (6) is a Korsmeyer±Peppas model equation concerning the diffusion mechanism, 
and it has been evaluated concerning pharmaceutical preparations of many matrix types. 
When both terms of Eq. (8.6) are converted to logarithms, the equation becomes ln F = lnK4 
+ n ln t, and the slope n can be determined by plotting the logarithm of the release rate against 
the logarithm of time (Fig. 8.5d). 
 
Fig. 8.5d: A plot of the logarithm of HCS released as a function of the logarithm of time 
according to the Korsmeyer±Peppas model. Each result shows the meanrS.D. (n=3). 
  
 The exponent (n) determined by this equation suggests that both the uncoated and 
coated tabletV VKRZ)LFN¶VGLIIXVLRQ when n = 0.40-0.45 (for tablets). It has been reported 
that a non-Fickian type release which is also known as anomalous transport occurs only when 
0.45 < n < 0.89, case-II transport can be observed when n = 0.89, and super case-II transport 
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when n > 0.89. From the results of analysis of the apparent diffusion pattern, the value of n, 
has represented the diffusion pattern according to the Fickian diffusion [17].  
 
Table 8.3: Dissolution rate constants and determination coefficients of HCS release from 
coated and uncoated tablets; n dissolution exponent. 
 
Dissolution models HCS/EC N10 
Uncoated 
HCS/EC P7 
Uncoated 
HCS/EC N10 
Coated 
HCS/EC P7 
Coated 
 
First order K1 (h-1) 
R2 
0.29 ± 0.013 
0.9922 
0.31 ± 0.027 
0.9709 
0.4215 ± 0.057 
0.9295 
0.456±0.068 
0.9153 
Higuchi K2 (% hr-1/2) 
R2 
29.29 ± 1.56 
0.9498 
29.48 ± 2.07 
0.9113 
34.41 ± 2.30 
0.9040 
34.418±2.303 
0.9040 
Hixson± 
Crowell 
K3 (%h-1/3) 
R2 
0.08 ± 0.005 
0.9838 
0.089 ± 0.008 
0.9622 
0.1182± 0.176 
0.8964 
0.126±0.197 
0.8829 
Krosmer-Peppas K4 (hr-n) 
R2 
n 
31.32 ± 3.91 
0.9532 
0.46 ± 0.06 
32.95 ± 5.14 
0.9214 
0.44 ± 0.08 
40.48 ± 4.77 
0.9375 
0.40± 0.069 
42.20±6.11 
0.8966 
0.40±0.069 
 
 
4.0 Conclusions  
 In the current study HME was used as a robust technique to develop time delayed 
coated extruded tablet to provide sustained-release of HCS. The release patterns are governed 
by the polymer selection while performing the extrusion process and the coating respectively. 
The tablet was designed to release HCS in a pattern that imitates a healthy individual. The 
development of the HCS extruded tablet by HME is preferable since its preparation is quick, 
economical with fewer process steps which will make the future pilot scale formulation 
developments much easier. Furthermore, a full comparative analysis of drug release 
mechanism confirmed the release of HCS in extruded tablets according to first order kinetic 
model.  
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CHAPTER 9:  CONCLUSIONS AND FUTURE WORK 
 
9.1 Overall conclusions 
 Hot-melt extrusion (HME) has proved to be a robust method of producing 
several drug delivery systems and therefore it has been found to be useful in the 
pharmaceutical industry enlarging the scope to include a range of polymers and APIs that can 
be processed with or without plasticizers. In this current study HME processing was 
employed as a means to increase the dissolution rates of three water insoluble drugs. INM 
and FMT were extruded with SOL, VA64 and S630 at different loadings up to 40% without 
the presence of traditional plasticizers while IBU was extruded and embedded within 
Eudragit EPO polymer matrix. The extrusion process was optimized to produce amorphous 
solid dispersions of the drug substances. Further physicochemical characterization studies 
confirmed the theoretical drug ± polymer miscibility for all binary mixtures as predicted by 
the theoretical approaches of Greenhalgh and Bagley. Increased aqueous solubility was 
observed in both API mixtures with all polymers, and the extruded solid dispersions resulted 
in greater dissolution rates compared to the bulk drugs. The in vivo taste-masking evaluation 
of extruded IBU formulations showed that HME processing can be used to efficiently mask 
the taste of bitter active substances without compromising tablet palatability. The ODTs 
developed displayed disintegration times and crushing resistance similar to commercial 
Nurofen® tablets but improved tablet friability. Finally the increased IBU release rates of the 
developed ODTs were faster than the commercial Nurofen® tablets.  
PMOL was found to exist in either the crystalline or amorphous state depending on 
the polymer used for extrusion. The optimized formulations were evaluated in terms of taste 
masking efficiency both by in vivo human panellists and an electronic tongue. The extruded 
formulations of VA64 demonstrated better taste masking compared to those of EPO while the 
e-tongue was found to be a valuable tool for taste masking assessments and formulation 
development.  Similarly, DPD, PRP, CTZ and VRP were found to be in the amorphous state 
after extrusion due to the formation of solid dispersions. The optimized formulations 
evaluated by both in vivo and in vitro taste masking tests correlated with each other very well. 
The extruded formulations of L100 demonstrated better taste masking compared to those of 
EZE while the e-tongues were found to be a valuable tool for taste masking assessments and 
formulation development. 
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Furthermore, HME has successfully been employed as a robust technique to form 
solid dispersions of APIs into polymer matrices via intermolecular interactions. The existence 
of amorphous APIs in the polymer matrices has been confirmed by thermal analysis. 
Molecular modelling was used to predict/assess the possible presence and strength of 
intermolecular interactions between drug and polymer molecules. The foregoing was 
confirmed by FT-IR and NMR studies. XPS analysis was used to confirm the mechanism of 
the interaction via H-bonding between the carboxyl group of the anionic methacrylate         
co-polymer and the amide group of the active substances and estimate the bond strengths 
involved. The foregoing studies confirmed that the stronger the interaction between 
oppositely charged drug and the polymer, the better the taste masking in extruded solid 
dispersions. 
The release patterns of HCS from tablets processed by HME were governed by the 
thermal characteristics of the polymer used as a carrier during the extrusion process and the 
enteric coatings of the polymer, respectively. The tablets were designed to release HCS in a 
pattern that imitates the cortisol level in healthy individuals. Furthermore, a full comparative 
analysis of the mechanism of drug release confirmed the release of HCS in extruded tablets 
according to a first order kinetic model. 
 
9.2 Future work 
The scope of the HME technology has already broadened to include a range of polymers 
and APIs that can be processed through the application of supercritical fluids and plasticizer 
assisted HME. 
Future work using HME could include the following. 
x Development, optimization and characterization of various orally                 
dispersible/bioadhesive film formulations. Hot-melt extruded films would be able to 
deliver high amounts of taste masked drugs and, therefore, would increase patient 
compliance. 
x Formulation of various APIs with lipids for sustained release of drugs, using HME 
also need to be explored in order to facilitate cold extrusion for heat sensitive APIs. 
x The growing market in medical devices, including incorporating drugs such as 
biodegradable stents and drug-loaded catheters will undoubtedly require HME 
manufacturing processes. These are required to be commercialised and may lead to 
new areas of inter-discipinary research in the areas of pharmaceutics, medical devices 
and biotechnology.  
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CHAPTER 10: SUPPLEMENTARY DATA 
 
10.1 Supplementary figures 
 
 
 
 
Supp. Fig. 1: N 1s BE peaks of DPD and DPD based extruded formulations. 
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Supp. Fig. 2: XPS O 1s peaks for PRP, L100 and PRP/L100 formulations. 
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Supp. Fig. 3: C 1s BE peaks for L100-55, PRP/L100-55 and DPD/L100-55. 
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Supp. Fig. 4: O 1s BE peaks for L100-55, DPD and DPD/L100-55 formulations. 
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Supp. Fig. 5: Part, 1H T1 spectra (aromatic region) for the propanolol HCl/ Eudragit    
L-100 formulation. 
 
ʏс 5 ms 
ʏс 65 ms 
ʏс 125 ms 
ʏс 185 ms 
ʏс 265 ms 
ʏс 345 ms 
ʏс 445 ms 
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Supp. Fig. 6: Part, 1H T1 spectra (aromatic region) for the propanolol HCl. 
 
 
 
 
 
 
 
ʏс 200 ms 
ʏс 1.8 s 
ʏс 6.2 s 
ʏс 8.2 s 
ʏс 3.8 s 
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Supp.Fig.7: Part, 1H T1 spectra for the diphenhydramine HCl / Eudragit L-100 
formulation. 
 
 
 
 
 
 
 
 
 
 
ʏс 500 ms 
ʏс1.5 s 
ʏс 2.5 s 
ʏс5.5 s 
ʏс  8.5 s 
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Supp. Fig.8: Part, 1H T1 spectra for the diphenhydramine HCl. 
 
 
 
 
 
 
 
 
 
 
 
 
ʏс ? ? ?ŵƐ 
ʏс1.8 s 
ʏс6.2 s 
ʏс12.2 s 
ʏс3.8 s 
ʏс9.0 s 
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10.2 Supplementary calculations 
 
Example of the calculations of Hansen solubility parameters of drug and polymer 
 
(1) Paracetamol:    
 
       Molecular formula:  C8H9NO2          
Molecular weight:   151 
Density:  1.263 gm/cm3 
Therefore, molecular Volume (V) = MM/density 
                                         = 151/1.263 
                                          = 119.56 cm3 (equal to the sum of the functional groups 
contribution from respective structure) 
Now, some known values for solubility parameter component group contribution (Table 
Suppl. 1)- 
Structural groups Fdi Fpi Fhi 
-CH3 420 0 0 
-OH 210 500 20000 
>C=O 290 770 200 
>N-H 160 210 3100 
- - 
1270 110 0 
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Supplementary table 1: Solubility parameter component group contribution 
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)di  )pi  )hi = 23300 
From Van krevelen Equation We know, 
)1(222 hpd GGGG    
Where, 
i
di
d V
F¦ G
 ,  
i
pi
p V
F¦ 2G
  , ¦ )/( ihip VEG  
i = structural groups within the molecule 
į WKHWRWDOVROXELOLW\SDUDPHWHU 
Fdi = molar attraction constant due to molar dispersion forces 
F2pi = molar attraction constant due to molar polarization forces 
Ehi = hydrogen bonding energy. 
Vi = group contribution to molar volume 
1RZįd =  Fdi / V = 2352/119.56 =  19.672 
 
$QGįp =  948.21/119 įh  ¥  
 
 6RQRZį ¥^2 +  (7.93)2 + (13.96)2} 20.25, 8.16, 14.16 
                    
                  = 25.77 MPa1/2 
 
 
(2) Kollidon VA64 
 
 
MW = 219.2 (above structure) 
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N = 55000/ 219.2 = 250.912 
Density: 1.29 g/cm3 
Molar Volume (v) = 55000/ 1.39 = 39568.35 cm3 (equal to the sum of the functional groups 
contribution from respective structure)  
Structural groups Fdi Fpi Fhi 
 -CH3 420 0 0 
                -CH2- 270 0 0 
                 -O- 100                  400 3000 
 >C=O 290 770 200 
1.2 x >C=O 348 924 240 
1.2 x >N- 24 960 6000 
4.8 x -CH2- 1296 0 0 
1.2 x  >CH- 96 0 0 
 
)di  )2pi  )hi = 2368609.28 
By using the same van krevelen calculation shown above for Temoporfin, we get 
įd  )di / V = 18 
 
$QGįp įh =  7.73 
 
 6RQRZį ¥^2 +  (0.64)2 + (7.73)2} 
                    
                  = 19.60 MPa1/2 
 
 
 
 
 
 
(3) Soluplus 
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= N (mw = 418 g/mol) 
Molecular Weight = 90000 g/mol 
N = 215.3; Density = 1.08 g/cm3 
Molar Volume (V) = 83333.33 cm3 (equal to the sum of the functional groups contribution 
from respective structure) 
Structural groups Fdi Fpi Fhi 
   -CH3 420 0 0 
14 x  -CH2- 3780 0 0 
   2 x  -OH 420                 1000 40000 
4 x    -O- 400 1600 12000 
2 x >C=O 580 1540 400 
3 x >CH- 240 0 0 
>N- 20 800 5000 
 
)di  )2pi  )hi = 12358220 
By using the same van krevelen calculation shown above for Temoporfin, we get 
įd )di / V = 15.14 
 
$QGįp =  0.45  įh =  12.18 
 
 So now, į ¥^2 +  (0.45)2 + (12.18)2} 
                    
                  = 19.43 MPa1/2 
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(4) Eudragit L100  
, N = (125000/202 = 618.81) 
 
Molecular Weight: 125000 g/mol 
 
Density: 1.25 g/cm3 
 
Molar Volume (V) = 125000/1.25 = 100000 cm3 (equal to the sum of the functional groups 
contribution from respective structure) 
 
 
Structural groups Fdi Fpi Fhi 
5 x -CH3 2100 0 0 
2  >C< -140 0 0 
2  >C=O 580 1540 400 
  -O- 100 400 3000 
-OH 210 500 20000 
-CH2- 270 0 0 
N= 618.81 )di = 1930687.2 )2pi = 1721281896 )hi = 14480154 
 
By using the same van krevelen calculation shown above, we get 
įd  )di / V =19.31 
 
$QGįp  DQGįh =  12.03 
 
 6RQRZį= 22.75 MPa1/2 
 
 
(5) Eudragit L100-55 (Acryl EZE) 
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 N = (320000/202= 1584.1584) 
 
Molecular Weight = 320000 g/mol 
 
Molecular Volume (V) = 320000/1.18 = 271186.4407 cm3 (equal to the sum of the functional 
groups contribution from respective structure)  
 
 
Structural groups Fdi Fpi Fhi 
4 x -CH3 1680 0 0 
  >C< -70 0 0 
2  >C=O 580 1540 400 
  -O- 100 400 3000 
-OH 210 500 20000 
2 x  -CH2- 540 0 0 
>CH- 80 0 0 
N= 1584.1584 )di = 4942574.208 )2pi= 4406495005 )hi = 37069306.56 
 
By using the same van krevelen calculation shown above, we get 
įd  )di / V = 4942574.208/271186.4407= 18.226 
 
And, įp =  0.245 and, įh =  11.692 
 
 6RQRZį ¥^2 +  (0.245)2 + (11.692)  
 
= 21.65 MPa1/2 
